

The Prevalence of Hepatitis C Virus Infection in the Uni

Annals of Internal Medicine

144, 705

DOI: 10.7326/0003-4819-144-10-200605160-00004

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Economics of Hepatitis C Virus. <i>Clinics in Liver Disease</i> , 2006, 10, 717-734.	1.0	24
2	Hepatitis C Virus Genotypes and Viral Concentrations in Participants of a General Population Survey in the United States. <i>Gastroenterology</i> , 2006, 131, 478-484.	0.6	142
3	Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1. <i>Gastroenterology</i> , 2006, 131, 470-477.	0.6	453
4	Peginterferon and Ribavirin for Chronic Hepatitis C. <i>New England Journal of Medicine</i> , 2006, 355, 2444-2451.	13.9	433
5	The Changing Epidemiology and Natural History of Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2006, 10, 697-715.	1.0	91
6	What's new in the other general journals. <i>BMJ: British Medical Journal</i> , 2006, 332, 1264-1265.	2.4	2
7	Hepatitis C: A Bitter Harvest. <i>Annals of Internal Medicine</i> , 2006, 144, 770.	2.0	14
8	What's new in the other general journals. <i>BMJ: British Medical Journal</i> , 2006, 332, 289-290.	2.4	1
9	Time trends in socioeconomic differences in incidence rates of cancers of gastro-intestinal tract in Finland. <i>BMC Gastroenterology</i> , 2006, 6, 41.	0.8	69
10	Psychiatric management of the hepatitis C patient. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 508-519.	0.3	24
11	Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. <i>Hepatology</i> , 2006, 44, 1675-1684.	3.6	145
12	Hepatitis C Virus Infections From a Contaminated Radiopharmaceutical Used in Myocardial Perfusion Studies. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2005.	3.8	61
13	Clinical Utility of AFP-L3% Measurement in North American Patients with HCV-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2007, 102, 2196-2205.	0.2	112
14	Comorbidities in older patients with HIV. <i>Journal of the American Dental Association</i> , 2007, 138, 1468-1475.	0.7	31
15	Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy. <i>Journal of Virology</i> , 2007, 81, 8211-8224.	1.5	106
16	Hepatitis C Virus Infection and the Prevalence of Renal Insufficiency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 715-721.	2.2	83
17	Injection Drug Users in the United States, 1979-2002. <i>Archives of Internal Medicine</i> , 2007, 167, 166.	4.3	109
18	Changes in Gene Expression during Pegylated Interferon and Ribavirin Therapy of Chronic Hepatitis C Virus Distinguish Responders from Nonresponders to Antiviral Therapy. <i>Journal of Virology</i> , 2007, 81, 3391-3401.	1.5	112

#	ARTICLE	IF	CITATIONS
19	Hepatitis C in Organ Donors and Heart Transplant Recipients. JAMA - Journal of the American Medical Association, 2007, 297, 696.	3.8	1
20	Hepatitis C Infection, Treatment Regimens, and Thyroid Function Abnormalities. , 2007, 17, 231-235.		13
21	Sex, Drugs, and Hepatitis C Virus. Journal of Infectious Diseases, 2007, 195, 1556-1559.	1.9	17
22	Emerging Paradigms in the Renal Pathology of Viral Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, S6-S12.	2.2	20
23	Use of national health interview data to measure the burden of disease and injuries. Injury Prevention, 2007, 13, 254-257.	1.2	2
24	Viral Encounters with 2â€™,5â€™-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response. Journal of Virology, 2007, 81, 12720-12729.	1.5	522
25	Risk of Non-Hodgkin Lymphoma and Lymphoproliferative Precursor Diseases in US Veterans With Hepatitis C Virus. JAMA - Journal of the American Medical Association, 2007, 297, 2010.	3.8	294
26	Association of Hepatitis C Seropositivity With Increased Risk for Developing End-stage Renal Disease. Archives of Internal Medicine, 2007, 167, 1271.	4.3	147
27	Acute Hepatitis C in a Contemporary US Cohort: Modes of Acquisition and Factors Influencing Viral Clearance. Journal of Infectious Diseases, 2007, 196, 1474-1482.	1.9	165
28	Hepatitis C Virus Infection Induces the Beta Interferon Signaling Pathway in Immortalized Human Hepatocytes. Journal of Virology, 2007, 81, 12375-12381.	1.5	46
29	Project ECHO: Linking University Specialists with Rural and Prison-Based Clinicians to Improve Care for People with Chronic Hepatitis C in New Mexico. Public Health Reports, 2007, 122, 74-77.	1.3	154
30	Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. Blood, 2007, 110, 4599-4605.	0.6	35
31	A Biological Substrate for Somatoform Disorders: Importance of Pathophysiology. Psychosomatic Medicine, 2007, 69, 850-854.	1.3	76
32	Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. Aids, 2007, 21, 1967-1969.	1.0	23
33	Peginterferon alfa-2b and ribavirin combination therapy for chronic hepatitis C. Future Virology, 2007, 2, 553-563.	0.9	0
34	Postexposure Immunization and Prophylaxis of Bloodborne Pathogens Following a Traumatic Explosive Event: Preliminary Recommendations. Disaster Medicine and Public Health Preparedness, 2007, 1, 106-109.	0.7	3
35	Hepatitis C virus RNA: Dinucleotide frequencies and cleavage by RNase L. Virus Research, 2007, 130, 85-95.	1.1	57
36	Hepatitis C management by addiction medicine physicians: Results from a national survey. Journal of Substance Abuse Treatment, 2007, 33, 99-105.	1.5	29

#	ARTICLE	IF	CITATIONS
37	Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. <i>Journal of Hepatology</i> , 2007, 46, 420-431.	1.8	125
38	Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study. <i>Journal of Hepatology</i> , 2007, 47, 51-59.	1.8	47
39	Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2007, 47, 777-783.	1.8	26
40	Economics of chronic hepatitis B and hepatitis C. <i>Journal of Hepatology</i> , 2007, 47, 608-617.	1.8	22
41	The Effect of Age on Response to Therapy With Peginterferon ? Plus Ribavirin in a Cohort of Patients With Chronic HCV Hepatitis Including Subjects Older Than 65 Yr. <i>American Journal of Gastroenterology</i> , 2007, 102, 1383-1391.	0.2	68
42	Synergy of Small Molecular Inhibitors of Hepatitis C Virus Replication Directed at Multiple Viral Targets. <i>Journal of Virology</i> , 2007, 81, 3005-3008.	1.5	30
43	FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy. <i>American Journal of Gastroenterology</i> , 2007, 102, 2589-2600.	0.2	337
44	Effect of Human Immunodeficiency Virus and Antiretrovirals on Outcomes of Hepatitis C: A Systematic Review From an Epidemiologic Perspective. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1321-1328.e7.	2.4	14
45	Relationship Between Transferrin-Iron Saturation, Alcohol Consumption, and the Incidence of Cirrhosis and Liver Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 624-629.	2.4	25
46	Nationwide Increase in Hospitalizations and Hepatitis C Among Inpatients With Cirrhosis and Sequelae of Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1092-1099.	2.4	81
48	Antiviral treatment of HCV-related cirrhosis. <i>Digestive and Liver Disease</i> , 2007, 39, S96-S101.	0.4	4
49	Reprocessing failure. <i>Gastrointestinal Endoscopy</i> , 2007, 66, 869-871.	0.5	18
50	Epidemiology of hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2007, 13, 2436.	1.4	1,101
51	Low Prevalence of Hepatitis C Virus Antibody in Men Who Have Sex with Men Who Do Not Inject Drugs. <i>Public Health Reports</i> , 2007, 122, 63-67.	1.3	37
52	Integrating Viral Hepatitis Prevention into Public Health Programs Serving People at High Risk for Infection: Good Public Health. <i>Public Health Reports</i> , 2007, 122, 1-5.	1.3	8
53	Texas Statewide Hepatitis C Counseling and Testing, 2000-2005. <i>Public Health Reports</i> , 2007, 122, 6-11.	1.3	11
54	Managing Chronic Hepatitis C in Primary-Care Settings: More than Antiviral Therapy. <i>Public Health Reports</i> , 2007, 122, 78-82.	1.3	11
55	A comparative review of HLA associations with hepatitis B and C viral infections across global populations. <i>World Journal of Gastroenterology</i> , 2007, 13, 1770.	1.4	206

#	ARTICLE	IF	CITATIONS
56	Surgical Options in the Treatment of Hepatocellular Carcinoma. <i>American Surgeon</i> , 2007, 73, 658-662.	0.4	3
58	Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: Recent trends. <i>International Journal of Cancer</i> , 2007, 121, 1624-1626.	2.3	57
59	The effects of HCV infection and management on health-related quality of life. <i>Hepatology</i> , 2007, 45, 806-816.	3.6	162
60	Engulfment of apoptotic cells expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells. <i>Hepatology</i> , 2007, 45, 1422-1432.	3.6	17
61	Predictors of response of U.S. veterans to treatment for the hepatitis C virus. <i>Hepatology</i> , 2007, 46, 37-47.	3.6	209
62	Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. <i>Hepatology</i> , 2007, 46, 350-358.	3.6	57
63	Liver disease in adolescents: A cohort study of high-risk individuals. <i>Hepatology</i> , 2007, 46, 1750-1758.	3.6	33
64	Predictors of treatment in patients with chronic hepatitis C infection-Role of patient versus nonpatient factors. <i>Hepatology</i> , 2007, 46, 1741-1749.	3.6	111
65	Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations. <i>Hepatology</i> , 2007, 46, 2014-2020.	3.6	23
66	Changing trends in hepatitis C-related mortality in the United States, 1995-2004. <i>Hepatology</i> , 2008, 47, 1128-1135.	3.6	191
67	Medical/Psychiatric Comanagement by Nurse Practitioners in Chronic Hepatitis C Treatment: A Case Study. <i>Archives of Psychiatric Nursing</i> , 2007, 21, 87-90.	0.7	5
68	Influence of epidemiological factors on blood transfusion. <i>ISBT Science Series</i> , 2007, 2, 78-84.	1.1	1
69	Severe mental illness is a new risk marker for blood-borne viruses and sexually transmitted infections. <i>Australian and New Zealand Journal of Public Health</i> , 2007, 31, 562-566.	0.8	24
70	Pegylated interferon-?? in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-?? in a hepatitis C population: Meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 472-476.	1.4	28
71	Hepatitis C virus E2 envelope protein induces dendritic cell maturation. <i>Journal of Viral Hepatitis</i> , 2007, 14, 070901052026004-???	1.0	16
72	Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 401-410.	1.9	17
73	Review article: vaccination and viral hepatitis – current status and future prospects. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1285-1292.	1.9	20
74	Alcohol and Hepatitis C Mortality Among Males and Females in the United States: A Life Table Analysis. <i>Alcoholism: Clinical and Experimental Research</i> , 2007, 31, 285-292.	1.4	49

#	ARTICLE	IF	CITATIONS
75	Managing chronic hepatitis C in the difficult-to-treat patient. <i>Liver International</i> , 2007, 27, 1297-1310.	1.9	20
76	A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 326-340.	157.7	28
77	Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. <i>BMC Health Services Research</i> , 2007, 7, 39.	0.9	43
78	Effectiveness and Hepatotoxicity of Statins in Men Seropositive for Hepatitis C Virus. <i>Pharmacotherapy</i> , 2007, 27, 845-851.	1.2	32
79	Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: A comprehensive approach. <i>International Journal of Drug Policy</i> , 2007, 18, 417-425.	1.6	51
80	Epidemiology of Hepatitis Virus B and C. <i>Archives of Medical Research</i> , 2007, 38, 606-611.	1.5	57
81	Interferon Alpha Treatment and Thyroid Dysfunction. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 1051-1066.	1.2	123
82	Effects Of A Brief Educational Program On Knowledge And Willingness To Accept Treatment Among Patients With Hepatitis C At Inner-City Hospitals. <i>Journal of Community Health</i> , 2007, 32, 221-230.	1.9	35
83	The epidemiology of hepatitis C infection in the United States. <i>Journal of Gastroenterology</i> , 2007, 42, 513-521.	2.3	149
84	Alcohol abuse and chronic hepatitis C. <i>Current Hepatitis Reports</i> , 2007, 6, 119-124.	0.3	1
85	Hepatitis C, insulin resistance, and steatosis. <i>Current Hepatitis Reports</i> , 2007, 6, 129-137.	0.3	2
86	Awareness of Hepatitis C Diagnosis is Associated with Less Alcohol Use Among Persons Co-Infected with HIV. <i>Journal of General Internal Medicine</i> , 2007, 22, 822-825.	1.3	30
87	Awareness of Hepatitis C Infection Among Women With and At Risk for HIV. <i>Journal of General Internal Medicine</i> , 2007, 22, 1689-1694.	1.3	15
88	The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. <i>Quality of Life Research</i> , 2008, 17, 715-724.	1.5	17
89	Ethnic Differences in Hepatocellular Carcinoma: Implications for Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2008, 53, 551-555.	1.1	21
90	Treatment Eligibility and Outcomes in Elderly Patients with Chronic Hepatitis C: Results from the VA HCV-001 Study. <i>Digestive Diseases and Sciences</i> , 2008, 53, 809-814.	1.1	29
91	Ethnic Variations in Chronic Liver Diseases. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1339-1344.	1.1	9
92	The Prevalence and Risk Factors for Abnormal Liver Enzymes in HIV-Positive Patients without Hepatitis B or C Coinfections. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1375-1382.	1.1	68

#	ARTICLE	IF	CITATIONS
93	Hepatic Sarcoidosis Associated with Pegylated Interferon Alfa Therapy for Chronic Hepatitis C—Case Report and Review of Literature. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2810-2812.	1.1	22
94	Compensated hepatitis C: unenhanced MR imaging correlated with pathologic grading and staging. <i>Abdominal Imaging</i> , 2008, 33, 58-64.	2.0	9
95	Modelling the spread of hepatitis C via commercial tattoo parlours: implications for public health interventions. <i>OR Spectrum</i> , 2008, 30, 269-288.	2.1	4
96	Sampling and Recruitment in Multilevel Studies among Marginalized Urban Populations: The IMPACT Studies. <i>Journal of Urban Health</i> , 2008, 85, 268-280.	1.8	31
97	Optimizing therapy in treatment-naïve genotype 1 patients. <i>Current Hepatitis Reports</i> , 2008, 7, 64-71.	0.3	1
98	Viral hepatitis in African Americans. <i>Current Hepatitis Reports</i> , 2008, 7, 120-126.	0.3	1
99	Hepatitis C in African Americans. <i>Current Hepatitis Reports</i> , 2008, 7, 139-144.	0.3	2
100	Noninvasive assessment of liver fibrosis in chronic hepatitis C infection. <i>Current Hepatitis Reports</i> , 2008, 7, 164-172.	0.3	1
101	Communicating about Alcohol Consumption to Nonharmful Drinkers with Hepatitis C: Patient and Provider Perspectives. <i>Journal of General Internal Medicine</i> , 2008, 23, 242-247.	1.3	13
103	Treatment strategy for hepatitis C after liver transplantation. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 111-123.	2.0	5
104	Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: A multicenter serosurvey. <i>Journal of Medical Virology</i> , 2008, 80, 53-57.	2.5	55
105	Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand. <i>Journal of Medical Virology</i> , 2008, 80, 808-815.	2.5	30
106	Hepatitis C virus seropositivity in a South African Cohort of HIV co-infected, ARV naïve patients is associated with renal insufficiency and increased mortality. <i>Journal of Medical Virology</i> , 2008, 80, 1530-1536.	2.5	30
107	Racial disparity in liver disease: Biological, cultural, or socioeconomic factors. <i>Hepatology</i> , 2008, 47, 1058-1066.	3.6	135
109	Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. <i>Hepatology</i> , 2008, 48, 1420-1429.	3.6	245
110	Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: A nationwide analysis. <i>Hepatology</i> , 2008, 48, 1336-1341.	3.6	92
111	Natural history: The importance of viral load, liver damage and HCC. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 1063-1079.	1.0	15
112	Hepatitis C virus infection among children in aboriginal areas in Taiwan. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2008, 102, 935-938.	0.7	9

#	ARTICLE	IF	CITATIONS
113	The natural history of recurrent hepatitis C and what influences this. <i>Liver Transplantation</i> , 2008, 14, S36-S44.	1.3	241
114	Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. <i>Nucleic Acids Research</i> , 2008, 36, 1482-1496.	6.5	96
115	Hepatitis C: current and future therapies. <i>Mount Sinai Journal of Medicine</i> , 2008, 75, 405-414.	1.9	0
116	Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. <i>Genes and Immunity</i> , 2008, 9, 328-333.	2.2	21
117	High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. <i>Liver International</i> , 2008, 28, 781-786.	1.9	76
118	Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. <i>Liver International</i> , 2008, 28, 705-712.	1.9	219
119	Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C endemic area: cross-sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination. <i>Liver International</i> , 2008, 28, 1298-1304.	1.9	6
120	Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. <i>Transfusion</i> , 2008, 48, 902-909.	0.8	37
121	Confirmatory testing of hepatitis C virus-positive enzyme immunoassay results in limited-resource countries: should it be attempted?. <i>Transfusion</i> , 2008, 48, 1239-1244.	0.8	8
122	Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. <i>Addiction</i> , 2008, 103, 905-918.	1.7	76
123	Review article: nonalcoholic fatty liver disease and hepatitis C virus – partners in crime. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 855-865.	1.9	29
124	Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large veterans administration medical centre. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1078-1087.	1.9	21
125	Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. <i>Journal of Viral Hepatitis</i> , 2008, 15, 551-570.	1.0	13
126	Persistence with hepatitis C therapy in the Department of Veterans Affairs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 251-261.	0.7	5
127	Anti-hepatitis C virus-positive blood donors: are women any different?. <i>Transfusion Medicine</i> , 2008, 18, 175-183.	0.5	12
128	Treatment Options for Patients with Hepatitis C: Role of Pharmacists in Optimizing Treatment Response and Managing Adverse Events. <i>Pharmacotherapy</i> , 2008, 28, 1151-1161.	1.2	18
129	KDOQI US Commentary on the KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in CKD. <i>American Journal of Kidney Diseases</i> , 2008, 52, 811-825.	2.1	43
130	Pain, Substance Use Disorders and Opioid Analgesic Prescription Patterns in Veterans with Hepatitis C. <i>Journal of Pain and Symptom Management</i> , 2008, 36, 39-45.	0.6	45

#	ARTICLE	IF	CITATIONS
131	End-point limiting-dilution real-time PCR assay for evaluation of hepatitis C virus quasispecies in serum: Performance under optimal and suboptimal conditions. <i>Journal of Virological Methods</i> , 2008, 151, 217-224.	1.0	58
132	Socioeconomic context, distance to primary care and detection of hepatitis C: A French population-based study. <i>Social Science and Medicine</i> , 2008, 66, 1046-1056.	1.8	29
133	High Prevalence of Hepatitis C Virus Infection Among Immigrants From the Former Soviet Union in the New York City Metropolitan Area: Results of a Community-Based Screening Program. <i>American Journal of Gastroenterology</i> , 2008, 103, 922-927.	0.2	19
134	Hepatitis C Virus (HCV): A Review of Immunological Aspects. <i>International Reviews of Immunology</i> , 2008, 27, 497-517.	1.5	41
135	AGA Institute Future Trends Committee Report: The Future of Gastroenterology Training Programs in the United States. <i>Gastroenterology</i> , 2008, 135, 1764-1789.e2.	0.6	11
136	Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e30.	1.6	36
137	Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. <i>Journal of Hepatology</i> , 2008, 49, 163-169.	1.8	129
138	HCV E2 protein binds directly to thyroid cells and induces IL-8 production: A new mechanism for HCV induced thyroid autoimmunity. <i>Journal of Autoimmunity</i> , 2008, 31, 339-344.	3.0	68
139	Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. <i>Journal of Clinical Virology</i> , 2008, 41, 255-263.	1.6	32
140	Racial and Ethnic Variations in Hepatocellular Carcinoma Incidence within the United States. <i>American Journal of Medicine</i> , 2008, 121, 525-531.	0.6	85
141	Hepatitis A: Disease Burden and Current Childhood Vaccination Strategies in the United States. <i>Journal of Pediatric Health Care</i> , 2008, 22, 3-11.	0.6	32
142	Profile of lifetime methamphetamine use among homeless adults in Los Angeles. <i>Drug and Alcohol Dependence</i> , 2008, 92, 277-281.	1.6	17
143	A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. <i>Drug and Alcohol Dependence</i> , 2008, 93, 148-154.	1.6	59
144	Racial and ethnic changes in heroin injection in the United States: Implications for the HIV/AIDS epidemic. <i>Drug and Alcohol Dependence</i> , 2008, 94, 221-233.	1.6	112
145	Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. <i>European Journal of Cancer</i> , 2008, 44, 847-853.	1.3	48
146	Management Complexities of HIV/Hepatitis C Virus Coinfection in the Twenty-First Century. <i>Clinics in Liver Disease</i> , 2008, 12, 587-609.	1.0	31
147	Increased All-Cause, Liver, and Cardiac Mortality among Hepatitis C Virus-seropositive Blood Donors. <i>American Journal of Epidemiology</i> , 2008, 167, 743-750.	1.6	122
148	Acute Hepatitis C: A Systematic Review.. <i>American Journal of Gastroenterology</i> , 2008, 103, 1283-1297.	0.2	158

#	ARTICLE	IF	CITATIONS
149	The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1604-1612.	1.4	166
150	A Patient with Diabetes, Hepatitis C Virus Infection, and Hemochromatosis Gene Mutation. <i>Clinical Diabetes</i> , 2008, 26, 174-176.	1.2	0
151	Impaired Hepatitis C Virus (HCV)-Specific Effector CD8 ⁺ T Cells Undergo Massive Apoptosis in the Peripheral Blood during Acute HCV Infection and in the Liver during the Chronic Phase of Infection. <i>Journal of Virology</i> , 2008, 82, 9808-9822.	1.5	93
152	The Role of Obstetrician/Gynecologists in the Management of Hepatitis C Virus Infection. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2008, 2008, 1-7.	0.4	3
153	Infection with Hepatitis C Virus among HIV-Infected Pregnant Women in Thailand. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2008, 2008, 1-7.	0.4	9
154	Viral-Associated Immune Thrombocytopenic Purpura. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 212-218.	0.9	73
155	Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration. <i>American Journal of Gastroenterology</i> , 2008, 103, 2757-2765.	0.2	41
156	Outcome of Screening for Hepatitis C Virus Infection Based on Risk Factors. <i>American Journal of Gastroenterology</i> , 2008, 103, 131-137.	0.2	30
157	Management of Chronic Hepatitis C in Veterans: The Potential of Integrated Care Models. <i>American Journal of Gastroenterology</i> , 2008, 103, 1810-1823.	0.2	50
158	Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. <i>Journal of Clinical Investigation</i> , 2008, 119, 225-36.	3.9	76
159	Validation of a Hepatitis C Screening Tool in Primary Care. <i>Archives of Internal Medicine</i> , 2008, 168, 2009.	4.3	33
160	Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates. <i>Journal of Clinical Microbiology</i> , 2008, 46, 499-506.	1.8	85
161	Hepatitis A: The Vaccine Dividend. <i>Journal of Infectious Diseases</i> , 2008, 197, 1220-1222.	1.9	3
162	Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. <i>New England Journal of Medicine</i> , 2008, 359, 2429-2441.	13.9	445
163	Diagnostic markers for hepatitis virus infection. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 303-314.	1.6	1
164	The Epidemiology of Newly Diagnosed Chronic Liver Disease in Gastroenterology Practices in the United States: Results From Population-Based Surveillance. <i>American Journal of Gastroenterology</i> , 2008, 103, 2727-2736.	0.2	131
165	HCV in Incarcerated Populations: An Analysis of Gender and Criminality on Risk. <i>Journal of Psychoactive Drugs</i> , 2008, 40, 493-501.	1.0	13
166	Postexposure Interventions to Prevent Infection With HBV, HCV, or HIV, and Tetanus in People Wounded During Bombings and Other Mass Casualty Events—United States, 2008: Recommendations of the Centers for Disease Control and Prevention and Disaster Medicine and Public Health Preparedness. <i>Disaster Medicine and Public Health Preparedness</i> , 2008, 2, 150-165.	0.7	21

#	ARTICLE	IF	CITATIONS
167	Hepatitis C. <i>Annals of Internal Medicine</i> , 2008, 148, ITC6-1.	2.0	10
168	iatrogenesis and hepatitis C infection: Implications for well-being. <i>Irish Journal of Psychology</i> , 2008, 29, 19-33.	0.2	2
169	Cryoglobulinemia and renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 243-249.	1.0	62
170	HCV and pregnancy: is now the time for universal testing?. <i>Future Virology</i> , 2008, 3, 1-5.	0.9	2
171	Acute Viral Hepatitis. , 0, , 1-25.		0
172	Uncommon Hepatitis B Virus and/or Hepatitis C Virus Occult Infection in HIV-Positive Patients With Abnormal Level of Hepatic Enzyme. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 233-234.	0.9	1
174	Changing Epidemiology of HCV and HBV Infections in Northern Italy. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 527-532.	1.1	76
175	Can We Predict the Degree of Fibrosis in Chronic Hepatitis C Patients Using Routine Blood Tests in Our Daily Practice?. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 827-834.	1.1	41
176	Silybin Treatment is Associated With Reduction in Serum Ferritin in Patients With Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 937-944.	1.1	42
177	Anti-HCV reactive blood donors: clinical and epidemiological factors associated with false-reactive results. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 1071-1076.	0.8	8
178	Neurologic Complications of Hepatitis C. <i>Neurologist</i> , 2008, 14, 151-156.	0.4	46
179	Wanted. <i>Journal of Public Health Management and Practice</i> , 2008, 14, 471-475.	0.7	4
180	Chronic Hepatitis C in the Hispanic/Latino Population Living in the United States. <i>Gastroenterology Nursing</i> , 2008, 31, 17-25.	0.2	6
181	Utility of point of care test devices for infectious disease testing of blood and oral fluid and application to rapid testing in the field. <i>Proceedings of SPIE</i> , 2008, , .	0.8	0
182	Time for Renewed Commitment to Viral Hepatitis Prevention. <i>American Journal of Public Health</i> , 2008, 98, 779-781.	1.5	15
183	Hepatitis C. <i>Gastroenterology Nursing</i> , 2008, 31, 346-352.	0.2	14
184	A Randomized Intervention Trial to Reduce the Lending of Used Injection Equipment Among Injection Drug Users Infected With Hepatitis C. <i>American Journal of Public Health</i> , 2008, 98, 853-861.	1.5	45
185	Impact of Geographic Location on Access to Liver Transplantation Among Ethnic Minorities. <i>Transplantation</i> , 2008, 85, 166-170.	0.5	26

#	ARTICLE	IF	CITATIONS
186	Lamivudine treatment for severe acute HBV hepatitis. <i>International Journal of Medical Sciences</i> , 2008, 5, 309-312.	1.1	31
187	The Burden of Hepatitis C Virus Infection Is Growing: A Canadian Population-Based Study of Hospitalizations from 1994 to 2004. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008, 22, 381-387.	1.8	47
188	Beyond the informed consent procedure: continuing consent in human research. <i>Ciencia E Saude Coletiva</i> , 2008, 13, 381-389.	0.1	13
189	Seroprevalence of HCV Infection in Homeless Baltimore Families. <i>Journal of Health Care for the Poor and Underserved</i> , 2008, 19, 580-587.	0.4	15
190	Hepatitis C in an Urban Cohort: Who's Not Being Treated?. <i>Journal of Health Care for the Poor and Underserved</i> , 2009, 20, 1068-1078.	0.4	3
191	Optimizing the Dose and Duration of Therapy for Chronic Hepatitis C. <i>Gut and Liver</i> , 2009, 3, 1-13.	1.4	2
192	Population-based Surveillance for Hepatitis C Virus, United States, 2006-2007. <i>Emerging Infectious Diseases</i> , 2009, 15, 1499-1502.	2.0	40
193	Hepatocellular Carcinoma Prevalence and Mortality in a Male State Prison Population. <i>Public Health Reports</i> , 2009, 124, 120-126.	1.3	15
195	Treatment of chronic hepatitis C: present and future. <i>Acta Hepatologica Japonica</i> , 2009, 50, 345-355.	0.0	0
196	Factors Associated with Prevalent Hepatitis C Infection Among HIV-Infected Women with No Reported History of Injection Drug Use: The Women's Interagency HIV Study (WIHS). <i>AIDS Patient Care and STDs</i> , 2009, 23, 915-923.	1.1	55
197	The Role of Nucleoside Transporters in the Erythrocyte Disposition and Oral Absorption of Ribavirin in the Wild-Type and Equilibrative Nucleoside Transporter 1 (eNTP1) Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 287-296.	1.3	32
198	Chronic Liver Disease Mortality Among Male Prison Inmates in Texas, 1989-2003. <i>American Journal of Gastroenterology</i> , 2009, 104, 1412-1419.	0.2	15
199	Response to Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis C in Hispanics Compared to Non-Hispanic Whites. <i>American Journal of Gastroenterology</i> , 2009, 104, 1686-1692.	0.2	30
200	Hepatitis C Performance Measure on Hepatitis A and B Vaccination: Missed Opportunities?. <i>American Journal of Gastroenterology</i> , 2009, 104, 1961-1967.	0.2	22
201	Alcohol Consumption Decisions Among Nonabusing Drinkers Diagnosed with Hepatitis C. <i>Journal of Mixed Methods Research</i> , 2009, 3, 65-86.	1.8	20
202	Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. <i>Dermatology</i> , 2009, 219, 158-161.	0.9	6
203	Sex Disparities in Cancer Incidence by Period and Age. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1174-1182.	1.1	355
205	Hepatitis C Virus Transmission at an Outpatient Hemodialysis Unit—New York, 2001-2008. <i>Nephrology Times</i> , 2009, 2, 14-16.	0.0	0

#	ARTICLE	IF	CITATIONS
206	Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C. <i>New England Journal of Medicine</i> , 2009, 360, 257-267.	13.9	185
207	Should antiviral therapy be offered to elderly patients?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 503-504.	8.2	7
208	Assessment and proposal of a new combination of screening criteria for hepatitis C in France. <i>European Journal of Public Health</i> , 2009, 19, 527-533.	0.1	9
209	Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. <i>Neurology</i> , 2009, 73, 309-314.	1.5	45
210	Chronic hepatitis B and C: update on therapy. <i>Future Virology</i> , 2009, 4, 437-452.	0.9	3
211	HBV and HCV Therapy. <i>Viruses</i> , 2009, 1, 484-509.	1.5	7
212	Early Changes in Hepatitis C Virus (HCV) Levels in Response to Peginterferon and Ribavirin Treatment in Patients with Chronic HCV Genotype 1 Infection. <i>Journal of Infectious Diseases</i> , 2009, 199, 1112-1120.	1.9	44
213	Age and Prediction of Sustained Virological Response to Hepatitis C Virus (HCV) Infection Treatment Based on 28â€­Day Decrease in HCV RNA Levels. <i>Journal of Infectious Diseases</i> , 2009, 200, 1484-1485.	1.9	13
214	Hepatitis C Virus Infection Does Not Preclude Standard Breast Cancerâ€­Directed Therapy. <i>Clinical Breast Cancer</i> , 2009, 9, 51-52.	1.1	5
215	Outcome After Liver Transplantation for NASH Cirrhosis. <i>American Journal of Transplantation</i> , 2009, 9, 782-793.	2.6	191
216	Geographic Variation in Organ Availability Is Responsible for Disparities in Liver Transplantation between Hispanics and Caucasians. <i>American Journal of Transplantation</i> , 2009, 9, 2113-2118.	2.6	46
217	Race and Ethnicity in Access to and Outcomes of Liver Transplantation: A Critical Literature Review. <i>American Journal of Transplantation</i> , 2009, 9, 2662-2668.	2.6	57
218	An Evidence-Based Review of Infectious Diseases. <i>Geriatric Nursing</i> , 2009, 30, 272-286.	0.9	1
219	Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. <i>Hepatology</i> , 2009, 49, 116-123.	3.6	253
220	Diagnosis, management, and treatment of hepatitis C: An update. <i>Hepatology</i> , 2009, 49, 1335-1374.	3.6	2,610
221	Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up. <i>Hepatology</i> , 2009, 50, 1030-1037.	3.6	169
222	Public health impact of antiviral therapy for hepatitis C in the United States. <i>Hepatology</i> , 2009, 50, 1750-1755.	3.6	195
223	HCV genotypes in Sicily: Is there any evidence of a shift?. <i>Journal of Medical Virology</i> , 2009, 81, 1040-1046.	2.5	17

#	ARTICLE	IF	CITATIONS
224	Drug Abuse and Hepatitis C Infection as Comorbid Features of HIV Associated Neurocognitive Disorder: Neurocognitive and Neuroimaging Features. <i>Neuropsychology Review</i> , 2009, 19, 215-231.	2.5	74
225	Marked Flare in Hepatic Aminotransferases During Treatment with Pegylated Interferon for Chronic Hepatitis C, Genotype 2: A Case Report. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1369-1372.	1.1	2
226	Sociodemographic Trends in National Ambulatory Care Visits for Hepatitis C Virus Infection. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2694-2698.	1.1	23
227	Survival Differences by Race/Ethnicity and Treatment for Localized Hepatocellular Carcinoma Within the United States. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2031-2039.	1.1	45
228	Hepatitis C Virus and Cancers: How Strong Is the Relationship?. <i>Current Hepatitis Reports</i> , 2009, 8, 1-7.	0.3	0
229	Prevalence of Infection with Hepatitis B and C Viruses and Co-infection with HIV in Three Jails: A Case for Viral Hepatitis Prevention in Jails in the United States. <i>Journal of Urban Health</i> , 2009, 86, 93-105.	1.8	67
230	Prevalence of Hepatitis C Infection in New York City, 2004. <i>Journal of Urban Health</i> , 2009, 86, 909-917.	1.8	20
231	Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 807-814.	0.9	60
232	Prevalence and risk factors for Hepatitis C and HIV-1 infections among pregnant women in Central Brazil. <i>BMC Infectious Diseases</i> , 2009, 9, 116.	1.3	42
233	Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 589-601.	1.9	19
234	Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1019-1024.	1.9	109
235	Specialty care and education associated with greater disease-specific knowledge but not satisfaction with care for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 275-282.	1.9	12
236	Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 597-602.	1.9	42
237	Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in subsets of older and younger HCV genotype 1 patients. <i>Journal of Viral Hepatitis</i> , 2009, 16, 724-731.	1.0	43
238	The disposition of hepatitis C antibody-positive patients in an urban hospital. <i>Journal of Viral Hepatitis</i> , 2009, 16, 814-821.	1.0	10
239	Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection. <i>Genes and Immunity</i> , 2009, 10, 365-372.	2.2	31
240	Postmortem Detection of Hepatitis B, C, and Human Immunodeficiency Virus Genomes in Blood Samples from Drug-Related Deaths in Denmark*. <i>Journal of Forensic Sciences</i> , 2009, 54, 1085-1088.	0.9	12
241	Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 955-961.	1.4	65

#	ARTICLE	IF	CITATIONS
242	Prevention of hepatocellular carcinoma complicating chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 531-536.	1.4	40
243	Development of thyroid diseases in the treatment of chronic hepatitis C with Interferon may be a good prognosticator in achieving a sustained virological response: A meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1163-1168.	1.4	26
244	Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. <i>Transplant International</i> , 2010, 23, 580-588.	0.8	21
245	Hepatitis C infection: recent insights relevant to transfusion safety. <i>ISBT Science Series</i> , 2009, 4, 72-79.	1.1	7
246	Hepatitis C virus incident cases open the possibility to study transmission route and source of infection. <i>Transfusion</i> , 2009, 49, 1270-1273.	0.8	0
247	The global burden of hepatitis C. <i>Liver International</i> , 2009, 29, 74-81.	1.9	1,150
248	INTRODUCTION. <i>Liver International</i> , 2009, 29, 1-2.	1.9	1
249	Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. <i>Liver International</i> , 2009, 29, 3-12.	1.9	51
250	Interferon alpha delivery systems for the treatment of hepatitis C. <i>International Journal of Pharmaceutics</i> , 2009, 369, 121-135.	2.6	26
251	Design and efficient synthesis of novel arylthiourea derivatives as potent hepatitis C virus inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6063-6068.	1.0	29
252	Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitals. <i>Journal of Infection</i> , 2009, 59, 62-69.	1.7	13
253	Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia. <i>Drug and Alcohol Review</i> , 2009, 28, 447-454.	1.1	15
254	Eltrombopag: the discovery of a second generation thrombopoietin-receptor agonist. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 85-93.	2.5	12
255	Toll-like receptors as targets in chronic liver diseases. <i>Gut</i> , 2009, 58, 704-720.	6.1	290
256	Infectious Causes of Chronic Immune Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 1275-1297.	0.9	62
257	Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005. <i>Journal of Clinical Oncology</i> , 2009, 27, 1485-1491.	0.8	1,489
258	Association of Hepatitis C Virus Seropositivity With Inflammatory Markers and Heart Failure in Persons With Coronary Heart Disease: Data From the Heart and Soul Study. <i>Journal of Cardiac Failure</i> , 2009, 15, 451-456.	0.7	60
259	The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. <i>Preventive Medicine</i> , 2009, 49, 68-73.	1.6	65

#	ARTICLE	IF	CITATIONS
260	Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. <i>Journal of Substance Abuse Treatment</i> , 2009, 37, 32-40.	1.5	101
261	Viral RNA Testing in Hepatitis C Antibody-Positive Veterans. <i>American Journal of Preventive Medicine</i> , 2009, 36, 235-238.	1.6	24
262	HCV-related mortality among male prison inmates in Texas, 1994-2003. <i>Annals of Epidemiology</i> , 2009, 19, 582-589.	0.9	27
263	Antiviral treatment for hepatitis C virus infection: Effectiveness at general population level in a highly endemic area. <i>Digestive and Liver Disease</i> , 2009, 41, 509-515.	0.4	14
264	Decline in Male Sexual Desire, Function, and Satisfaction During and After Antiviral Therapy for Chronic Hepatitis C. <i>Gastroenterology</i> , 2009, 137, 873-884.e1.	0.6	31
265	Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States. <i>Gastroenterology</i> , 2009, 137, 1680-1686.	0.6	149
266	Hepatitis C in the Elderly: Epidemiology, Natural History, and Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 128-134.	2.4	26
267	Monoclonal and Polyclonal Antibodies Against the HCV Envelope Proteins. <i>Clinics in Liver Disease</i> , 2009, 13, 477-486.	1.0	6
268	Review: Predicting the probable outcome of treatment in HCV patients. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 287-302.	1.4	29
269	Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 689-699.	1.5	49
270	Molecular and Contextual Markers of Hepatitis C Virus and Drug Abuse. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 153-179.	1.6	5
271	Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 975-983.	0.6	6
272	Liver cancer mortality among male prison inmates in Texas, 1992-2003. <i>Preventive Medicine</i> , 2009, 48, 588-592.	1.6	7
273	Clinical Case Registries: Simultaneous Local and National Disease Registries for Population Quality Management. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2009, 16, 775-783.	2.2	95
274	Therapeutic Strategies for Hepatitis- and Other Infection-Related Immune Thrombocytopenias. <i>Seminars in Hematology</i> , 2009, 46, S15-S25.	1.8	18
275	Hepatitis C and diabetes: the inevitable coincidence?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 293-308.	2.0	66
276	Noninvasive assessment of fibrosis and steatosis in NASH and ASH. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, 940-948.	0.9	16
277	Surgery in the Patient with Liver Disease. <i>Clinics in Liver Disease</i> , 2009, 13, 211-231.	1.0	84

#	ARTICLE	IF	CITATIONS
278	Benefits of Retention in Methadone Maintenance and Chronic Medical Conditions as Risk Factors for Premature Death Among Older Heroin Addicts. <i>Journal of Psychiatric Practice</i> , 2009, 15, 227-234.	0.3	89
279	Hepatitis C. <i>Gastroenterology Nursing</i> , 2009, 32, 94-104.	0.2	18
280	Effects of a Hepatitis C Virus Educational Intervention or a Motivational Intervention on Alcohol Use, Injection Drug Use, and Sexual Risk Behaviors Among Injection Drug Users. <i>American Journal of Public Health</i> , 2009, 99, S180-S186.	1.5	42
281	Risky Sexual Behavior, Bleeding Caused by Intimate Partner Violence, and Hepatitis C Virus Infection in Patients of a Sexually Transmitted Disease Clinic. <i>American Journal of Public Health</i> , 2009, 99, S173-S179.	1.5	18
282	Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 661-671.	1.1	26
283	Estimating the Applicability of Wound Care Randomized Controlled Trials to General Wound-Care Populations by Estimating the Percentage of Individuals Excluded from a Typical Wound-Care Population in Such Trials. <i>Advances in Skin and Wound Care</i> , 2009, 22, 316-324.	0.5	44
284	Effects of hepatitis C virus infection on menopause status and symptoms. <i>Menopause</i> , 2009, 16, 401-406.	0.8	8
285	The Multidimensional Burden of Hepatitis C and Its Treatment. <i>Gastroenterology Nursing</i> , 2009, 32, 180-187.	0.2	11
287	Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <i>Haematologica</i> , 2009, 94, 249-257.	1.7	43
288	Prevalence and Predictors of Hepatic Steatosis in Adults With Newly Diagnosed Chronic Liver Disease due to Hepatitis C. <i>Medicine (United States)</i> , 2009, 88, 302-306.	0.4	4
289	Risk of Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia Among 120,908 US Veterans With Hepatitis C Virus Infection. <i>Archives of Internal Medicine</i> , 2009, 169, 357.	4.3	67
290	Pandemic Influenza: Implications for Programs Controlling for HIV Infection, Tuberculosis, and Chronic Viral Hepatitis. <i>American Journal of Public Health</i> , 2009, 99, S333-S339.	1.5	12
291	An Escalating Dose Regimen of Pegylated Interferon and Ribavirin in HCV Cirrhotic Patients Referred for Liver Transplant. <i>Transplantation</i> , 2009, 88, 729-735.	0.5	18
292	Lay Management of Chronic Disease: A Qualitative Study of Living with Hepatitis C Infection. <i>American Journal of Health Behavior</i> , 2009, 33, 376-90.	0.6	13
293	Risk Assessment and Screening for Sexually Transmitted Infections, HIV, and Hepatitis Virus Among Long-Distance Truck Drivers in New Mexico, 2004-2006. <i>American Journal of Public Health</i> , 2009, 99, 2063-2068.	1.5	23
294	Factors Associated With Hepatic Fibrosis In Patients With Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 758-764.	1.1	41
295	Successful Integration of Hepatitis C Evaluation and Treatment Services With Methadone Maintenance. <i>Journal of Addiction Medicine</i> , 2010, 4, 20-26.	1.4	60
296	Impact of Depressive Symptoms and Their Treatment on Completing Antiviral Treatment in Patients With Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e178-e185.	1.1	18

#	ARTICLE	IF	CITATIONS
297	Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. <i>Current Opinion in Hematology</i> , 2010, 17, 550-557.	1.2	9
298	Trends in Hepatitis C Virus Infection Among Patients in the HIV Outpatient Study, 1996–2007. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 388-396.	0.9	47
299	New therapies in the management of hepatitis C virus. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 196-201.	1.0	12
300	Perspectives on Fibrosis Progression in Hepatitis C: An À la Carte Approach to Risk Factors and Staging of Fibrosis. <i>Antiviral Therapy</i> , 2010, 15, 281-291.	0.6	19
301	Importance of Hepatitis Vaccination in Patients with Chronic Liver Disease. <i>Southern Medical Journal</i> , 2010, 103, 1223-1231.	0.3	13
302	Prognostic Factors Associated with Hepatitis C Disease: A Case-Control Study Utilizing U.S. Multiple-Cause-of-Death Data. <i>Public Health Reports</i> , 2010, 125, 414-422.	1.3	20
303	Hepatitis C Transmission, Prevention, and Treatment Knowledge Among Patients with HIV. <i>Southern Medical Journal</i> , 2010, 103, 635-641.	0.3	9
304	Use of Statins in Patients with Chronic Hepatitis C. <i>Southern Medical Journal</i> , 2010, 103, 1018-1024.	0.3	13
305	Quality of Care in Patients With Chronic Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2010, 153, 231.	2.0	55
306	Hepatitis C in the rituximab era. <i>Blood</i> , 2010, 116, 5081-5082.	0.6	12
307	Viral Hepatitis and Injection Drug Use in Appalachian Kentucky: A Survey of Rural Health Department Clients. <i>Public Health Reports</i> , 2010, 125, 121-128.	1.3	16
308	Evaluation of nonprescription syringe sales in San Francisco. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2010, 50, 595-599.	0.7	9
309	Emerging therapies for hepatitis C virus. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 535-544.	1.0	22
310	Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 6414-6421.	1.4	29
311	Autoimmune hemolytic anemia in treatment-naïve chronic hepatitis C infection: a case report and review of literature. <i>Clinical Journal of Gastroenterology</i> , 2010, 3, 237-242.	0.4	8
312	Three Years after Legalization of Nonprescription Pharmacy Syringe Sales in California: Where Are We Now?. <i>Journal of Urban Health</i> , 2010, 87, 576-585.	1.8	14
313	Pharmacy Participation in Non-Prescription Syringe Sales in Los Angeles and San Francisco Counties, 2007. <i>Journal of Urban Health</i> , 2010, 87, 543-552.	1.8	29
314	Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. <i>Hepatology International</i> , 2010, 4, 523-529.	1.9	38

#	ARTICLE	IF	CITATIONS
315	Training for a Career in Hepatology: Which Path to Take?. <i>Current Gastroenterology Reports</i> , 2010, 12, 76-81.	1.1	5
316	The Healthcare Burden Imposed by Liver Disease in Aging Baby Boomers. <i>Current Gastroenterology Reports</i> , 2010, 12, 1-6.	1.1	39
317	Natural History and Treatment of Hepatitis C in Liver Transplant Recipients. <i>Current Hepatitis Reports</i> , 2010, 9, 30-37.	0.3	0
318	Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response. <i>Current Hepatitis Reports</i> , 2010, 9, 147-154.	0.3	7
319	Liver Transplantation in the Ethnic Minority Population: Challenges and Prospects. <i>Digestive Diseases and Sciences</i> , 2010, 55, 883-889.	1.1	15
320	Utilization and Antiviral Therapy in Patients with Chronic Hepatitis C: Analysis of Ambulatory Care Visits in the US. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1744-1751.	1.1	14
321	Predictive Factors for Response to Peginterferon-Alpha and Ribavirin Treatment of Chronic HCV Infection in Patients Aged 65 Years and More. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3193-3199.	1.1	14
322	Epidemiology, Surveillance, and Prevention of Hepatitis C Virus Infections in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2010, 56, 371-378.	2.1	65
323	Ligand-induced changes in hepatitis C virus NS5B polymerase structure. <i>Antiviral Research</i> , 2010, 88, 197-206.	1.9	29
324	Alternative strategies in assuring blood safety: An Overview. <i>Biologicals</i> , 2010, 38, 31-35.	0.5	25
325	The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. <i>Cellular Immunology</i> , 2010, 262, 96-104.	1.4	10
326	Predictors of pain intensity and pain functioning in patients with the hepatitis C virus. <i>General Hospital Psychiatry</i> , 2010, 32, 413-418.	1.2	26
327	A review of the treatment of chronic hepatitis C virus infection in cirrhosis. <i>Clinical Therapeutics</i> , 2010, 32, 2117-2138.	1.1	87
328	Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors. <i>Cancer</i> , 2010, 116, 974-982.	2.0	7
329	Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. <i>Hepatology</i> , 2010, 51, 1137-1143.	3.6	60
330	Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions. <i>Hepatology</i> , 2010, 51, NA-NA.	3.6	81
331	Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. <i>Hepatology</i> , 2010, 51, 1514-1522.	3.6	90
332	Associations between serum lipids and hepatitis C antiviral treatment efficacy. <i>Hepatology</i> , 2010, 52, 854-863.	3.6	71

#	ARTICLE	IF	CITATIONS
333	GBV α C/hepatitis G virus infection and non α C Hodgkin lymphoma: a case control study. International Journal of Cancer, 2010, 126, 2885-2892.	2.3	51
334	The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003 \hat{a} €“2009. Birth Defects Research Part A: Clinical and Molecular Teratology, 2010, 88, 551-559.	1.6	60
335	Ten years later: A single hospital experience with malignancy in HIV/AIDS. Journal of Surgical Oncology, 2010, 102, 282-286.	0.8	8
336	Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: Social factors are important predictors after adjusting for known risk factors. Journal of Medical Virology, 2010, 82, 546-555.	2.5	185
337	Seroepidemiology of viral hepatitis, HIV and herpes simplex type 2 in the household population aged 21-64 years in Puerto Rico. BMC Infectious Diseases, 2010, 10, 76.	1.3	36
338	Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups. BMC Infectious Diseases, 2010, 10, 97.	1.3	13
339	The seroprevalence of hepatitis C virus (HCV) among 559,890 first \hat{a} €time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models. Transfusion, 2010, 50, 1505-1511.	0.8	18
340	Hepatitis C treatment completion rates in routine clinical care. Liver International, 2010, 30, 240-250.	1.9	58
341	Is the hepatitis C virus epidemic over in Egypt? Incidence and risk factors of new hepatitis C virus infections. Liver International, 2010, 30, 560-566.	1.9	60
342	Hepatitis C treatment completion in veterans: authors reply. Liver International, 2010, 30, 1083-1083.	1.9	2
343	Treatment Patterns and Adherence among Patients with Chronic Hepatitis C Virus in a US Managed Care Population. Value in Health, 2010, 13, 479-486.	0.1	29
344	17 β -estradiol inhibits the production of infectious particles of hepatitis C virus. Microbiology and Immunology, 2010, 54, 684-690.	0.7	54
345	Changes in quality of life and sexual health are associated with low \hat{a} €dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2010, 31, 719-734.	1.9	22
346	Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Alimentary Pharmacology and Therapeutics, 2010, 32, 535-542.	1.9	13
347	Meta \hat{a} €analysis: re \hat{a} €treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Alimentary Pharmacology and Therapeutics, 2010, 32, 969-983.	1.9	21
348	Understanding non-disclosure of deferrable risk: a study of blood donors with a history of intravenous drug use. Transfusion Medicine, 2010, 20, 15-21.	0.5	45
349	Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. Journal of Viral Hepatitis, 2010, 17, 59-64.	1.0	18
350	Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6. Journal of Viral Hepatitis, 2010, 17, 691-697.	1.0	38

#	ARTICLE	IF	CITATIONS
351	Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with Hepatitis C or HIV. <i>Journal of Viral Hepatitis</i> , 2010, 17, 720-729.	1.0	19
352	Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. <i>Transplant International</i> , 2010, 23, 1038-1044.	0.8	99
353	Routes of transmission of hepatitis C virus. <i>Annals of Hepatology</i> , 2010, 9, S30-S33.	0.6	10
354	Indications for treatment in chronic HCV infection. <i>Annals of Hepatology</i> , 2010, 9, S49-S53.	0.6	3
355	The management of HCV-infected pregnant women. <i>Annals of Hepatology</i> , 2010, 9, S92-S97.	0.6	28
357	Liver Disease After the Fontan Procedure. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 428-431.	1.1	33
358	Seroprevalence and risk factors of Hepatitis C Virus in patients and blood donors in Kano, Nigeria. <i>African Journal of Clinical and Experimental Microbiology</i> , 2010, 11, .	0.1	0
359	Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil. <i>Cadernos De Saude Publica</i> , 2010, 26, 1693-1704.	0.4	41
360	Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients. <i>PLoS ONE</i> , 2010, 5, e9032.	1.1	34
361	Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment. <i>International Journal of Medical Sciences</i> , 2010, 7, 36-42.	1.1	22
362	Seroprevalence of HCV and its co-infection with HBV and HIV among liver disease patients of South Tamil Nadu. <i>World Journal of Hepatology</i> , 2010, 2, 42.	0.8	16
363	Thyroid Function Outcomes after Pegylated Interferon- α and Ribavirin Therapy - For Chronic Hepatitis C. <i>Endocrine Practice</i> , 2010, 16, 934-939.	1.1	5
364	Hepatitis C Virus Infections from Unsafe Injection Practices at an Endoscopy Clinic in Las Vegas, Nevada, 2007-2008. <i>Clinical Infectious Diseases</i> , 2010, 51, 267-273.	2.9	101
365	Risk for Renal Cell Carcinoma in Chronic Hepatitis C Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1066-1073.	1.1	56
366	Hepatitis C Virus Infection Impairs IRF-7 Translocation and Alpha Interferon Synthesis in Immortalized Human Hepatocytes. <i>Journal of Virology</i> , 2010, 84, 10991-10998.	1.5	44
367	RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. <i>Rna</i> , 2010, 16, 2108-2119.	1.6	117
368	Hepatitis C Virus Prevalence and Clearance among US Blood Donors, 2006-2007: Associations with Birth Cohort, Multiple Pregnancies, and Body Mass Index. <i>Journal of Infectious Diseases</i> , 2010, 202, 576-584.	1.9	32
369	Prospective Follow-Up of Patients with Acute Hepatitis C Virus Infection in Brazil. <i>Clinical Infectious Diseases</i> , 2010, 50, 1222-1230.	2.9	21

#	ARTICLE	IF	CITATIONS
370	Disparities in Liver Cancer Incidence by Nativity, Acculturation, and Socioeconomic Status in California Hispanics and Asians. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3106-3118.	1.1	84
371	How Persons With Chronic Hepatitis C in Residential Substance Abuse Treatment Programs Think About Depression and Interferon Therapy. <i>Journal of the American Psychiatric Nurses Association</i> , 2010, 16, 350-356.	0.4	3
372	Prevalence of Hepatitis C in Two Inpatient Psychiatry Populations. <i>Australasian Psychiatry</i> , 2010, 18, 330-334.	0.4	16
373	Un sustrato biolÃ³gico para los trastornos somatomorfos. , 2010, , 61-70.		0
374	Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. <i>Gut</i> , 2010, 59, 1245-1251.	6.1	273
375	The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. <i>Oncologist</i> , 2010, 15, 5-13.	1.9	817
376	Preventive Healthcare for Underserved Women: Results of a Prison Survey. <i>Journal of Women's Health</i> , 2010, 19, 17-22.	1.5	78
377	Provider Reports on the Ability to Implement Changes in Practice Following HIV-HCV Training. <i>Journal of HIV/AIDS and Social Services</i> , 2010, 9, 27-44.	0.7	1
378	Global hepatitis, migration and its impact on Western healthcare. <i>Gut</i> , 2010, 59, 1009-1011.	6.1	24
379	Antiviral therapy for hepatitis C: why are so few patients being treated?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1327-1329.	1.3	29
380	A New Insight into Hepatitis C Vaccine Development. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-12.	3.0	37
381	Hepatitis C Increases the Risk of Progression of Chronic Kidney Disease in Patients with Glomerulonephritis. <i>American Journal of Nephrology</i> , 2010, 32, 311-316.	1.4	27
382	Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. <i>Modern Pathology</i> , 2010, 23, 276-283.	2.9	42
383	Associations Among Behavior-Related Susceptibility Factors in Porphyria Cutanea Tarda. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 297-302.e1.	2.4	61
384	A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 280-288.e1.	2.4	328
385	Lack of Association Between Hepatitis C Infection and Chronic Kidney Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 79-84.	2.4	44
386	Predictors of Early Treatment Discontinuation Among Patients With Genotype 1 Hepatitis C and Implications for Viral Eradication. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 972-978.	2.4	41
387	Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 924-933.	2.4	103

#	ARTICLE	IF	CITATIONS
388	Identification of substance use and dependence among patients with viral hepatitis. <i>Digestive and Liver Disease</i> , 2010, 42, 650-656.	0.4	8
389	Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C. <i>Optometry - Journal of the American Optometric Association</i> , 2010, 81, 580-586.	0.6	6
390	Incidence and mortality rates of selected infection-related cancers in Puerto Rico and in the United States. <i>Infectious Agents and Cancer</i> , 2010, 5, 10.	1.2	30
391	Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. <i>Gastroenterology</i> , 2010, 138, 513-521.e6.	0.6	797
392	Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin. <i>Gastroenterology</i> , 2010, 138, 2307-2314.	0.6	331
393	The Dawn of a New Era: Transforming Our Domestic Response to Hepatitis B & C. <i>Gastroenterology</i> , 2010, 138, 1225-1230.e3.	0.6	5
394	Multiple Clusters of Hepatitis Virus Infections Associated With Anesthesia for Outpatient Endoscopy Procedures. <i>Gastroenterology</i> , 2010, 139, 163-170.	0.6	51
395	Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate. <i>Gastroenterology</i> , 2010, 139, 1602-1611.e1.	0.6	102
396	Review: Hepatitis C virus replication and potential targets for direct-acting agents. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 43-53.	1.4	15
397	Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in Taiwan. <i>Journal of Hepatology</i> , 2010, 52, 160-166.	1.8	47
398	The natural history of hepatitis C infection acquired through injection drug use: Meta-analysis and meta-regression. <i>Journal of Hepatology</i> , 2010, 53, 245-251.	1.8	40
399	Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. <i>Journal of Clinical Virology</i> , 2010, 48, 15-17.	1.6	69
400	Socio-behavioral and geographic correlates of prevalent hepatitis C virus infection among young injection drug users in metropolitan Baltimore and Chicago. <i>Drug and Alcohol Dependence</i> , 2010, 111, 136-145.	1.6	31
401	Seropositive Abdominal and Thoracic Donor Organs Are Largely Underutilized. <i>Transplantation Proceedings</i> , 2010, 42, 4479-4487.	0.3	5
402	Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C. <i>Vaccine</i> , 2010, 28, 1726-1731.	1.7	5
403	Combined effects of alcohol and hepatitis C: A secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence. <i>Addictive Behaviors</i> , 2010, 35, 123-128.	1.7	6
404	An intervention to prevent symptoms associated with hepatitis C: a pilot study. <i>Applied Nursing Research</i> , 2010, 23, 116-120.	1.0	4
405	Interferon-Induced Psychosis as a "Psychiatric Contraindication" to Hepatitis C Treatment: A Review and Case-Based Discussion. <i>Psychosomatics</i> , 2010, 51, 1-7.	2.5	11

#	ARTICLE	IF	CITATIONS
406	Prophylactic Antidepressant Treatment in Patients With Hepatitis C on Antiviral Therapy: A Double-Blind, Placebo-Controlled Trial. <i>Psychosomatics</i> , 2010, 51, 401-408.	2.5	40
407	Epidemiology of Hepatitis B and C Viruses: A Global Overview. <i>Clinics in Liver Disease</i> , 2010, 14, 1-21.	1.0	389
408	Peginterferon $\hat{1}\pm$ 2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATINO Study. <i>American Journal of Gastroenterology</i> , 2010, 105, 2177-2185.	0.2	17
409	Preventing infections in patients undergoing hemodialysis. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 643-655.	2.0	25
410	Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 349-356.	0.6	31
411	Hepatitis C and metabolic syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 209-215.	1.2	0
412	Pegylated interferons $\hat{1}\pm$ 2a and $\hat{1}\pm$ 2b in the treatment of chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 485-494.	8.2	62
413	Treatment of chronic hepatitis C in elderly patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 571-577.	0.9	7
414	Role of ribavirin in HCV treatment response: now and in the future. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 673-683.	0.9	25
415	Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure. <i>Current Medical Research and Opinion</i> , 2011, 27, 1339-1346.	0.9	6
416	Treatment of acute HCV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 265-274.	8.2	53
417	Does a Little Bit Really Go a Long Way? Infection Prevention in Ambulatory Healthcare Facilities. <i>Infection Control and Hospital Epidemiology</i> , 2011, 32, 425-427.	1.0	0
418	Patient-Care Practices Associated with an Increased Prevalence of Hepatitis C Virus Infection among Chronic Hemodialysis Patients. <i>Infection Control and Hospital Epidemiology</i> , 2011, 32, 415-424.	1.0	42
419	Naives, Nonresponders, Relapsers: Who Is There Left to Treat?. <i>Clinics in Liver Disease</i> , 2011, 15, 483-495.	1.0	6
420	Nonalcoholic Fatty Liver Disease: Pharmacologic and Surgical Options. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 541-559.	1.0	4
421	The NS5A Replication Complex Inhibitors: Difference Makers?. <i>Clinics in Liver Disease</i> , 2011, 15, 627-639.	1.0	28
422	Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study. <i>Gastroenterology</i> , 2011, 140, 124-131.	0.6	1,856
423	Changes in Insulin Sensitivity and Body Weight During and After Peginterferon and Ribavirin Therapy for Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 469-477.	0.6	63

#	ARTICLE	IF	CITATIONS
424	Increasing Prevalence of HCC and Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2011, 140, 1182-1188.e1.	0.6	349
425	Lymphocytosis as a predictor of poor response to treatment of hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 34-40.	0.7	2
426	Chronic hepatitis C infection in the elderly. <i>Kaohsiung Journal of Medical Sciences</i> , 2011, 27, 533-537.	0.8	20
427	Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2429-2438.	13.9	403
428	Simultaneous Genotyping of rs12979860 and rs8099917 Variants Near the IL28B Locus Associated with HCV Clearance and Treatment Response. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 446-451.	1.2	26
429	Level of α -Fetoprotein Predicts Mortality Among Patients With Hepatitis C-Related Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 989-994.	2.4	45
430	Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C. <i>Annals of Pharmacotherapy</i> , 2011, 45, 639-648.	0.9	20
431	A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 509-516.e1.	2.4	431
432	Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymorphisms in hepatitis C virus (HCV) infection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1247-1256.	1.4	18
433	Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia. <i>Journal of Medical Economics</i> , 2011, 14, 194-206.	1.0	19
434	Familismo: influence on Hispanic health behaviors. <i>Applied Nursing Research</i> , 2011, 24, e67-e72.	1.0	57
435	Number of portal tract macrophages correlates with the modified hepatic activity index in chronic hepatitis C infection. <i>Annals of Diagnostic Pathology</i> , 2011, 15, 103-107.	0.6	1
436	Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users. <i>Drug and Alcohol Dependence</i> , 2011, 119, 166-171.	1.6	16
437	Cervicovaginal shedding of hepatitis C viral RNA is associated with the presence of menstrual or other blood in cervicovaginal fluids. <i>Journal of Clinical Virology</i> , 2011, 50, 4-7.	1.6	6
438	A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 182 Td	2.0	50
439	Visualizing ATP-Dependent RNA Translocation by the NS3 Helicase from HCV. <i>Journal of Molecular Biology</i> , 2011, 405, 1139-1153.	2.0	98
440	Current drug discovery strategies for treatment of hepatitis C virus infection. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 883-892.	1.2	9
441	An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C. <i>Clinics in Liver Disease</i> , 2011, 15, 515-536.	1.0	20

#	ARTICLE	IF	CITATIONS
442	Involvement of autophagy in alcoholic liver injury and hepatitis C pathogenesis. <i>World Journal of Gastroenterology</i> , 2011, 17, 2507.	1.4	34
443	Electronic Matching of HIV/AIDS and Hepatitis C Surveillance Registries in Three States. <i>Public Health Reports</i> , 2011, 126, 344-348.	1.3	9
444	The Prevalence of Viral Hepatitis C in Latvia: A Population-Based Study. <i>Medicina (Lithuania)</i> , 2011, 47, 76.	0.8	13
445	Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. <i>Annals of Hepatology</i> , 2011, 10, 452-457.	0.6	22
446	Heavy Alcohol Use and Premature Death from Hepatocellular Carcinoma in the United States, 1999-2006. <i>Journal of Studies on Alcohol and Drugs</i> , 2011, 72, 892-902.	0.6	12
447	Durability of Sustained Virologic Response in Chronic Hepatitis C: Analysis of Factors Related to Relapse after Sustained Virologic Response with Peginterferon Plus Ribavirin Combination Therapy. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2011, 57, 173.	0.2	4
448	All-Cause and Incremental Per Patient Per Year Cost Associated with Chronic Hepatitis C Virus and Associated Liver Complications in the United States: A Managed Care Perspective. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 531-546.	2.2	144
449	Prevalence of HCV Risk Behaviors Among Prison Inmates: Tattooing and Injection Drug Use. <i>Journal of Health Care for the Poor and Underserved</i> , 2011, 22, 962-982.	0.4	22
450	Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis. <i>PLoS ONE</i> , 2011, 6, e20104.	1.1	11
451	Prevalence of Metabolic Syndrome and Risks of Abnormal Serum Alanine Aminotransferase in Hispanics: A Population-Based Study. <i>PLoS ONE</i> , 2011, 6, e21515.	1.1	42
452	Unmet Needs Among People Reported With Hepatitis C, New York City. <i>Journal of Public Health Management and Practice</i> , 2011, 17, E9-E17.	0.7	6
453	Economic Costs of Nonmedical Use of Prescription Opioids. <i>Clinical Journal of Pain</i> , 2011, 27, 194-202.	0.8	164
454	Hepatitis C Treatment Completion in Individuals With Psychiatric Comorbidity and Depression. <i>Gastroenterology Nursing</i> , 2011, 34, 102-106.	0.2	5
455	Public Health Implications of Rapid Hepatitis C Screening With an Oral Swab for Community-Based Organizations Serving High-Risk Populations. <i>American Journal of Public Health</i> , 2011, 101, 2151-2155.	1.5	67
456	An Overview of Elastography-An Emerging Branch of Medical Imaging. <i>Current Medical Imaging</i> , 2011, 7, 255-282.	0.4	340
457	Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006. <i>Archives of Internal Medicine</i> , 2011, 171, 242.	4.3	144
458	Changing Trends in Viral Hepatitis-Associated Hospitalizations in the American Indian/Alaska Native Population, 1995-2007. <i>Public Health Reports</i> , 2011, 126, 816-825.	1.3	10
459	Psychosocial Correlates of Alcohol Use and Reduction for Individuals With Hepatitis C. <i>Journal of Studies on Alcohol and Drugs</i> , 2011, 72, 787-798.	0.6	7

#	ARTICLE	IF	CITATIONS
460	Human cytomegalovirus infection inhibits response of chronic hepatitis C virus-infected patients to interferon-based therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 55-62.	1.4	27
461	Use of the AST to platelet ratio index in HCV/HIV co-infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 566-577.	1.9	30
462	Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver. <i>Journal of Viral Hepatitis</i> , 2011, 18, 53-60.	1.0	15
463	The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. <i>Journal of Viral Hepatitis</i> , 2011, 18, 506-512.	1.0	30
464	Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. <i>Journal of Viral Hepatitis</i> , 2011, 18, 474-481.	1.0	58
465	Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys. <i>Journal of Viral Hepatitis</i> , 2011, 18, 571-579.	1.0	17
466	Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort. <i>Journal of Viral Hepatitis</i> , 2011, 18, e144-52.	1.0	22
467	Hepatitis C virus infection during pregnancy and the newborn period “ are they opportunities for treatment?. <i>Journal of Viral Hepatitis</i> , 2011, 18, 229-236.	1.0	83
468	Expression of common housekeeping genes is affected by disease in human hepatitis C virus-infected liver. <i>Liver International</i> , 2011, 31, 386-390.	1.9	18
469	Future hepatitis C virus treatment: interferon-sparing combinations. <i>Liver International</i> , 2011, 31, 62-67.	1.9	36
470	The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients. <i>Liver International</i> , 2011, 31, 53-57.	1.9	28
471	Hepatitis C virus infection in USA: an estimate of true prevalence. <i>Liver International</i> , 2011, 31, 1090-1101.	1.9	355
472	Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. <i>Liver International</i> , 2011, 31, 4-17.	1.9	42
473	Trends and projections of hepatitis C virus epidemiology in Latin America. <i>Liver International</i> , 2011, 31, 18-29.	1.9	115
474	Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes. <i>Liver International</i> , 2011, 31, 1163-1170.	1.9	138
475	Psychiatric and Substance Use Disorders among Methadone Maintenance Patients with Chronic Hepatitis C Infection: Effects on Eligibility for Hepatitis C Treatment. <i>American Journal on Addictions</i> , 2011, 20, 312-318.	1.3	22
476	Alcohol-Related and Viral Hepatitis C-Related Cirrhosis Mortality among Hispanic Subgroups in the United States, 2000-2004. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 240-249.	1.4	35
477	Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. <i>Oncogene</i> , 2011, 30, 1969-1983.	2.6	187

#	ARTICLE	IF	CITATIONS
478	Perspective: Test and treat this silent killer. <i>Nature</i> , 2011, 474, s18-s19.	13.7	69
479	Risk of Window Period Hepatitis-C Infection in High Infectious Risk Donors: Systematic Review and Meta-Analysis. <i>American Journal of Transplantation</i> , 2011, 11, 1188-1200.	2.6	138
480	Hepatitis C Virus Infection Among Adolescents and Young Adults—Massachusetts, 2002–2009. <i>American Journal of Transplantation</i> , 2011, 11, 1535-1538.	2.6	51
481	Does geographic access to primary healthcare influence the detection of hepatitis C?. <i>Social Science and Medicine</i> , 2011, 72, 1472-1481.	1.8	27
482	Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. <i>Journal of Virological Methods</i> , 2011, 172, 27-31.	1.0	94
483	Current Therapies for Chronic Hepatitis C. <i>Pharmacotherapy</i> , 2011, 31, 92-111.	1.2	9
484	Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. <i>Pharmacotherapy</i> , 2011, 31, 951-974.	1.2	8
485	Importance of Low Preoperative Platelet Count in Selecting Patients for Resection of Hepatocellular Carcinoma: A Multi-Institutional Analysis. <i>Journal of the American College of Surgeons</i> , 2011, 212, 638-648.	0.2	105
486	Economic Burden Associated With Patients Diagnosed With Hepatitis C. <i>Clinical Therapeutics</i> , 2011, 33, 1268-1280.	1.1	43
487	Transmission of Hepatitis C Virus During Myocardial Perfusion Imaging in an Outpatient Clinic. <i>American Journal of Cardiology</i> , 2011, 108, 126-132.	0.7	26
488	Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity?. <i>General Hospital Psychiatry</i> , 2011, 33, 354-362.	1.2	44
489	Formal Patient Education Improves Patient Knowledge of Hepatitis C in Vulnerable Populations. <i>Digestive Diseases and Sciences</i> , 2011, 56, 213-219.	1.1	62
490	U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for "Difficult-to-Treat" HCV Genotype 1 Patients. <i>Digestive Diseases and Sciences</i> , 2011, 56, 880-888.	1.1	6
491	Dietary History and Physical Activity and Risk of Advanced Liver Disease in Veterans with Chronic Hepatitis C Infection. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1835-1847.	1.1	4
492	Clinical Significance of Perihepatic Lymphadenopathy in Patients with Chronic Hepatitis C Infection. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2137-2144.	1.1	7
493	Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1509-1515.	1.1	8
494	Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to Pegylated Interferon and Ribavirin: A National VA Clinical Practice Study. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2439-2448.	1.1	7
495	Peginterferon Alfa-2a Is Superior to Peginterferon Alfa-2b in the Treatment of Naïve Patients with Hepatitis C Virus Infection: Meta-Analysis of Randomized Controlled Trials. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2221-2226.	1.1	22

#	ARTICLE	IF	CITATIONS
496	An Interrupted Time Series Evaluation of a Hepatitis C Intervention for Persons with HIV. <i>AIDS and Behavior</i> , 2011, 15, 1721-1731.	1.4	7
497	Quantitative measurement of human anti-HCV Core immunoglobulins on an electrical biochip platform. <i>Biosensors and Bioelectronics</i> , 2011, 26, 1895-1901.	5.3	11
498	News from the CDC: Translating science into HCV infection screening recommendations. <i>Translational Behavioral Medicine</i> , 2011, 1, 509-510.	1.2	0
499	Hepatitis Bâ€”More Treatments, More Testing, Not Enough Data. <i>Journal of General Internal Medicine</i> , 2011, 26, 232-233.	1.3	0
500	Extrahepatic Manifestations of Hepatitis C Virus Infection: Mixed Cryoglobulinemia and Beyond. <i>Current Hepatitis Reports</i> , 2011, 10, 11-18.	0.3	0
501	Management of Hepatitis C Antiviral Therapy Adverse Effects. <i>Current Hepatitis Reports</i> , 2011, 10, 33-40.	0.3	31
502	Patient acceptance of universal screening for hepatitis C virus infection. <i>BMC Infectious Diseases</i> , 2011, 11, 160.	1.3	14
503	Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study. <i>BMC Endocrine Disorders</i> , 2011, 11, 10.	0.9	4
504	The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. <i>Thrombosis Journal</i> , 2011, 9, 1.	0.9	94
505	Risk factors associated with Hepatitis C among female substance users enrolled in community-based HIV prevention studies. <i>BMC Research Notes</i> , 2011, 4, 126.	0.6	20
506	Outcomes of orthotopic liver transplantation for hepatic sarcoidosis: An analysis of the United Network for organ sharing/organ Procurement and Transplantation Network data files for a comparative study with cholestatic liver diseases. <i>Liver Transplantation</i> , 2011, 17, 1027-1034.	1.3	44
507	Genotypes and viral load of hepatitis C virus among persons attending a voluntary counseling and testing center in Ethiopia. <i>Journal of Medical Virology</i> , 2011, 83, 776-782.	2.5	14
508	Transmission of Hepatitis C virus among spouses in Cameroon and the Central African Republic. <i>Journal of Medical Virology</i> , 2011, 83, 2113-2118.	2.5	6
509	Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. <i>Hepatology</i> , 2011, 53, 42-52.	3.6	49
510	Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes. <i>Hepatology</i> , 2011, 53, 406-414.	3.6	179
511	Racial differences in hepatitis C treatment eligibility. <i>Hepatology</i> , 2011, 54, 70-78.	3.6	47
512	Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?. <i>Hepatology</i> , 2011, 54, 1118-1120.	3.6	19
513	Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: Inhibitors of hepatitis C virus and HIV-1 replication. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 4616-4625.	1.4	16

#	ARTICLE	IF	CITATIONS
514	Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment. <i>Infection, Genetics and Evolution</i> , 2011, 11, 382-390.	1.0	8
515	Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. <i>Rheumatology</i> , 2011, 50, 1700-1711.	0.9	127
516	Therapeutic Targeting of HCV Internal Ribosomal Entry Site RNA. <i>Antiviral Chemistry and Chemotherapy</i> , 2011, 21, 117-128.	0.3	35
517	Importance of Patient, Provider, and Facility Predictors of Hepatitis C Virus Treatment in Veterans: A National Study. <i>American Journal of Gastroenterology</i> , 2011, 106, 483-491.	0.2	71
518	A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 973-979.	0.5	14
519	Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 365-370.	1.4	41
520	Evaluation of Three Rapid Screening Assays for Detection of Antibodies to Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2011, 204, 825-831.	1.9	89
521	All-Cause, Liver-Related, and Non-Liver-Related Mortality Among HCV-Infected Individuals in the General US Population. <i>Clinical Infectious Diseases</i> , 2011, 53, 150-157.	2.9	133
522	Performance of Premarket Rapid Hepatitis C Virus Antibody Assays in 4 National Human Immunodeficiency Virus Behavioral Surveillance System Sites. <i>Clinical Infectious Diseases</i> , 2011, 53, 780-786.	2.9	71
523	Multiple Comorbid Conditions among Middle-Aged and Elderly Hemophilia Patients: Prevalence Estimates and Implications for Future Care. <i>Journal of Aging Research</i> , 2011, 2011, 1-8.	0.4	20
524	Total Numbers of Undiagnosed Carriers of Hepatitis C and B Viruses in Japan Estimated by Age- and Area-Specific Prevalence on the National Scale. <i>Intervirology</i> , 2011, 54, 185-195.	1.2	146
525	Enhancing Drug Treatment Program Staff's Self-Efficacy to Support Patients' HCV Needs. <i>Journal of Social Work Practice in the Addictions</i> , 2011, 11, 254-269.	0.4	3
526	Comparison of Serial Hepatitis C Virus Detection in Samples Submitted through Serology for Reflex Confirmation versus Samples Directly Submitted for Quantitation. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3036-3039.	1.8	15
527	Hepatitis C Virus Genotypes in Clinical Specimens Tested at a National Reference Testing Laboratory in the United States. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3040-3043.	1.8	29
528	Improved Reflexive Testing Algorithm for Hepatitis C Infection Using Signal-to-Cutoff Ratios of a Hepatitis C Virus Antibody Assay. <i>Clinical Chemistry</i> , 2011, 57, 1050-1056.	1.5	27
529	The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. <i>Journal of Medical Economics</i> , 2011, 14, 253-261.	1.0	60
530	Telaprevir for the treatment of chronic hepatitis C infection. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 1105-1114.	2.0	12
531	Barriers to Providing Health Services for HIV/AIDS, Hepatitis C Virus Infection and Sexually Transmitted Infections in Substance Abuse Treatment Programs in the United States. <i>Journal of Addictive Diseases</i> , 2011, 30, 98-109.	0.8	31

#	ARTICLE	IF	CITATIONS
532	A Multicenter Retrospective Study on Clinical Characteristics, Treatment Patterns, and Outcome in Elderly Patients with Hepatocellular Carcinoma. <i>Oncologist</i> , 2011, 16, 310-318.	1.9	33
533	Community and personal risk factors for hepatitis C virus infection: a survey of 23 820 residents in Taiwan in 1991-2. <i>Gut</i> , 2011, 60, 688-694.	6.1	66
534	It Is Time to Change the Paradigm for Hepatitis C Virus Testing. <i>Clinical Infectious Diseases</i> , 2012, 54, 1272-1274.	2.9	6
535	Boceprevir and personalized medicine in hepatitis C virus infection. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, Volume 5, 125-137.	0.4	4
536	Hepatitis C Virus in American Indian/Alaskan Native and Aboriginal Peoples of North America. <i>Viruses</i> , 2012, 4, 3912-3931.	1.5	25
537	Differences in substance-related risk behavior between dual and triple diagnosed severely mentally ill adults. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2012, 5, 52-63.	0.5	2
538	New Protease Inhibitors for the Treatment of Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 2012, 156, 279.	2.0	176
539	Hepatitis C Virus Upregulates Beclin1 for Induction of Autophagy and Activates mTOR Signaling. <i>Journal of Virology</i> , 2012, 86, 8705-8712.	1.5	145
540	Hepatitis C therapy update. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 188-192.	1.0	27
541	Performance of the Abbott RealTime HCV Genotype II RUO Assay. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3099-3101.	1.8	16
542	Evolving Epidemiology of Hepatitis C Virus in the United States. <i>Clinical Infectious Diseases</i> , 2012, 55, S3-S9.	2.9	179
543	Compliance With Bloodborne Pathogen Standards at Eight Correctional Facilities. <i>Journal of Correctional Health Care</i> , 2012, 18, 29-44.	0.2	5
544	Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. <i>Clinical Trials</i> , 2012, 9, 102-112.	0.7	19
545	Overcoming Barriers to Care for Hepatitis C. <i>New England Journal of Medicine</i> , 2012, 366, 2436-2438.	13.9	26
546	New challenges in viral hepatitis. <i>Gut</i> , 2012, 61, i1-i5.	6.1	24
547	Prevalence and Temporal Trends of Hepatitis B, Hepatitis C, and HIV/AIDS Co-infection During Pregnancy Across the Decade, 1998-2007. <i>Journal of Women's Health</i> , 2012, 21, 66-72.	1.5	12
548	Boceprevir: A recently approved protease inhibitor for hepatitis C virus infection. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 2135-2139.	0.5	4
549	Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence. <i>Clinical Infectious Diseases</i> , 2012, 55, 1047-1055.	2.9	154

#	ARTICLE	IF	CITATIONS
550	The Performance of Process Measures in Hepatitis C. <i>American Journal of Gastroenterology</i> , 2012, 107, 1512-1521.	0.2	17
551	Multiple Mutations in Hepatitis C Virus NS5A Domain II Are Required To Confer a Significant Level of Resistance to Alisporivir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5113-5121.	1.4	39
552	Identification of Hepatitis C Virus Inhibitors Targeting Different Aspects of Infection Using a Cell-Based Assay. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6109-6120.	1.4	9
553	The association between use of non-injection drug implements and hepatitis C virus antibody status in homeless and marginally housed persons in San Francisco. <i>Journal of Public Health</i> , 2012, 34, 330-339.	1.0	11
554	Cyclophilin involvement in the replication of hepatitis C virus and other viruses. <i>Biological Chemistry</i> , 2012, 393, 579-587.	1.2	19
555	Compliance of Healthcare Professionals with Safety Measures for Control of Hepatitis Viruses in Hemodialysis Centers: An Experience from Southeast Iran. <i>Hepatitis Research and Treatment</i> , 2012, 2012, 1-5.	2.0	2
556	The Cyclophilin Inhibitor SCY-635 Disrupts Hepatitis C Virus NS5A-Cyclophilin A Complexes. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3888-3897.	1.4	54
557	Neurocognitive Effects of HIV, Hepatitis C, and Substance Use History. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 68-78.	1.2	60
558	Hepatitis C and substance use. <i>Current Opinion in Psychiatry</i> , 2012, 25, 206-212.	3.1	6
559	Centers for Disease Control and Prevention Initiatives to Prevent Hepatitis C Virus Infection: A Selective Update. <i>Clinical Infectious Diseases</i> , 2012, 55, S49-S53.	2.9	38
560	Viral Hepatitis in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 500-505.	0.9	11
561	Prevalence of Fibromyalgia Among Patients With Chronic Hepatitis C Infection. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 407-412.	1.1	33
562	Demographic, Risk, and Spatial Factors Associated With Over-the-Counter Syringe Purchase Among Injection Drug Users. <i>American Journal of Epidemiology</i> , 2012, 176, 14-23.	1.6	19
563	Improving Access to Hepatitis C Care for Urban, Underserved Patients Using a Primary Care-Based Hepatitis C Clinic. <i>Journal of the National Medical Association</i> , 2012, 104, 244-250.	0.6	17
564	Effectiveness of a Risk Screener in Identifying Hepatitis C Virus in a Primary Care Setting. <i>American Journal of Public Health</i> , 2012, 102, e115-e121.	1.5	39
565	NASPGHAN Practice Guidelines. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 838-855.	0.9	176
566	Hepatitis C virus infection in alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1178-1184.	0.8	48
567	African Americans Are Less Likely to Have Clearance of Hepatitis C Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, e62-e65.	1.1	15

#	ARTICLE	IF	CITATIONS
568	Comparison of Current US Risk Strategy to Screen for Hepatitis C Virus With a Hypothetical Targeted Birth Cohort Strategy. <i>American Journal of Public Health</i> , 2012, 102, e101-e106.	1.5	17
570	Rapid diagnostic HCV antibody assays. <i>Antiviral Therapy</i> , 2012, 17, 1409-1413.	0.6	11
571	Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection. <i>International Journal of Circumpolar Health</i> , 2012, 71, 18445.	0.5	10
572	The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007. <i>Annals of Internal Medicine</i> , 2012, 156, 271.	2.0	643
573	The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings. <i>Annals of Internal Medicine</i> , 2012, 156, 263.	2.0	278
574	Hepatitis C Virus Testing of Persons Born During 1945-1965: Recommendations From the Centers for Disease Control and Prevention. <i>Annals of Internal Medicine</i> , 2012, 157, 817.	2.0	263
575	Impact of hepatitis B and C infection on health services utilization in homeless adults: A test of the Gelberg-Andersen behavioral model for vulnerable populations.. <i>Health Psychology</i> , 2012, 31, 20-30.	1.3	58
576	A telehealth intervention for veterans on antiviral treatment for the hepatitis C virus.. <i>Psychological Services</i> , 2012, 9, 163-173.	0.9	10
578	Chronic Pain Treatment and Health Service Utilization of Veterans with Hepatitis C Virus Infection. <i>Pain Medicine</i> , 2012, 13, 1407-1416.	0.9	9
579	Suppression of Viral RNA Binding and the Assembly of Infectious Hepatitis C Virus Particles <i>In Vitro</i> by Cyclophilin Inhibitors. <i>Journal of Virology</i> , 2012, 86, 12616-12624.	1.5	31
580	Knowledge, attitudes and barriers regarding vaccination against hepatitis A and B in patients with chronic hepatitis C virus infection: a survey of family medicine and internal medicine physicians in the United States. <i>International Journal of Clinical Practice</i> , 2012, 66, 1009-1013.	0.8	14
581	The Burden of Untreated Hepatitis C Virus Infection: A US Patients' Perspective. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2995-3003.	1.1	37
582	A Pharmacological Profile of Ribavirin and Monitoring of its Plasma Concentration in Chronic Hepatitis C Infection. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 42-54.	0.4	19
583	Population Pharmacokinetics and Pharmacodynamics of Ribavirin in Patients with Chronic Hepatitis C Genotype 1 Infection. <i>AAPS Journal</i> , 2012, 14, 571-580.	2.2	18
584	Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. <i>Hepatology</i> , 2012, 56, 1651-1660.	3.6	98
585	Risk of hip fracture associated with hepatitis c virus infection and hepatitis C/human immunodeficiency virus coinfection. <i>Hepatology</i> , 2012, 56, 1688-1698.	3.6	68
586	Projected future increase in aging hepatitis C virus-infected liver transplant candidates: A potential effect of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2012, 18, 1471-1478.	1.3	66
587	Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. <i>Human Genetics</i> , 2012, 131, 1911-1920.	1.8	13

#	ARTICLE	IF	CITATIONS
588	Prevalence of Hepatitis C Virus Infection in the Veteran Population Undergoing Total Joint Arthroplasty. <i>Journal of Arthroplasty</i> , 2012, 27, 1772-1776.	1.5	22
589	Screening for Infectious Diseases in the Dental Setting. <i>Dental Clinics of North America</i> , 2012, 56, 809-818.	0.8	7
590	Expected and Actual Case Ascertainment and Treatment Rates for Children Infected with Hepatitis C in Florida and the United States: Epidemiologic Evidence from Statewide and Nationwide Surveys. <i>Journal of Pediatrics</i> , 2012, 161, 915-921.	0.9	59
591	Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 424-432.	1.5	57
592	Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey. <i>Indian Journal of Gastroenterology</i> , 2012, 31, 232-236.	0.7	45
593	Viral Hepatitis Among Somali Immigrants in Minnesota: Association of Hepatitis C With Hepatocellular Carcinoma. <i>Mayo Clinic Proceedings</i> , 2012, 87, 17-24.	1.4	36
594	Process of Care for Hepatitis C Infection Is Linked to Treatment Outcome and Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1270-1277.e3.	2.4	16
595	Hepatitis C and the Hand Surgeon: What You Should Know. <i>Journal of Hand Surgery</i> , 2012, 37, 1711-1713.	0.7	1
596	Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 820-827.	0.6	15
597	Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 35-40.	1.2	9
598	Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. <i>New England Journal of Medicine</i> , 2012, 366, 216-224.	13.9	580
599	GS-7977: a promising nucleotide analog NS5B polymerase inhibitor of HCV. <i>Future Virology</i> , 2012, 7, 537-546.	0.9	7
600	Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C. <i>Clinical Infectious Diseases</i> , 2012, 54, 1259-1271.	2.9	95
601	Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness. <i>Addictive Behaviors</i> , 2012, 37, 552-555.	1.7	17
602	Gaps in the achievement of effectiveness of HCV treatment in national VA practice. <i>Journal of Hepatology</i> , 2012, 56, 320-325.	1.8	86
603	A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. <i>Journal of Hepatology</i> , 2012, 56, 1012-1018.	1.8	34
604	A population-based study of the epidemiology of hepatitis C in a North American population. <i>Journal of Hepatology</i> , 2012, 57, 736-742.	1.8	22
605	Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Tj ETQq1 1 0.784314 rgBT /Cue Virology, 2012, 54, 213-217.	1.6	38

#	ARTICLE	IF	CITATIONS
606	Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States. <i>Journal of Substance Abuse Treatment</i> , 2012, 42, 438-445.	1.5	13
607	The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan. <i>Hepatology</i> , 2012, 56, 1223-1230.	3.6	27
608	Comparison of hepatitis C virus treatment between incarcerated and community patients. <i>Hepatology</i> , 2012, 56, 1252-1260.	3.6	32
609	A great time to invest in baby Boomer's hepatitis C!. <i>Hepatology</i> , 2012, 56, 1575-1577.	3.6	0
610	The high comorbidity burden of the hepatitis C virus infected population in the United States. <i>BMC Infectious Diseases</i> , 2012, 12, 86.	1.3	70
611	Diagnosis and Treatment of Acute Hepatitis C Virus Infection. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 995-1010.	1.9	16
612	Factors associated with <scp>HCV</scp> antiviral treatment uptake among participants of a community-based <scp>HCV</scp> programme for marginalized patients. <i>Journal of Viral Hepatitis</i> , 2012, 19, 836-842.	1.0	49
613	The expression kinetics of CD137 in chronic hepatitis C patients treated with pegylated-interferon and ribavirin. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 601-606.	0.6	3
614	IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population. <i>PLoS ONE</i> , 2012, 7, e37054.	1.1	85
615	Ethanol and Hepatitis <scp>C</scp> Virus Suppress Peptide- <i>“</i> <scp>MHC</scp> Class <scp>I</scp> Presentation in Hepatocytes by Altering Proteasome Function. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 2028-2035.	1.4	17
616	Accessing Hepatitis <scp>C</scp> patients who are difficult to reach: it is time to overcome barriers. <i>Journal of Viral Hepatitis</i> , 2012, 19, 829-835.	1.0	80
617	Cancer-related risk factors and preventive measures in US Hispanics/Latinos. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 353-363.	157.7	46
618	New Pharmacotherapy for Hepatitis C. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 294-305.	2.3	24
619	Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 962-968.	0.6	26
620	Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. <i>Antiviral Research</i> , 2012, 96, 82-89.	1.9	27
621	Public health issues of hepatitis C virus infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 371-380.	1.0	30
622	Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. <i>Digestive and Liver Disease</i> , 2012, 44, 497-503.	0.4	72
623	Alcohol's Effect on Other Chronic Liver Diseases. <i>Clinics in Liver Disease</i> , 2012, 16, 827-837.	1.0	21

#	ARTICLE	IF	CITATIONS
624	Neutralization Interfering Antibodies: A "Novel" Example of Humoral Immune Dysfunction Facilitating Viral Escape?. <i>Viruses</i> , 2012, 4, 1731-1752.	1.5	26
625	Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). <i>Clinical and Translational Oncology</i> , 2012, 14, 564-574.	1.2	12
626	Prevalence and clinical presentations of hepatitis C virus among patients admitted to the rheumatology ward. <i>Rheumatology International</i> , 2012, 32, 2691-2695.	1.5	17
627	Transmission of Hepatitis C Virus Infection Through Tattooing and Piercing: A Critical Review. <i>Clinical Infectious Diseases</i> , 2012, 54, 1167-1178.	2.9	108
628	Hepatorenal Index as an Accurate, Simple, and Effective Tool in Screening for Steatosis. <i>American Journal of Roentgenology</i> , 2012, 199, 997-1002.	1.0	95
629	Viral Hepatitis in the Elderly. <i>American Journal of Gastroenterology</i> , 2012, 107, 691-697.	0.2	40
630	Association between Serum Interleukin-6 Concentrations and Mortality in Older Adults: The Rancho Bernardo Study. <i>PLoS ONE</i> , 2012, 7, e34218.	1.1	58
631	Incidence Analyses and Space-Time Cluster Detection of Hepatitis C in Fujian Province of China from 2006 to 2010. <i>PLoS ONE</i> , 2012, 7, e40872.	1.1	6
632	Analysis of the Virus Dynamics Model Reveals That Early Treatment of HCV Infection May Lead to the Sustained Virological Response. <i>PLoS ONE</i> , 2012, 7, e41209.	1.1	5
633	Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users. <i>PLoS ONE</i> , 2012, 7, e45176.	1.1	52
634	Animal Models of Cutaneous and Hepatic Fibrosis. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 105, 371-409.	0.9	7
635	Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients. <i>Annals of Hepatology</i> , 2012, 11, 450-463.	0.6	0
636	Risk Factors for Infection with Different Hepatitis C Virus Genotypes in Southern Brazil. <i>Scientific World Journal</i> , The, 2012, 2012, 1-6.	0.8	11
637	Hepatitis in the Elderly: Still a Scourge. <i>The Consultant Pharmacist</i> , 2012, 27, 472-481.	0.4	2
638	Prevalence, Distribution, and Correlates of Hepatitis C Virus Infection among Homeless Adults in Los Angeles. <i>Public Health Reports</i> , 2012, 127, 407-421.	1.3	69
639	Hepatitis C among Clients of Health Care for the Homeless Primary Care Clinics. <i>Journal of Health Care for the Poor and Underserved</i> , 2012, 23, 811-833.	0.4	48
640	Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. <i>Patient Preference and Adherence</i> , 2012, 6, 285.	0.8	17
641	Epidemiology of Lymphoid Malignancy in Asia. , 0, , .		9

#	ARTICLE	IF	CITATIONS
642	An Investigation of Bloodborne Pathogen Transmission Due to Multipatient Sharing of Insulin Pens. <i>Military Medicine</i> , 2012, 177, 930-938.	0.4	9
643	Raising Awareness of Viral Hepatitis: National Hepatitis Testing Day, May 19. <i>Public Health Reports</i> , 2012, 127, 244-245.	1.3	3
644	Prevalência da hepatite viral C em adultos usuÁrios de serviço pblico de sade do municpio de So Jos dos Pinhais - Paran. <i>Revista Brasileira De Epidemiologia</i> , 2012, 15, 627-638.	0.3	12
645	Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. <i>Pharmacotherapy</i> , 2012, 32, 173-190.	1.2	18
646	Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 1225-1232.	1.3	6
647	Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. <i>Journal of Medical Virology</i> , 2012, 84, 1376-1387.	2.5	21
648	ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfectd with HIV and HCV. <i>Journal of Medical Virology</i> , 2012, 84, 1106-1114.	2.5	15
649	Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 765-769.	0.9	121
650	Economic model of a birth cohort screening program for hepatitis C virus. <i>Hepatology</i> , 2012, 55, 1344-1355.	3.6	102
651	Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. <i>Hepatology</i> , 2012, 55, 1652-1661.	3.6	319
652	Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users. <i>Hepatology</i> , 2012, 56, 544-554.	3.6	15
653	Hepatitis A virus vaccination in persons with hepatitis C virus infection: Consequences of quality measure implementation. <i>Hepatology</i> , 2012, 56, 501-506.	3.6	10
654	Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). <i>Brain and Behavior</i> , 2012, 2, 525-531.	1.0	12
655	Demographics of hepatitis C virus today. <i>Clinical Liver Disease</i> , 2012, 1, 2-5.	1.0	1
656	Hepatitis C viral infection in incarcerated patients. <i>Clinical Liver Disease</i> , 2012, 1, 84-86.	1.0	3
657	The long-term horizon: Patients who will remain untreated in the era of triple therapy. <i>Clinical Liver Disease</i> , 2012, 1, 20-23.	1.0	1
658	Hepatitis C viral infection in patients with chronic kidney disease. <i>Clinical Liver Disease</i> , 2012, 1, 91-94.	1.0	0
659	Hepatitis C viral infection in children. <i>Clinical Liver Disease</i> , 2012, 1, 77-80.	1.0	2

#	ARTICLE	IF	CITATIONS
660	Chronic hepatitis. , 2012, , 992-998.e1.		0
661	Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. <i>Clinical Infectious Diseases</i> , 2012, 55, S10-S15.	2.9	263
662	Hepatitis C Virus Prevention, Care, and Treatment: From Policy to Practice. <i>Clinical Infectious Diseases</i> , 2012, 55, S58-S63.	2.9	36
663	An Integrated Alcohol Abuse and Medical Treatment Model for Patients with Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1083-1091.	1.1	27
664	Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents. <i>Immunologic Research</i> , 2012, 52, 200-210.	1.3	41
665	Characteristics, Services, and Infection Control Practices of New York City Assisted Living Facilities, 2010. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 284-289.	1.3	4
666	Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients. <i>Journal of Viral Hepatitis</i> , 2012, 19, e105-11.	1.0	18
667	Examining hepatitis c virus testing practices in primary care clinics. <i>Journal of Viral Hepatitis</i> , 2012, 19, e163-9.	1.0	18
668	Use of modelling and simulation techniques to support decision making on the progression of PFâ€œ04878691, a TLR7 agonist being developed for hepatitis C. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 77-92.	1.1	9
669	Depressive and anxiety disorders in chronic hepatitis C patients: Reliability and validity of the Patient Health Questionnaire. <i>Journal of Affective Disorders</i> , 2012, 138, 343-351.	2.0	58
670	Mechanism of thrombocytopenia in chronic hepatitis C as evaluated by the immature platelet fraction. <i>International Journal of Laboratory Hematology</i> , 2012, 34, 525-532.	0.7	21
671	Donor Testing and Risk: Current Prevalence, Incidence, and Residual Risk of Transfusion-Transmissible Agents in US Allogeneic Donations. <i>Transfusion Medicine Reviews</i> , 2012, 26, 119-128.	0.9	172
672	Cancers with increasing incidence trends in the United States: 1999 through 2008. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 118-128.	157.7	606
673	Risk of myocardial infarction associated with chronic hepatitis C virus infection: a populationâ€œbased cohort study*. <i>Journal of Viral Hepatitis</i> , 2012, 19, 271-277.	1.0	57
674	Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CHâ€œC). <i>Journal of Viral Hepatitis</i> , 2012, 19, 414-422.	1.0	9
675	Treating hepatitis C: current standard of care and emerging directâ€œacting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2012, 19, 449-464.	1.0	160
676	Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. <i>Transplant International</i> , 2012, 25, 825-829.	0.8	15
677	Higher serum testosterone is associated with increased risk of advanced hepatitis Câ€œrelated liver disease in males. <i>Hepatology</i> , 2012, 55, 759-768.	3.6	69

#	ARTICLE	IF	CITATIONS
678	Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b "infected null responders. <i>Hepatology</i> , 2012, 55, 742-748.	3.6	318
679	Upper limits of normal for alanine aminotransferase activity in the United States population. <i>Hepatology</i> , 2012, 55, 447-454.	3.6	126
681	Demographics, socio-behavioral factors, and drug use patterns: What matters in spontaneous HCV clearance?. <i>Journal of Medical Virology</i> , 2012, 84, 235-241.	2.5	12
682	HCV and Chemotherapy: Does Infection Change Management?. <i>Current Hepatitis Reports</i> , 2012, 11, 34-40.	0.3	0
683	HCV In At Risk Populations: Who Can be Treated and How?. <i>Current Hepatitis Reports</i> , 2012, 11, 1-9.	0.3	0
684	Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: A review and analysis of 36 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 771-778.	1.3	65
685	Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in pre-donation screening in emergency settings. <i>Transfusion</i> , 2013, 53, 505-517.	0.8	29
686	The Role of Attachment Style and Depression in Patients with Hepatitis C. <i>Journal of Clinical Psychology in Medical Settings</i> , 2013, 20, 227-233.	0.8	8
687	Epidemiology and natural history of HCV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 553-562.	8.2	833
688	Global control of hepatitis C: where challenge meets opportunity. <i>Nature Medicine</i> , 2013, 19, 850-858.	15.2	250
689	Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. <i>BMC Infectious Diseases</i> , 2013, 13, 190.	1.3	48
690	Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2013, 13, 60.	1.3	123
691	Relation of HLA class I and II supertypes with spontaneous clearance of hepatitis C virus. <i>Genes and Immunity</i> , 2013, 14, 330-335.	2.2	12
692	Hepatocellular Carcinoma Screening Practices in the Department of Veterans Affairs: Findings from a National Facility Survey. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3117-3126.	1.1	18
693	HCV Infection Prevalence Lower Than Expected among 18-40-Year-Old Injection Drug Users in San Diego, CA. <i>Journal of Urban Health</i> , 2013, 90, 516-528.	1.8	33
694	Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 804.	3.8	265
695	The Value Of Improving Treatment Adherence In Chronic Hepatitis C Infectio. <i>Value in Health</i> , 2013, 16, A214.	0.1	0
696	Hepatitis Outreach Network: A practical strategy for hepatitis screening with linkage to care in foreign-born communities. <i>Journal of Hepatology</i> , 2013, 58, 890-897.	1.8	58

#	ARTICLE	IF	CITATIONS
697	Effects of Hepatitis C virus on cardiovascular risk in infected patients: A comparative study. <i>International Journal of Cardiology</i> , 2013, 164, 221-226.	0.8	73
698	An anonymous unlinked sero-prevalence survey of HIV/HCV in an urban Emergency Department. <i>Journal of Clinical Virology</i> , 2013, 58, e19-e23.	1.6	7
699	Hepatitis C Virus Screening and Management of Seroconversions in Hemodialysis Facilities. <i>Seminars in Dialysis</i> , 2013, 26, 439-446.	0.7	26
700	CDC and USPSTF 2012 Recommendations for Screening for Hepatitis C Virus Infection: Overview and Take-Home Messages. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 200-203.	2.4	9
701	The persistence of hepatitis C virus transmission risk in China despite serologic screening of blood donations. <i>Transfusion</i> , 2013, 53, 2489-2497.	0.8	10
702	Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1407-15.	3.3	141
703	Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 124-133.	1.9	41
704	The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1647-1657.	1.5	6
705	Hepatitis C Patients on Maintenance Hemodialysis Show Complex Immune Disturbances in the Peripheral Blood. <i>Viral Immunology</i> , 2013, 26, 351-356.	0.6	2
706	The Impact of Ethnicity on Hepatitis C Virus Treatment Decisions and Outcomes. <i>Digestive Diseases and Sciences</i> , 2013, 58, 621-629.	1.1	4
707	Animal Models of Fibrosis in Human Disease. , 2013, , 435-458.		2
708	The longitudinal association between homelessness, injection drug use, and injection-related risk behavior among persons with a history of injection drug use in Baltimore, MD. <i>Drug and Alcohol Dependence</i> , 2013, 132, 457-465.	1.6	94
709	Less-Established Risk Factors Are Common in Asian Americans with Hepatitis C Virus: A Case-Controlled Study. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3342-3347.	1.1	15
710	Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan. <i>BMC Nephrology</i> , 2013, 14, 187.	0.8	37
711	Sexual Risk Behavior Associated with Transition to Injection Among Young Non-Injecting Heroin Users. <i>AIDS and Behavior</i> , 2013, 17, 2459-2466.	1.4	17
712	The Prevalence and Clinical Correlates of Nonalcoholic Fatty Liver Disease (NAFLD) in African Americans: The Multiethnic Study of Atherosclerosis (MESA). <i>Digestive Diseases and Sciences</i> , 2013, 58, 2392-2398.	1.1	43
713	Hepatic Preservation Injury: Severity of Hepatitis C Recurrence and Survival After Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1403-1409.	1.1	1
714	Clinical Outcomes of Hepatitis C Treated with Pegylated Interferon and Ribavirin via Telemedicine Consultation in Northern California. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3620-3625.	1.1	35

#	ARTICLE	IF	CITATIONS
715	Half a Diagnosis: Gap in Confirming Infection among Hepatitis C Antibody-positive Patients. <i>American Journal of Medicine</i> , 2013, 126, 718-722.	0.6	36
716	Impact of rapid point-of-care screening tests for the identification of chronic hepatitis C infection. <i>Hepatology</i> , 2013, 58, 822-826.	3.6	2
717	Chronic hepatitis C virus (HCV) disease burden and cost in the United States. <i>Hepatology</i> , 2013, 57, 2164-2170.	3.6	397
718	Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2013, 158, 807.	2.0	294
719	The Role of Public Health in an Era of All-Oral Therapy for Hepatitis C Infection. <i>Current Hepatitis Reports</i> , 2013, 12, 220-226.	0.3	0
720	Perspectivas a largo plazo: pacientes que seguirán sin tratamiento en la era de la terapia triple. <i>Clinical Liver Disease</i> , 2013, 2, S16A-S19A.	1.0	0
721	Clinical and epidemiological features of hepatitis C virus infection in South Korea: A prospective, multicenter cohort study. <i>Journal of Medical Virology</i> , 2013, 85, 1724-1733.	2.5	65
722	Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. <i>Hepatology</i> , 2013, 57, 1333-1342.	3.6	2,118
723	The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States. <i>Clinics in Liver Disease</i> , 2013, 17, 1-11.	1.0	52
724	Viral infections and their management in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1602-1613.	0.6	32
725	Early-stage splenic diffuse large B-cell lymphoma is highly associated with hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 150-156.	0.8	13
726	Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: Early effects of active substance use. <i>Antiviral Research</i> , 2013, 97, 347-355.	1.9	6
727	Emerging Therapeutic Targets for Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 612-619.e1.	2.4	14
728	Risk factor profiles among intravenous drug using young adults: A latent class analysis (LCA) approach. <i>Addictive Behaviors</i> , 2013, 38, 1804-1811.	1.7	13
729	CDC and USPSTF 2012 Recommendations for Screening for Hepatitis C Virus Infection: Overview and Take-Home Messages. <i>Gastroenterology</i> , 2013, 144, 478-481.	0.6	6
730	Thyroid Disease in Chronic Hepatitis C Infection Treated With Combination Interferon- α and Ribavirin: Management Strategies and Future Perspective. <i>Endocrine Practice</i> , 2013, 19, 292-300.	1.1	14
731	A new system to measure and compare hepatitis C virus replication capacity using full-length, replication competent viruses. <i>Journal of Virological Methods</i> , 2013, 194, 82-88.	1.0	0
732	Serum γ -Glutamyltranspeptidase Predicts All-cause, Cardiovascular and Liver Mortality in Older Adults. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 4-11.	0.4	33

#	ARTICLE	IF	CITATIONS
733	Infectivity of hepatitis C virus correlates with the amount of envelope protein E2: Development of a new aptamer-based assay system suitable for measuring the infectious titer of HCV. <i>Virology</i> , 2013, 439, 13-22.	1.1	42
734	The effect of stimulant use on antiviral treatment in an integrated hepatitis clinic. <i>General Hospital Psychiatry</i> , 2013, 35, 387-392.	1.2	2
735	Prevalence of Antibodies for the Hepatitis C Virus in the Lowland (Bajío) Region of Mexico. <i>Archives of Medical Research</i> , 2013, 44, 390-393.	1.5	2
736	Prevalence and impact of chronic hepatitis C virus infection on the clinical manifestations and disease activity among patients suffering from systemic lupus erythematosus. <i>Egyptian Rheumatologist</i> , 2013, 35, 9-14.	0.5	7
737	Therapy for Hepatitis C Virus Infection Increases Survival of Patients With Pretreatment Anemia. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 741-747.e3.	2.4	12
738	An Epidemiologic Update on Hepatitis C Infection in Persons Living With or at Risk of HIV Infection. <i>Journal of Infectious Diseases</i> , 2013, 207, S1-S6.	1.9	88
739	Hepatitis C virus vaccines in the era of new direct-acting antivirals. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 171-185.	1.4	12
740	Best strategies for global HCV eradication. <i>Liver International</i> , 2013, 33, 68-79.	1.9	97
741	Viral Diseases and the Kidney. , 2013, , 577-589.		0
742	The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. <i>Hepatology</i> , 2013, 58, 54-64.	3.6	71
743	Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3991-3996.	3.3	298
744	Predictors of Active Injection Drug Use in a Cohort of Patients Infected With Hepatitis C Virus. <i>American Journal of Public Health</i> , 2013, 103, 105-111.	1.5	9
745	Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 527-536.	1.9	71
746	Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 887-894.	1.9	44
747	Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. <i>Hepatology</i> , 2013, 57, 881-889.	3.6	195
748	Systematic review: Asian patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 921-936.	1.9	105
749	The Association of IL28B Polymorphism and Graft Survival in Patients with Hepatitis C Undergoing Liver Transplantation. <i>PLoS ONE</i> , 2013, 8, e54854.	1.1	10
750	Viral Infections in Patients with Hematological Malignancies. , 2013, , 1193-1239.		0

#	ARTICLE	IF	CITATIONS
751	Hepatitis C virus targets the interferon- α JAK/STAT pathway by promoting proteasomal degradation in immune cells and hepatocytes. <i>FEBS Letters</i> , 2013, 587, 1571-1578.	1.3	45
752	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1878-1887.	13.9	1,605
754	Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 707-716.	1.4	24
755	All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. <i>Journal of Viral Hepatitis</i> , 2013, 20, 847-857.	1.0	53
756	Current progress in development of hepatitis C virus vaccines. <i>Nature Medicine</i> , 2013, 19, 869-878.	15.2	144
757	Hepatitis C in the United States. <i>New England Journal of Medicine</i> , 2013, 368, 1859-1861.	13.9	279
758	Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993-2007. <i>Cancer Causes and Control</i> , 2013, 24, 559-565.	0.8	29
759	Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy. <i>Clinical Infectious Diseases</i> , 2013, 56, 1466-1470.	2.9	10
760	Sexual Transmission of Viral Hepatitis. <i>Infectious Disease Clinics of North America</i> , 2013, 27, 811-836.	1.9	25
761	Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States. <i>Clinical Infectious Diseases</i> , 2013, 56, 1382-1393.	2.9	80
762	Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: Implications for treatment cost-effectiveness. <i>Hepatology</i> , 2013, 57, 451-460.	3.6	51
763	Regional and global summary estimates of antibody to hepatitis C virus prevalence in detainee populations: Seeing the forest and the trees?. <i>Hepatology</i> , 2013, 58, 1197-1199.	3.6	2
764	Influence of Age and Gender Before and After Liver Transplantation. <i>Liver Transplantation</i> , 2013, 19, 122-134.	1.3	55
765	Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. <i>BMJ Open</i> , 2013, 3, e003231.	0.8	8
766	Costs of a Public Health Model to Increase Receipt of Hepatitis-Related Services for Persons With Mental Illness. <i>Psychiatric Services</i> , 2013, 64, 127-133.	1.1	3
767	The Current Hepatitis C Virus Prevalence in China May Have Resulted Mainly from an Officially Encouraged Plasma Campaign in the 1990s: a Coalescence Inference with Genetic Sequences. <i>Journal of Virology</i> , 2013, 87, 12041-12050.	1.5	19
768	Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2013, 57, S80-S89.	2.9	280
769	Serum alpha-fetoprotein level is higher in hepatitis C than hepatitis B infected chronic liver disease patients. <i>Nigerian Medical Journal</i> , 2013, 54, 426.	0.6	4

#	ARTICLE	IF	CITATIONS
770	Hepatitis C Virus in Pregnancy. <i>American Journal of Perinatology</i> , 2013, 30, 149-160.	0.6	92
771	Successful Integration of Hepatitis C Virus Point-of-Care Tests into the Denver Metro Health Clinic. <i>AIDS Research and Treatment</i> , 2013, 2013, 1-8.	0.3	16
772	Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users. <i>Hepatitis Monthly</i> , 2013, 13, e12411.	0.1	32
773	Evaluation of the Significance of Pretreatment Liver Biopsy and Baseline Mental Health Disorder Diagnosis on Hepatitis C Treatment Completion Rates at a Veterans Affairs Medical Center. <i>Hepatitis Research and Treatment</i> , 2013, 2013, 1-6.	2.0	1
774	Explaining Differences in Hepatitis C Between U.S. Veterans and Nonveterans in Treatment for Substance Abuse: Results From a Regression Decomposition. <i>Substance Use and Misuse</i> , 2013, 48, 854-862.	0.7	5
775	Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. <i>Hepatology</i> , 2013, 58, 538-545.	3.6	75
776	Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort. <i>Clinical Infectious Diseases</i> , 2013, 57, 240-246.	2.9	118
777	Hepatitis C virus therapy update 2013. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 1.	1.0	55
778	A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 800-806.	1.1	3
779	A Unique Model for Treating Chronic Hepatitis C in Patients With Psychiatric Disorders, Substance Abuse, and/or Housing Instability. <i>Journal of Addiction Medicine</i> , 2013, 7, 320-324.	1.4	17
780	Dietary Fructose Intake and Severity of Liver Disease in Hepatitis C Virus-infected Patients. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 545-552.	1.1	4
781	Baseline Characteristics and Mortality Among People in Care for Chronic Viral Hepatitis: The Chronic Hepatitis Cohort Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 40-50.	2.9	159
782	Ipilimumab-Induced Hepatitis C Viral Suppression. <i>Journal of Clinical Oncology</i> , 2013, 31, e307-e308.	0.8	21
783	Detection of Hepatitis C Virus Transmission by Use of DNA Mass Spectrometry. <i>Journal of Infectious Diseases</i> , 2013, 207, 999-1006.	1.9	11
784	A Canadian screening program for hepatitis C: Is now the time?. <i>Cmaj</i> , 2013, 185, 1325-1328.	0.9	40
785	Lessons Learned From Exploratory Research About Viral Hepatitis. <i>Health Promotion Practice</i> , 2013, 14, 364-369.	0.9	7
786	Age and Gender Distribution of Hepatitis C Virus Genotypes in the Metropolitan Area of Naples. <i>Intervirology</i> , 2013, 56, 206-212.	1.2	33
787	Systematic Analysis of Enhancer and Critical cis-Acting RNA Elements in the Protein-Encoding Region of the Hepatitis C Virus Genome. <i>Journal of Virology</i> , 2013, 87, 5678-5696.	1.5	31

#	ARTICLE	IF	CITATIONS
788	"To Share or Not to Share?" Serosorting by Hepatitis C Status in the Sharing of Drug Injection Equipment Among NHBS-IDU2 Participants. <i>Journal of Infectious Diseases</i> , 2013, 208, 1934-1942.	1.9	28
789	Model for hepatitis C virus transmissions. <i>Mathematical Biosciences and Engineering</i> , 2013, 10, 1045-1065.	1.0	28
790	Birth Cohort Testing for Hepatitis C Virus: Implications for Clinical Social Workers in Health Care Settings. <i>Social Work in Health Care</i> , 2013, 52, 689-703.	0.8	4
791	Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 573-582.	1.9	5
792	Association of tattooing and hepatitis C virus infection: A multicenter case-control study. <i>Hepatology</i> , 2013, 57, 2117-2123.	3.6	66
793	Formal hepatitis C education enhances <sc>HCV</sc> care coordination, expedites <sc>HCV</sc> treatment and improves antiviral response. <i>Liver International</i> , 2013, 33, 999-1007.	1.9	46
794	Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, e90-5.	1.0	6
795	Hepatitis C virus. <i>Journal of the American Dental Association</i> , 2013, 144, 1340-1347.	0.7	16
796	Alcohol consumption as a cofactor for other liver diseases. <i>Clinical Liver Disease</i> , 2013, 2, 72-75.	1.0	6
797	The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. <i>Journal of Viral Hepatitis</i> , 2013, 20, 745-760.	1.0	78
798	A nationwide seroepidemiology of hepatitis C virus infection in South Korea. <i>Liver International</i> , 2013, 33, 586-594.	1.9	81
799	Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide. <i>Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment</i> , 2013, 30, 534-540.	1.1	31
800	Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. <i>Leukemia and Lymphoma</i> , 2013, 54, 1380-1386.	0.6	52
801	Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. <i>Liver International</i> , 2013, 33, 727-738.	1.9	32
802	Knowledge and attitudes about hepatitis C virus (<sc>HCV</sc>) infection and its treatment in <sc>HCV</sc> mono-infected and <sc>HCV</sc>/<sc>HIV</sc> co-infected adults. <i>Journal of Viral Hepatitis</i> , 2013, 20, 708-714.	1.0	32
803	Características demográficas actuales del virus de la hepatitis C. <i>Clinical Liver Disease</i> , 2013, 2, S12A-S15A.	1.0	0
806	Hepatitis <sc>C</sc> virus treatment and survival in patients with hepatitis <sc>C</sc> and human immunodeficiency virus co-infection and baseline anaemia. <i>Journal of Viral Hepatitis</i> , 2013, 20, 463-469.	1.0	7
807	Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels. <i>Journal of the National Cancer Institute</i> , 2013, 105, 175-201.	3.0	886

#	ARTICLE	IF	CITATIONS
808	Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e123.	2.3	13
809	Editorial : Killing Two Birds With One Stone: Screening for Chronic Hepatitis C at the Time of Colonoscopy in the Baby Boomer Cohort. <i>American Journal of Gastroenterology</i> , 2013, 108, 990-992.	0.2	3
810	Birth Cohort Screening for Chronic Hepatitis During Colonoscopy Appointments. <i>American Journal of Gastroenterology</i> , 2013, 108, 981-989.	0.2	32
811	How outpatient substance abuse treatment unit director activities may affect provision of community outreach services. <i>Drugs: Education, Prevention and Policy</i> , 2013, 20, 149-159.	0.8	3
812	Short Communication: Interferon/Ribavirin Treatment for HCV Is Associated with the Development of Hypophosphatemia in HIV/Hepatitis C Virus-Coinfected Patients. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1190-1194.	0.5	9
813	Screening for Hepatitis C Virus Infection in Adults: A Systematic Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2013, 158, 101.	2.0	79
814	Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma. <i>Annals of Internal Medicine</i> , 2013, 158, 329.	2.0	734
815	Reducing Risk for Mother-to-Infant Transmission of Hepatitis C Virus: A Systematic Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2013, 158, 109.	2.0	165
816	Chronic hepatitis C and antiviral treatment regimens: Where can psychology contribute?. <i>Journal of Consulting and Clinical Psychology</i> , 2013, 81, 361-374.	1.6	24
817	Women with Chronic Hepatitis C Virus Infection. <i>Southern Medical Journal</i> , 2013, 106, 422-426.	0.3	3
818	Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2013, 159, 372.	2.0	47
819	Distribution of Viral Hepatitis in Indigenous Populations of North America and the Circumpolar Arctic. <i>Antiviral Therapy</i> , 2013, 18, 467-473.	0.6	42
820	PHS Guideline for Reducing Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Transmission through Organ Transplantation. <i>Public Health Reports</i> , 2013, 128, 247-344.	1.3	224
821	Missed Opportunities for Hepatitis C Testing in Opioid Treatment Programs. <i>American Journal of Public Health</i> , 2013, 103, 1028-1030.	1.5	23
822	Estimating HCV Prevalence at the State Level: A Call to Increase and Strengthen Current Surveillance Systems. <i>American Journal of Public Health</i> , 2013, 103, 1402-1405.	1.5	7
823	Case-control study of hepatitis B and hepatitis C in older adults: Do healthcare exposures contribute to burden of new infections?. <i>Hepatology</i> , 2013, 57, 917-924.	3.6	32
824	Social networks and HCV viraemia in anti-HCV-positive rural drug users. <i>Epidemiology and Infection</i> , 2013, 141, 402-411.	1.0	10
825	Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. <i>Hepatology</i> , 2013, 58, 497-504.	3.6	50

#	ARTICLE	IF	CITATIONS
826	Potential consequences of healthcare recommendations: A focus on the U.S. Preventive Services Task Force. <i>Hepatology</i> , 2013, 58, 422-427.	3.6	2
827	Hepatitis C screening: Getting it right. <i>Hepatology</i> , 2013, 57, 1644-1650.	3.6	11
828	Hepatitis C Testing, Infection, and Linkage to Care Among Racial and Ethnic Minorities in the United States, 2009â€“2010. <i>American Journal of Public Health</i> , 2013, 103, 112-119.	1.5	55
829	Indications for Testing Among Reported Cases of HCV Infection From Enhanced Hepatitis Surveillance Sites in the United States, 2004â€“2010. <i>American Journal of Public Health</i> , 2013, 103, 1445-1449.	1.5	26
830	Hepatic Steatosis in Human Immunodeficiency Virus. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 182-187.	1.1	80
831	Association of Hepatitis C With Markers of Hemostasis In HIV-Infected and Uninfected Women in the Women's Interagency HIV Study (WIHS). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 301-310.	0.9	7
832	Hepatitis C Virus Screening and Prevalence Among US Veterans in Department of Veterans Affairs Care. <i>JAMA Internal Medicine</i> , 2013, 173, 1549.	2.6	47
833	Risky Alcohol Use and Serum Aminotransferase Levels in HIV-Infected Adults With and Without Hepatitis C. <i>Journal of Studies on Alcohol and Drugs</i> , 2013, 74, 266-270.	0.6	13
834	Effect of the Coadministration of Daclatasvir on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate. <i>Antiviral Therapy</i> , 2014, 19, 511-519.	0.6	14
835	Predictors of Alcohol Use Among Rural Drug Users After Disclosure of Hepatitis C Virus Status. <i>Journal of Studies on Alcohol and Drugs</i> , 2013, 74, 386-395.	0.6	7
836	Socioeconomic status in HCV infected patients – risk and prognosis. <i>Clinical Epidemiology</i> , 2013, 5, 163.	1.5	59
837	Profile of alisporivir and its potential in the treatment of hepatitis C. <i>Drug Design, Development and Therapy</i> , 2013, 7, 105.	2.0	87
838	Hepatitis C Virus Testing of Persons Born During 1945â€“1965. <i>Annals of Internal Medicine</i> , 2013, 158, 704.	2.0	3
839	Daclatasvir: potential role in hepatitis C. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1223.	2.0	37
840	Novel drugs in the management of difficult-to-treat hepatitis C genotypes. <i>Hepatic Medicine: Evidence and Research</i> , 2013, 5, 53.	0.9	8
841	Prevalence and Risk Factors for Hepatitis C and Human Immunodeficiency Virus Coinfection among Children in Enugu, Nigeria. <i>African Journal of Infectious Diseases</i> , 2013, 8, 5-8.	0.5	13
842	Enhanced Chronic Hepatitis C Surveillance in New York City, April 2009â€“January 2011. <i>Public Health Reports</i> , 2013, 128, 510-518.	1.3	5
843	Profound jaundice in a patient with acute hepatitis C. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013200233-bcr2013200233.	0.2	1

#	ARTICLE	IF	CITATIONS
844	Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States. PLoS ONE, 2013, 8, e58975.	1.1	61
845	Nonresponse to Interferon-Î± Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis. PLoS ONE, 2013, 8, e61568.	1.1	8
846	Current and Future Disease Progression of the Chronic HCV Population in the United States. PLoS ONE, 2013, 8, e63959.	1.1	28
847	The Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting. PLoS ONE, 2013, 8, e64321.	1.1	34
848	Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e65726.	1.1	35
849	Chimeric Mouse Model for the Infection of Hepatitis B and C Viruses. PLoS ONE, 2013, 8, e77298.	1.1	54
850	Liver physiology and liver diseases in the elderly. World Journal of Gastroenterology, 2013, 19, 8459.	1.4	135
851	The Epidemiology of Hepatitis C in a Canadian Indigenous Population. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 336-340.	1.8	29
852	Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C. PLoS ONE, 2014, 9, e90295.	1.1	19
853	Estimating the Number of Persons Who Inject Drugs in the United States by Meta-Analysis to Calculate National Rates of HIV and Hepatitis C Virus Infections. PLoS ONE, 2014, 9, e97596.	1.1	198
854	The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e101554.	1.1	362
855	Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation Guideline. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 529-534.	0.8	5
856	Hepatitis C Worldwide and in Brazil: Silent Epidemicâ€”Data on Disease including Incidence, Transmission, Prevention, and Treatment. Scientific World Journal, The, 2014, 2014, 1-10.	0.8	25
857	A Population Approach to Disease Management: Hepatitis C Direct-Acting Antiviral Use in a Large Health Care System. Journal of Managed Care Pharmacy, 2014, 20, 533-540.	2.2	15
859	Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2014, 1, 9.	1.8	5
861	Quality of Hepatitis C Care at an Urban Tertiary Care Medical Center. Journal of Health Care for the Poor and Underserved, 2014, 25, 705-716.	0.4	2
862	Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virusâ€infectected patients. Hepatology, 2014, 60, 1871-1878.	3.6	67
864	Causes of Death and Characteristics of Decedents With Viral Hepatitis, United States, 2010. Clinical Infectious Diseases, 2014, 58, 40-49.	2.9	64

#	ARTICLE	IF	CITATIONS
865	Hepatitis C for Primary Care Physicians. <i>Journal of the American Board of Family Medicine</i> , 2014, 27, 284-291.	0.8	9
866	Eltrombopag in patients with chronic hepatitis C and thrombocytopenia. <i>Future Virology</i> , 2014, 9, 9-20.	0.9	0
867	A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. <i>Kidney International</i> , 2014, 85, 1200-1207.	2.6	103
868	Migration Patterns of Hepatitis C Virus in China Characterized for Five Major Subtypes Based on Samples from 411 Volunteer Blood Donors from 17 Provinces and Municipalities. <i>Journal of Virology</i> , 2014, 88, 7120-7129.	1.5	32
869	National Estimates of Healthcare Utilization by Individuals With Hepatitis C Virus Infection in the United States. <i>Clinical Infectious Diseases</i> , 2014, 59, 755-764.	2.9	64
870	Elevated liver enzymes following polytraumatic injury. <i>Journal of Rehabilitation Research and Development</i> , 2014, 51, 869-874.	1.6	11
871	Proteasome- and Ethanol-Dependent Regulation of HCV-Infection Pathogenesis. <i>Biomolecules</i> , 2014, 4, 885-896.	1.8	9
872	Resistance to Cyclophilin Inhibitors. , 2014, , 1-24.		0
873	Editorial Commentary: Hepatitis C Virus Testing and Drug Use in North America; Is There More Than Meets the Eye?. <i>Clinical Infectious Diseases</i> , 2014, 58, 762-764.	2.9	1
874	Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy. <i>Annals of Pharmacotherapy</i> , 2014, 48, 826-836.	0.9	2
875	A novel nested reverse-transcriptase polymerase chain reaction method for rapid hepatitis C virus detection and genotyping. <i>Indian Journal of Medical Microbiology</i> , 2014, 32, 130-136.	0.3	5
876	Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort. <i>BMJ Open</i> , 2014, 4, e004988.	0.8	55
877	Reducing Barriers to Hepatitis C Treatment among Drug Users: An Integrated Hepatitis C Peer Education and Support Program. <i>Journal of Health Care for the Poor and Underserved</i> , 2014, 25, 652-662.	0.4	42
878	Historical trends and projected hospital admissions for chronic hepatitis C infection in Canada: a birth cohort analysis. <i>CMAJ Open</i> , 2014, 2, E139-E144.	1.1	18
879	The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions. <i>Annals of Internal Medicine</i> , 2014, 161, 170.	2.0	129
880	Prediction of morbidity and mortality in patients with chronic hepatitis C by noninvasive liver fibrosis models. <i>Liver International</i> , 2014, 34, 720-727.	1.9	26
881	Costs of telaprevir-based triple therapy for hepatitis C: \$189,000 per sustained virological response. <i>Hepatology</i> , 2014, 60, 1187-1195.	3.6	39
882	Vitamin D and Calcium Abnormalities in the HIV-Infected Population. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 743-767.	1.2	8

#	ARTICLE	IF	CITATIONS
883	Hepatitis C screening beyond <scp>CDC</scp> guidelines in an Egyptian immigrant community. <i>Liver International</i> , 2014, 34, 253-258.	1.9	12
884	Sofosbuvir. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1019-1029.	0.9	52
885	What are the Management Issues for Hepatitis C in Dialysis Patients?. <i>Seminars in Dialysis</i> , 2014, 27, 455-458.	0.7	1
886	A functional role for <scp>NS</scp>5<scp>ATP</scp>9 in the induction of <scp>HCV</scp> NS<scp>5A</scp>-mediated autophagy. <i>Journal of Viral Hepatitis</i> , 2014, 21, 405-415.	1.0	20
887	Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. <i>Liver International</i> , 2014, 34, 668-671.	1.9	13
888	Multiple Infections and Cancer: Implications in Epidemiology. <i>Technology in Cancer Research and Treatment</i> , 2014, 13, 177-194.	0.8	38
889	Maternal hepatitis <scp>B</scp> and hepatitis <scp>C</scp> infection and neonatal neurological outcomes. <i>Journal of Viral Hepatitis</i> , 2014, 21, e144-53.	1.0	37
890	Hepatitis <scp>C</scp> virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis <scp>C</scp> after pegylated interferon plus ribavirin treatment. <i>Hepatology Research</i> , 2014, 44, 597-607.	1.8	2
891	Daclatasvir for the treatment of hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 725-738.	1.4	7
892	Differences in hepatitis <scp>C</scp> virus prevalence and clearance by mode of acquisition among men who have sex with men. <i>Journal of Viral Hepatitis</i> , 2014, 21, 696-705.	1.0	17
893	Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. <i>BMC Health Services Research</i> , 2014, 14, 429.	0.9	5
894	Multiple Factors Predict Physical Performance in People with Chronic Liver Disease. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2014, 93, 470-476.	0.7	20
895	Hepatitis C Virus-Related Knowledge and Willingness to Receive Treatment Among Patients on Methadone Maintenance. <i>Journal of Addiction Medicine</i> , 2014, 8, 249-257.	1.4	37
896	Prevalence of HIV, Sexually Transmitted Infections, and Viral Hepatitis by Urbanicity, Among Men Who Have Sex With Men, Injection Drug Users, and Heterosexuals in the United States. <i>Sexually Transmitted Diseases</i> , 2014, 41, 272-279.	0.8	30
897	Infectious Diseases and the Kidney in Children. , 2014, , 1-53.		0
898	Physician Nonadherence With a Hepatitis C Screening Program. <i>Quality Management in Health Care</i> , 2014, 23, 1-9.	0.4	20
899	Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1073-1082.	0.8	46
900	Hepatitis C and Work Impairment. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 595-599.	1.1	19

#	ARTICLE	IF	CITATIONS
901	Interventions Using Electronic Medical Records Improve Follow Up of Infants Born to Hepatitis C Virus Infected Mothers. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 376-380.	1.1	9
902	Statins and Hepatitis C Virus Infection: An Old Therapy With New Scope. <i>American Journal of the Medical Sciences</i> , 2014, 348, 426-430.	0.4	6
903	Hepatitis C in the pediatric population: Transmission, natural history, treatment and liver transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 11281.	1.4	24
904	Relationship Between Hepatitis C Clinical Testing Site and Linkage to Care. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu009.	0.4	17
905	Mortality Among Persons in Care With Hepatitis C Virus Infection: The Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. <i>Clinical Infectious Diseases</i> , 2014, 58, 1055-1061.	2.9	108
906	Integration of Screening for Syphilis, Hepatitis C, and Other Sexually Transmitted Infections with HIV Testing in a Community-Based HIV Prevention Program in Miami, Florida. <i>LGBT Health</i> , 2014, 1, 82-85.	1.8	8
907	The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C. <i>JAMA Internal Medicine</i> , 2014, 174, 204.	2.6	113
908	The Association between Female Genital Cutting and Spousal HCV Infection in Egypt. <i>International Journal of Hepatology</i> , 2014, 2014, 1-10.	0.4	3
909	A case study of a real-time evaluation of the risk of disease transmission associated with a failure to follow recommended sterilization procedures. <i>Antimicrobial Resistance and Infection Control</i> , 2014, 3, 4.	1.5	6
910	Prevalence of Hepatitis C Virus Infection in US Hispanic/Latino Adults: Results From the NHANES 2007-2010 and HCHS/SOL Studies. <i>Journal of Infectious Diseases</i> , 2014, 209, 1585-1590.	1.9	50
911	Clinical Factors Associated with Biochemical Adrenal-cortisol Insufficiency in Hospitalized Patients. <i>American Journal of Medicine</i> , 2014, 127, 754-762.	0.6	10
912	Hepatitis C treatment: an incipient therapeutic revolution. <i>Trends in Molecular Medicine</i> , 2014, 20, 315-321.	3.5	42
913	Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens. <i>Journal of Clinical Virology</i> , 2014, 59, 223-227.	1.6	43
914	Impact of New Hepatitis C Treatments in Different Regions of the World. <i>Gastroenterology</i> , 2014, 146, 1145-1150.e4.	0.6	48
915	Increasing Hepatitis C Knowledge Among Homeless Adults: Results of a Community-Based, Interdisciplinary Intervention. <i>Journal of Behavioral Health Services and Research</i> , 2014, 41, 37-49.	0.6	10
916	Measurement properties of the Flu-Like Symptom Index from the Hepatitis Physical Symptom Severity Diary. <i>Quality of Life Research</i> , 2014, 23, 1489-1496.	1.5	1
917	Biopsychosocial factors associated with pain in veterans with the hepatitis C virus. <i>Journal of Behavioral Medicine</i> , 2014, 37, 902-911.	1.1	17
918	Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 491-498.	1.3	3

#	ARTICLE	IF	CITATIONS
919	Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 209-216.	1.9	16
920	Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 93-103.	1.9	49
921	Racial Disparities in the Proportion of Current, Unresolved Hepatitis C Virus Infections in the United States, 2003–2010. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1950-1957.	1.1	13
922	Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection. <i>Digestive Diseases and Sciences</i> , 2014, 59, 273-281.	1.1	4
923	The Prevalence of Harmful and Hazardous Alcohol Consumption in Older U.S. Adults: Data from the 2005–2008 National Health and Nutrition Examination Survey (NHANES). <i>Journal of General Internal Medicine</i> , 2014, 29, 312-319.	1.3	45
924	Awareness of Biologically Confirmed HCV Among a Community Residing Sample of Drug Users in Baltimore City. <i>Journal of Community Health</i> , 2014, 39, 487-493.	1.9	2
925	Boceprevir and telaprevir–based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. <i>Journal of Viral Hepatitis</i> , 2014, 21, e98-e107.	1.0	23
926	Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1213-1224.	1.9	25
927	Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. <i>Hepatology</i> , 2014, 60, 37-45.	3.6	103
928	The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010. <i>Journal of Hepatology</i> , 2014, 60, 691-698.	1.8	145
929	Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: “A Flood of Opportunity” <i>American Journal of Transplantation</i> , 2014, 14, 994-1002.	2.6	72
930	Historical epidemiology of hepatitis C virus (HCV) in selected countries. <i>Journal of Viral Hepatitis</i> , 2014, 21, 5-33.	1.0	211
931	Deaths Among People With Hepatitis C in New York City, 2000-2011. <i>Clinical Infectious Diseases</i> , 2014, 58, 1047-1054.	2.9	19
932	Effect of Ritonavir–Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy. <i>Pharmacotherapy</i> , 2014, 34, 220-226.	1.2	3
933	Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2288-2294.	1.0	22
934	HCV RNA detection in HCV antibody-positive patients with the COBAS® AmpliPrep/COBAS® TaqMan® HCV test, v2.0 in comparison with FDA-approved nucleic acid tests. <i>Journal of Clinical Virology</i> , 2014, 60, 336-340.	1.6	9
935	Hepatitis C Virus Screening in Patients With Cancer Receiving Chemotherapy. <i>Journal of Oncology Practice</i> , 2014, 10, e167-e174.	2.5	19
936	Complement activation correlates with liver necrosis and fibrosis in chronic hepatitis C. <i>Clinical Immunology</i> , 2014, 150, 149-156.	1.4	16

#	ARTICLE	IF	CITATIONS
937	Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees. <i>Hepatology</i> , 2014, 59, 803-813.	3.6	21
938	REMOVED: An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C. <i>Medical Clinics of North America</i> , 2014, 98, 17.	1.1	18
939	Sequence Analysis of Hepatitis C Virus From Patients With Relapse After a Sustained Virological Response: Relapse or Reinfection?. <i>Journal of Infectious Diseases</i> , 2014, 209, 38-45.	1.9	30
940	Estimating the prevalence of hepatitis C infection in New York City using surveillance data. <i>Epidemiology and Infection</i> , 2014, 142, 262-269.	1.0	25
941	Outcomes of a Hepatitis C Screening Protocol in At-Risk Adults With Prior Cardiac Surgery. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 2014, 5, 503-506.	0.3	14
942	Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis <scp>C</scp>: a randomized controlled trial. <i>Addiction</i> , 2014, 109, 1869-1877.	1.7	32
943	Large scale screening of human sera for HCV RNA and GBVâ€C RNA. <i>Journal of Medical Virology</i> , 2014, 86, 473-477.	2.5	13
944	Immune Markers Associated with Host Susceptibility to Infection with West Nile Virus. <i>Viral Immunology</i> , 2014, 27, 39-47.	0.6	31
946	Global epidemiology and genotype distribution of the hepatitis C virus infection. <i>Journal of Hepatology</i> , 2014, 61, S45-S57.	1.8	1,560
947	HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. <i>Hepatology</i> , 2014, 60, 98-105.	3.6	248
948	Hepatitis C Virus NS5A Protein Modulates IRF-7-Mediated Interferon-Î± Signaling. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 16-21.	0.5	16
949	Hepatitis C Virus: Epidemiology and Clinical Features of Related Cancer. , 2014, , 87-112.		0
950	Optimal Management of the Hepatitis C Patient: Review of the AASLD/IDSA Guidelines. <i>Current Hepatology Reports</i> , 2014, 13, 314-320.	0.4	0
951	Highly Potent HCV NS4B Inhibitors with Activity against Multiple Genotypes. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2161-2166.	2.9	24
952	Admixture analysis of spontaneous hepatitis C virus clearance in individuals of African descent. <i>Genes and Immunity</i> , 2014, 15, 241-246.	2.2	9
953	Hepatitis C in African Americans. <i>American Journal of Gastroenterology</i> , 2014, 109, 1576-1584.	0.2	33
954	Preparation of genosensor for detection of specific DNA sequence of the hepatitis B virus. <i>Applied Surface Science</i> , 2014, 314, 273-279.	3.1	39
955	Screening, Diagnosis, Treatment, and Management of Hepatitis C: A Novel, Comprehensive, Online Resource Center for Primary Care Providers and Specialists. <i>American Journal of Medicine</i> , 2014, 127, e11-e14.	0.6	8

#	ARTICLE	IF	CITATIONS
956	Hepatitis C virus screening practices and seropositivity among US veterans born during 1945 – 1965. <i>BMC Research Notes</i> , 2014, 7, 449.	0.6	15
957	Split-luciferase complementary assay: applications, recent developments, and future perspectives. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 5541-5560.	1.9	86
958	Chronic hepatitis C as a risk factor for colorectal adenoma. <i>International Journal of Colorectal Disease</i> , 2014, 29, 75-80.	1.0	29
959	Cost-Effectiveness of Interventions to Prevent HIV and STDs Among Women: A Randomized Controlled Trial. <i>AIDS and Behavior</i> , 2014, 18, 1913-1923.	1.4	7
960	Risk Factors for Hepatitis C Infection Among Vietnam Era Veterans Versus Nonveterans: Results from the Chronic Hepatitis Cohort Study (CHeCS). <i>Journal of Community Health</i> , 2014, 39, 914-921.	1.9	8
962	Impact of Birth Cohort Screening for Hepatitis C. <i>Current Gastroenterology Reports</i> , 2014, 16, 381.	1.1	17
963	Clinical characteristics, treatment patterns and survival outcome of hepatocellular carcinoma patients aged 70 years or older: a single-center retrospective study from China. <i>Aging Clinical and Experimental Research</i> , 2014, 26, 123-130.	1.4	6
964	Community-based HCV screening: knowledge and attitudes in a high risk urban population. <i>BMC Infectious Diseases</i> , 2014, 14, 74.	1.3	45
965	Tickling the TLR7 to cure viral hepatitis. <i>Journal of Translational Medicine</i> , 2014, 12, 129.	1.8	26
966	Natural History and Management of Hepatitis C: Does Sex Play a Role?. <i>Journal of Infectious Diseases</i> , 2014, 209, S81-S85.	1.9	101
967	Comparison of Hepatitis C Virus Testing Strategies. <i>American Journal of Preventive Medicine</i> , 2014, 47, 233-241.	1.6	16
968	Can hepatitis C be eradicated in the United States?. <i>Antiviral Research</i> , 2014, 110, 79-93.	1.9	35
969	The Contribution of Viral Hepatitis to the Burden of Chronic Liver Disease in the United States. <i>American Journal of Gastroenterology</i> , 2014, 109, 387-393.	0.2	17
970	Hepatitis B and C in African Americans: Current Status and Continued Challenges. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 738-748.	2.4	38
971	Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?. <i>Antiviral Research</i> , 2014, 107, 23-30.	1.9	115
972	Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C. <i>Mayo Clinic Proceedings</i> , 2014, 89, 595-601.	1.4	3
973	Hepatitis C Screening Trends in a Large Integrated Health System. <i>American Journal of Medicine</i> , 2014, 127, 398-405.	0.6	29
974	Hepatitis C Virus Treatment: The Unyielding Chasm Between Efficacy and Effectiveness. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1381-1383.	2.4	16

#	ARTICLE	IF	CITATIONS
975	Commentary. <i>Annals of Emergency Medicine</i> , 2014, 63, 635-636.	0.3	0
976	Determination of simeprevir: A novel, hepatitis C protease inhibitor in human plasma by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 958, 43-47.	1.2	32
977	HCV and HBV testing acceptability and knowledge among urban emergency department patients and pharmacy clients. <i>Preventive Medicine</i> , 2014, 61, 29-33.	1.6	8
978	Efficacy and safety of peginterferon plus ribavirin for patients aged 65 years with chronic hepatitis C: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 440-450.	0.7	17
979	Injection and non-injection drug use and infectious disease in Baltimore City: Differences by race. <i>Addictive Behaviors</i> , 2014, 39, 1325-1328.	1.7	24
980	Hepatitis B and C. <i>Clinics in Geriatric Medicine</i> , 2014, 30, 149-167.	1.0	4
981	Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: Results from the ANRS CO13 HEPAVIH cohort study. <i>Journal of Hepatology</i> , 2014, 60, 46-53.	1.8	19
982	Many Patients With Interleukin 28B Genotypes Associated With Response to Therapy Are Ineligible for Treatment Because of Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 327-333.e1.	2.4	11
983	The Rapid Evolution of Treatment Strategies for Hepatitis C. <i>American Journal of Gastroenterology</i> , 2014, 109, 628-635.	0.2	71
984	Gene Expression Profiling of Immune Responsive and Fibrosis Genes in Hepatitis C Virus Infected Patients. <i>Viral Immunology</i> , 2014, 27, 250-254.	0.6	2
985	Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 264-269.	1.3	22
986	Sofosbuvir (Sovaldi) for the treatment of hepatitis C. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 555-566.	1.3	22
987	My Treatment Approach to Chronic Hepatitis C Virus. <i>Mayo Clinic Proceedings</i> , 2014, 89, 934-942.	1.4	3
988	How and how much do endoscopy professionals protect themselves against infection?. <i>International Journal of Surgery</i> , 2014, 12, 720-724.	1.1	3
989	Epidemiology of the Viral Hepatitis-HIV Syndemic in San Francisco: A Collaborative Surveillance Approach. <i>Public Health Reports</i> , 2014, 129, 95-101.	1.3	18
990	Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. <i>Hepatic Medicine: Evidence and Research</i> , 2014, 6, 61.	0.9	27
991	Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication. <i>World Journal of Gastroenterology</i> , 2014, 20, 2927.	1.4	48
992	Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. <i>Annals of Internal Medicine</i> , 2014, 160, 293-300.	2.0	644

#	ARTICLE	IF	CITATIONS
993	Implementation and Evaluation of a Multicomponent Quality Improvement Intervention to Improve Efficiency of Hepatitis C Screening and Diagnosis. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2014, 40, 351-AP1.	0.4	20
994	Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA. <i>Epidemiology and Infection</i> , 2014, 142, 1459-1466.	1.0	5
995	Testing Baby Boomers for Hepatitis C Virus Infection. <i>Public Health Reports</i> , 2014, 129, 220-221.	1.3	1
996	Hepatitis C Seroprevalence among Prison Inmates since 2001: Still High but Declining. <i>Public Health Reports</i> , 2014, 129, 187-195.	1.3	103
997	Determinants of the Availability of Hepatitis C Testing Services in Opioid Treatment Programs: Results From a National Study. <i>American Journal of Public Health</i> , 2014, 104, e75-e82.	1.5	23
998	Confronting the Emerging Epidemic of HCV Infection Among Young Injection Drug Users. <i>American Journal of Public Health</i> , 2014, 104, 816-821.	1.5	75
999	Impact of Race/Ethnicity and Gender on HCV Screening and Prevalence Among US Veterans in Department of Veterans Affairs Care. <i>American Journal of Public Health</i> , 2014, 104, S555-S561.	1.5	48
1000	Prevalence of HCV Infection Among Clients in Community-Based Health Settings in Hawaii, 2002–2010: Assessing Risk Factors. <i>American Journal of Public Health</i> , 2014, 104, 1534-1539.	1.5	8
1001	Mortality Caused by Chronic Liver Disease Among American Indians and Alaska Natives in the United States, 1999–2009. <i>American Journal of Public Health</i> , 2014, 104, S350-S358.	1.5	24
1002	Risk Factors for HCV Infection Among Young Adults in Rural New York Who Inject Prescription Opioid Analgesics. <i>American Journal of Public Health</i> , 2014, 104, 2226-2232.	1.5	89
1003	Estimating Acute Viral Hepatitis Infections From Nationally Reported Cases. <i>American Journal of Public Health</i> , 2014, 104, 482-487.	1.5	68
1004	Epidemiology of Hepatitis C Virus in Pennsylvania State Prisons, 2004–2012: Limitations of 1945–1965 Birth Cohort Screening in Correctional Settings. <i>American Journal of Public Health</i> , 2014, 104, e69-e74.	1.5	26
1005	Assessment of Hepatitis C Risk Factors and Infection Prevalence in a Jail Population. <i>American Journal of Public Health</i> , 2014, 104, 1722-1727.	1.5	24
1006	Previous Exposure to HCV Among Persons Born During 1945–1965: Prevalence and Predictors, United States, 1999–2008. <i>American Journal of Public Health</i> , 2014, 104, 474-481.	1.5	40
1007	P0879 : Examining the clinical course of genotype 1 chronic Hepatitis C patients treated with the COSMOS regimen: including patients with advanced liver disease, and East Asian ancestry. <i>Journal of Hepatology</i> , 2015, 62, S671.	1.8	1
1008	Increased Risk of Intracerebral Hemorrhage Among Patients With Hepatitis C Virus Infection. <i>Medicine (United States)</i> , 2015, 94, e2132.	0.4	17
1009	Training the next generation of hepatologist: What will they need to know?. <i>Clinical Liver Disease</i> , 2015, 5, 129-131.	1.0	9
1010	Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. <i>Hepatology</i> , 2015, 62, 1339-1341.	3.6	33

#	ARTICLE	IF	CITATIONS
1011	Seroprevalencia de hepatitis C en usuarios de unidades de medicina familiar en Quer�taro, M�xico. <i>Atenci�n Familiar</i> , 2015, 22, 2-6.	0.0	2
1013	The epidemiology of hepatitis C virus in Afghanistan: systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2015, 40, 54-63.	1.5	33
1014	Directly acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 394-402.	2.3	15
1015	Cost-effectiveness of strategies for testing current hepatitis C virus infection. <i>Hepatology</i> , 2015, 62, 1396-1404.	3.6	34
1016	Awareness of HCV Infection Among Persons Who Inject Drugs in San Diego, California. <i>American Journal of Public Health</i> , 2015, 105, 302-303.	1.5	11
1017	The birth and potential death of <i>IL28B</i> genotyping for hepatitis C therapy. <i>Personalized Medicine</i> , 2015, 12, 55-57.	0.8	2
1018	Treatment of hepatitis C in patients with HIV. <i>Lancet HIV</i> , 2015, 2, e308-e309.	2.1	4
1019	Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment. <i>BMC Gastroenterology</i> , 2015, 15, 124.	0.8	7
1020	Use of parenteral caffeineum natrio-benzoicum: an underestimated risk factor for HCV transmission in China. <i>BMC Public Health</i> , 2015, 15, 928.	1.2	11
1021	Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. <i>Cancer</i> , 2015, 121, 2874-2882.	2.0	63
1022	Survey of US Correctional Institutions for Routine HCV Testing. <i>American Journal of Public Health</i> , 2015, 105, 68-71.	1.5	29
1023	A Window of Opportunity: Maximizing the Effectiveness of New HCV Regimens in the United States With the Expansion of the Affordable Care Act. <i>American Journal of Public Health</i> , 2015, 105, 457-463.	1.5	7
1024	Increasing Volume but Decreasing Mortality of Hospitalized Hepatitis C Patients in the United States, 2005 to 2011. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 620-627.	1.1	8
1025	Reappraisal of the hepatitis C virus-positive donor in solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 267-275.	0.8	8
1026	A Comparison of Liver Disease Mortality With HIV and Overdose Mortality Among Georgia Prisoners and Releasees: A 2-Decade Cohort Study of Prisoners Incarcerated in 1991. <i>American Journal of Public Health</i> , 2015, 105, e51-e57.	1.5	27
1027	Toward a more accurate estimate of the prevalence of hepatitis C in the United States. <i>Hepatology</i> , 2015, 62, 1353-1363.	3.6	364
1028	Measuring chronic liver disease mortality using an expanded cause of death definition and medical records in Connecticut, 2004. <i>Hepatology Research</i> , 2015, 45, 960-968.	1.8	10
1029	Predictors of Early Discontinuation of Pegylated Interferon for Reasons Other Than Lack of Efficacy in United States Veterans With Chronic Hepatitis C. <i>Gastroenterology Nursing</i> , 2015, 38, 417-428.	0.2	3

#	ARTICLE	IF	CITATIONS
1030	Kidney Transplantation Threshold in Patients With Hepatitis C. <i>Transplantation</i> , 2015, 99, 829-834.	0.5	2
1031	Changing the face of hepatitis C management – the design and development of sofosbuvir. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2367.	2.0	21
1032	Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. <i>World Journal of Hepatology</i> , 2015, 7, 1843.	0.8	41
1033	Liver Cell Carcinoma in Poland: Data Reported to the National Health Fund in the Years 2008-2012. <i>Journal of Liver</i> , 2015, 04, .	0.3	2
1034	Hepatitis: Prevalence, Risk Factors and Associated Co-morbidities in Local Population of Karachi, Pakistan. <i>Journal of Bioequivalence & Bioavailability</i> , 2015, 07, .	0.1	1
1036	The Prevalence and Presumed Etiology of Elevated Aminotransferase Levels in a Pacific Northwest Tribal Community. <i>Journal of Health Care for the Poor and Underserved</i> , 2015, 26, 957-966.	0.4	2
1037	Seroprevalence and risk factors of Hepatitis B and Hepatitis C infections among pregnant women in the Asante Akim North Municipality of the Ashanti region, Ghana; a cross sectional study. <i>African Health Sciences</i> , 2015, 15, 709.	0.3	30
1038	Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. <i>PLoS ONE</i> , 2015, 10, e0125214.	1.1	25
1039	Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. <i>PLoS ONE</i> , 2015, 10, e0129053.	1.1	67
1040	Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004&ac82202009. <i>PLoS ONE</i> , 2015, 10, e0132056.	1.1	8
1041	The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0135281.	1.1	48
1042	Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago. <i>PLoS ONE</i> , 2015, 10, e0135901.	1.1	30
1043	Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder. <i>BioMed Research International</i> , 2015, 2015, 1-18.	0.9	81
1044	Evaluation of Liver Fibrosis Using Texture Analysis on Combined-Contrast-Enhanced Magnetic Resonance Images at 3.0T. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	28
1045	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. <i>Annals of Hepatology</i> , 2015, 14, 181-189.	0.6	18
1046	Reasons for HCV non-treatment in underserved African Americans: Implications for treatment with new therapeutics. <i>Annals of Hepatology</i> , 2015, 14, 234-242.	0.6	15
1048	Self-Efficacy and Adherence to Antiviral Treatment for Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 76-83.	1.1	24
1049	Hepatitis C Virus Screening. <i>Journal of Pharmacy Technology</i> , 2015, 31, 13-19.	0.5	2

#	ARTICLE	IF	CITATIONS
1050	New hepatitis C virus therapies. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 235-241.	0.8	59
1051	Hepatitis C Infection in the Elderly. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3170-3180.	1.1	33
1052	Prevalence and risk factors for patient-reported joint pain among patients with HIV/Hepatitis C coinfection, Hepatitis C mono-infection, and HIV mono-infection. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 93.	0.8	12
1053	Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission. <i>BMC Research Notes</i> , 2015, 8, 367.	0.6	21
1054	Screening for hepatitis C in average and high-risk populations of Qatar using rapid point-of-care testing. <i>United European Gastroenterology Journal</i> , 2015, 3, 364-370.	1.6	3
1055	Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 319-342.	1.4	12
1056	Hepatitis C therapy: Looking toward interferon-sparing regimens. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, e72-e86.	0.7	8
1057	Can statistical linkage of missing variables reduce bias in treatment effect estimates in comparative effectiveness research studies?. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 455-463.	0.6	1
1058	Variation in cancer risk among tissues can be explained by the number of stem cell divisions. <i>Science</i> , 2015, 347, 78-81.	6.0	1,561
1059	Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 443-450.	0.7	5
1060	Cyclophilin and NS5A Inhibitors, but Not Other Anti-Hepatitis C Virus (HCV) Agents, Preclude HCV-Mediated Formation of Double-Membrane-Vesicle Viral Factories. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2496-2507.	1.4	52
1061	Chronic Hepatitis C Infection as a Risk Factor for Renal Cell Carcinoma. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1820-1824.	1.1	21
1062	Hepatitis A and B Immunity and Vaccination in Chronic Hepatitis B and C Patients in a Large United States Cohort. <i>Clinical Infectious Diseases</i> , 2015, 60, 514-522.	2.9	11
1063	Viral Infections During Pregnancy. <i>American Journal of Reproductive Immunology</i> , 2015, 73, 199-213.	1.2	391
1064	Historical epidemiology of hepatitis C virus (<sc>HCV</sc>) in select countries – volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 6-25.	1.0	92
1065	A path to eradication of hepatitis C in low- and middle-income countries. <i>Antiviral Research</i> , 2015, 119, 89-96.	1.9	87
1066	Hepatitis C Surveillance among Youth and Young Adults in New York City, 2009–2013. <i>Journal of Urban Health</i> , 2015, 92, 387-399.	1.8	19
1067	Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. <i>Journal of Gastroenterology</i> , 2015, 50, 667-674.	2.3	36

#	ARTICLE	IF	CITATIONS
1068	Reliability of risk-based screening for hepatitis C virus infection among pregnant women in Egypt. <i>Journal of Infection</i> , 2015, 70, 512-519.	1.7	26
1069	Enhancing Our Understanding of Current Therapies for Hepatitis C Virus (HCV). <i>Current HIV/AIDS Reports</i> , 2015, 12, 68-78.	1.1	29
1070	Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2015, 61, 1381-1388.	2.9	29
1071	An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. <i>International Journal of Drug Policy</i> , 2015, 26, 1056-1063.	1.6	33
1072	Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006â€“2013. <i>Drug and Alcohol Dependence</i> , 2015, 152, 194-200.	1.6	42
1073	Pay for Performance in Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2042-2047.	2.4	8
1074	Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. <i>Clinical Therapeutics</i> , 2015, 37, 1713-1725.e3.	1.1	7
1075	Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1015-1030.	0.9	14
1076	The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 298-312.	1.4	90
1077	Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 4-14.	1.1	38
1078	Outcomes in liver transplantation: Does sex matter?. <i>Journal of Hepatology</i> , 2015, 62, 946-955.	1.8	79
1079	Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitisâ€“Virus Patients?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2166-2172.	2.4	40
1080	High Frequency of Active HCV Infection Among Seropositive Cases in West Africa and Evidence for Multiple Transmission Pathways. <i>Clinical Infectious Diseases</i> , 2015, 60, 1033-1041.	2.9	21
1081	Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs?. <i>Journal of Addictive Diseases</i> , 2015, 34, 198-205.	0.8	13
1082	Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C. <i>Addiction Science & Clinical Practice</i> , 2015, 10, 6.	1.2	1
1083	Gender differences in planning ability and hepatitis C virus among people who inject drugs. <i>Addictive Behaviors</i> , 2015, 47, 33-37.	1.7	1
1084	Natural History of Hepatitis C. , 2015, , 120-130.		0
1085	Utility of Evaluating HCV in an Uninsured Population. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1092-1097.	1.1	7

#	ARTICLE	IF	CITATIONS
1086	Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1813-1819.	1.1	31
1087	Unmet Health Care Needs and Hepatitis C Infection Among Persons Who Inject Drugs in Denver and Seattle, 2009. <i>Prevention Science</i> , 2015, 16, 330-340.	1.5	12
1088	Comparison of Risk-Based Hepatitis C Screening and the True Seroprevalence in an Urban Prison System. <i>Journal of Urban Health</i> , 2015, 92, 379-386.	1.8	33
1089	The association of perceived stress and verbal memory is greater in HIV-infected versus HIV-uninfected women. <i>Journal of NeuroVirology</i> , 2015, 21, 422-432.	1.0	55
1090	Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus. <i>Annals of Internal Medicine</i> , 2015, 162, 407-419.	2.0	186
1091	Hepatitis C Virus Antibody Positivity and Predictors Among Previously Undiagnosed Adult Primary Care Outpatients: Cross-Sectional Analysis of a Multisite Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 1145-1152.	2.9	30
1092	Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans Affairs. <i>Epidemiologic Reviews</i> , 2015, 37, 131-143.	1.3	53
1093	Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. <i>Neurology</i> , 2015, 84, 241-250.	1.5	40
1094	Fibrosing Cholestatic Hepatitis C After Hematopoietic Cell Transplantation. <i>American Journal of Surgical Pathology</i> , 2015, 39, 212-220.	2.1	26
1095	Alcoholic hepatitis and <scp>HCV</scp> interactions in the modulation of liver disease. <i>Journal of Viral Hepatitis</i> , 2015, 22, 769-776.	1.0	31
1096	Prevalence of Major Risk Factors and Use of Screening Tests for Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 637-652.	1.1	60
1097	Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. <i>Annals of Internal Medicine</i> , 2015, 162, 397-406.	2.0	303
1098	Effect of the Hepatitis C Virus Protease Inhibitor Faldaprevir on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 514-519.	1.4	5
1099	Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. <i>Journal of General Internal Medicine</i> , 2015, 30, 950-957.	1.3	76
1100	HIV and viral hepatitis co-infection in New York City, 2000â€“2010: prevalence and case characteristics. <i>Epidemiology and Infection</i> , 2015, 143, 1408-1416.	1.0	22
1101	Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 555-565.	0.7	5
1102	Hepatitis C Genotype 3: The Remaining Problem. <i>Current Hepatology Reports</i> , 2015, 14, 267-273.	0.4	0
1103	Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing. <i>Integrative Biology (United Kingdom)</i> , 2015, 7, 1587-1597.	0.6	80

#	ARTICLE	IF	CITATIONS
1104	Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C. <i>General Hospital Psychiatry</i> , 2015, 37, 533-537.	1.2	10
1105	Regulation of HepG2 cell apoptosis by hepatitis C virus (HCV) core protein via the sirt1-p53-bax pathway. <i>Virus Genes</i> , 2015, 51, 338-346.	0.7	15
1106	Hepatitis C. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 901-909.	1.0	16
1107	What does the pharmacological future of treating chronic hepatitis C look like?. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 605-622.	1.3	5
1108	Involuntary treatment of psychiatric inpatients certified under the Saskatchewan Mental Health Services Act in a secure forensic psychiatric treatment center. <i>Medicine, Science and the Law</i> , 2015, 55, 113-120.	0.6	1
1109	Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. <i>Current Gastroenterology Reports</i> , 2015, 17, 462.	1.1	1
1110	Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study. <i>CMAJ Open</i> , 2015, 3, E62-E67.	1.1	9
1111	The safety of daclatasvir for the treatment of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1787-1797.	1.0	3
1112	Epidemiology of Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 699-716.	1.0	30
1113	Interferon- α plus ribavirin yields 98% sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C. <i>Hepatology International</i> , 2015, 9, 578-585.	1.9	5
1114	The continuum of hepatitis C testing and care. <i>Hepatology</i> , 2015, 61, 783-789.	3.6	64
1115	Seroprevalence Rates of Hepatitis C Virus (Hcv) Antibody And Hepatitis B Virus Surface Antigen (Hbsag) in Blood Donors in A Southwestern Nigerian City. <i>Journal of Immunoassay and Immunochemistry</i> , 2015, 36, 91-99.	0.5	10
1117	Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. <i>Journal of Hepatology</i> , 2015, 62, 18-23.	1.8	96
1118	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015, 64, 948-956.	6.1	101
1119	Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2015, 60, 573-581.	1.1	34
1120	Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. <i>Journal of Gastroenterology</i> , 2015, 50, 191-202.	2.3	76
1121	Hepatitis C Virus. , 0, , 351-361.		0
1122	Hepatitis C Virus. , 2016, , 1313-1345.		61

#	ARTICLE	IF	CITATIONS
1123	High Hepatitis C Infection Rate among Baby Boomers in an Urban Primary Care Clinic: Results from the HepTLC Initiative. <i>Public Health Reports</i> , 2016, 131, 49-56.	1.3	20
1124	THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017019.	0.5	34
1125	Hepatitis C Virus universal screening versus risk based selective screening during pregnancy. <i>Journal of Neonatal-Perinatal Medicine</i> , 2016, 8, 371-378.	0.4	34
1126	Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. <i>World Journal of Hepatology</i> , 2016, 8, 1295.	0.8	37
1127	Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data. <i>World Journal of Gastroenterology</i> , 2016, 22, 1684.	1.4	110
1128	Integrating Routine HCV Testing in Primary Care: Lessons Learned from Five Federally Qualified Health Centers in Philadelphia, Pennsylvania, 2012â€“2014. <i>Public Health Reports</i> , 2016, 131, 65-73.	1.3	29
1129	Primary Care Providers Knowledge, Attitude and Practices Related to Hepatitis C Screening and Treatment in the Oral Direct Acting Antiviral Agents Era. , 2016, 06, .		18
1130	Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 714-722b.	0.5	17
1131	Health Disparities in Hepatitis C Screening and Linkage to Care at an Integrated Health System in Southeast Michigan. <i>PLoS ONE</i> , 2016, 11, e0161241.	1.1	51
1132	Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C. <i>PLoS ONE</i> , 2016, 11, e0163945.	1.1	4
1133	Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. <i>Medicine (United States)</i> , 2016, 95, e2482.	0.4	13
1134	Epidemiology and outcomes of hepatitis C infection in elderly <sc>US</sc> Veterans. <i>Journal of Viral Hepatitis</i> , 2016, 23, 687-696.	1.0	39
1135	High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in <sc>HCV</sc>-infected patients treated with sofosbuvir-containing regimens. <i>Journal of Viral Hepatitis</i> , 2016, 23, 667-676.	1.0	5
1136	Public health clinic-based hepatitis C testing and linkage to care in baltimore. <i>Journal of Viral Hepatitis</i> , 2016, 23, 366-374.	1.0	51
1137	The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics. <i>Hepatology</i> , 2016, 63, 1135-1144.	3.6	26
1138	Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. <i>Hepatology</i> , 2016, 64, 47-57.	3.6	147
1139	Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012â€“2014. <i>Public Health Reports</i> , 2016, 131, 91-97.	1.3	16
1140	Real-World Effectiveness and Predictors of Sustained Virological Response with All-Oral Therapy in 21,242 Hepatitis C Genotype-1 Patients. <i>Antiviral Therapy</i> , 2017, 22, 481-493.	0.6	67

#	ARTICLE	IF	CITATIONS
1141	Current Management of Hepatitis C Virus Infection. North Carolina Medical Journal, 2016, 77, 188-193.	0.1	4
1142	Genotype 1 hepatitis C virus and the pharmacist's role in treatment. American Journal of Health-System Pharmacy, 2016, 73, 764-774.	0.5	19
1143	A Large Outbreak of Hepatitis C Virus Infections in a Hemodialysis Clinic. Infection Control and Hospital Epidemiology, 2016, 37, 125-133.	1.0	47
1144	County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 323-331.	0.9	333
1145	Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012-2014. Public Health Reports, 2016, 131, 12-19.	1.3	34
1146	Development and Preliminary Evaluation of an Integrated Cognitive-Behavior Treatment for Chronic Pain and Substance Use Disorder in Patients with the Hepatitis C Virus. Pain Medicine, 2016, 17, 2280-2290.	0.9	17
1147	Hepatitis C virus infection in the 1945-1965 birth cohort (baby boomers) in a large urban ED. American Journal of Emergency Medicine, 2016, 34, 697-701.	0.7	27
1148	Demographic, risk factor, and provider characteristics associated with confirmatory hepatitis C testing. Annals of Epidemiology, 2016, 26, 157-159.	0.9	1
1149	Effect of Hepatitis C Positivity on Survival in Adult Patients Undergoing Heart Transplantation (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	29
1150	Hepatitis C virus in Mexican Americans: a population-based study reveals relatively high prevalence and negative association with diabetes. Epidemiology and Infection, 2016, 144, 297-305.	1.0	4
1151	Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C. Journal of Medical Economics, 2016, 19, 364-373.	1.0	9
1152	A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment. Journal of the National Medical Association, 2016, 108, 24-29.	0.6	30
1153	Association Between Hepatitis C Virus and Head and Neck Cancers. Journal of the National Cancer Institute, 2016, 108, djw035.	3.0	57
1154	Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients. Metabolic Brain Disease, 2016, 31, 869-880.	1.4	31
1155	Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. International Journal of Infectious Diseases, 2016, 46, 116-125.	1.5	55
1156	Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States. Clinical Infectious Diseases, 2016, 62, 1290-1296.	2.9	46
1157	No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening. Clinical Gastroenterology and Hepatology, 2016, 14, 1356-1360.	2.4	13
1158	The ABCs of STIs: An Update on Sexually Transmitted Infections. Clinical Chemistry, 2016, 62, 811-823.	1.5	19

#	ARTICLE	IF	CITATIONS
1159	Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry. <i>Hepatology International</i> , 2016, 10, 616-623.	1.9	5
1160	Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2505-2515.	1.1	12
1161	Acceptance, yield and feasibility of attaching HCV birth cohort screening to colorectal cancer screening in Spain. <i>Digestive and Liver Disease</i> , 2016, 48, 1237-1242.	0.4	7
1162	Genotype distribution of hepatitis C virus among Lebanese patients: Results from a major tertiary care center. <i>Gene Reports</i> , 2016, 4, 190-193.	0.4	0
1163	Diagnostic value of blood tests for occult causes of initially idiopathic small-fiber polyneuropathy. <i>Journal of Neurology</i> , 2016, 263, 2515-2527.	1.8	35
1164	Hepatitis C Treatment and Barriers to Eradication. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e193.	1.3	57
1165	New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners. <i>Health Affairs</i> , 2016, 35, 1893-1901.	2.5	63
1166	HCV dispersal patterns among intravenous drug users (IDUs) in Athens metropolitan area. <i>Infection, Genetics and Evolution</i> , 2016, 45, 415-419.	1.0	3
1167	Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6207-6215.	1.4	3
1169	Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States. <i>Advances in Therapy</i> , 2016, 33, 1316-1330.	1.3	11
1170	Last gasps of the hepatitis C virus dragon: Direct acting antiviral failures and hepatitis C virusâ€“positive donors. <i>Liver Transplantation</i> , 2016, 22, 47-51.	1.3	1
1171	Associations of place characteristics with HIV and HCV risk behaviors among racial/ethnic groups of people who inject drugs in the United States. <i>Annals of Epidemiology</i> , 2016, 26, 619-630.e2.	0.9	6
1172	Annual Report to the Nation on the Status of Cancer, 1975â€“2012, featuring the increasing incidence of liver cancer. <i>Cancer</i> , 2016, 122, 1312-1337.	2.0	761
1173	A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. <i>Phytotherapy Research</i> , 2016, 30, 160-168.	2.8	71
1174	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. <i>Journal of Infectious Diseases</i> , 2016, 214, 1383-1389.	1.9	16
1175	Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. <i>Journal of Viral Hepatitis</i> , 2016, 23, 545-559.	1.0	43
1176	High-Yield Birth-Cohort Hepatitis C Virus Screening and Linkage to Care among Underserved African Americans, Atlanta, Georgia, 2012â€“2013. <i>Public Health Reports</i> , 2016, 131, 84-90.	1.3	22
1177	Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. <i>Drug and Alcohol Dependence</i> , 2016, 169, 101-109.	1.6	58

#	ARTICLE	IF	CITATIONS
1178	Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort. <i>BMC Infectious Diseases</i> , 2016, 16, 334.	1.3	38
1179	The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. <i>Trials</i> , 2016, 17, 592.	0.7	36
1180	Racial Disparities in Treatment Rates for Chronic Hepatitis C. <i>Medicine (United States)</i> , 2016, 95, e3719.	0.4	36
1181	Prevalence and association of hepatitis C virus infection with different types of lymphoma. <i>International Journal of Cancer</i> , 2016, 138, 1035-1037.	2.3	24
1182	Cascade of Care for Hepatitis C Virus Infection Within the US Veterans Health Administration. <i>American Journal of Public Health</i> , 2016, 106, 353-358.	1.5	60
1183	Alcohol intake alters immune responses and promotes CNS viral persistence in mice. <i>Behavioural Brain Research</i> , 2016, 312, 1-8.	1.2	3
1184	Apportioning blame in the North American hepatitis C virus epidemic. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 626-627.	4.6	4
1185	Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections. <i>Mathematical Biosciences</i> , 2016, 273, 102-113.	0.9	13
1186	Disparities in hepatitis C testing in U.S. veterans born 1945-1965. <i>Journal of Hepatology</i> , 2016, 65, 259-265.	1.8	22
1187	Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders. <i>Journal of Substance Abuse Treatment</i> , 2016, 66, 54-59.	1.5	15
1188	High-impact hepatitis C virus testing for injection drug users in an urban ED. <i>American Journal of Emergency Medicine</i> , 2016, 34, 1108-1111.	0.7	10
1189	Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2016, 11, 13.	1.0	6
1190	On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial. <i>Trials</i> , 2016, 17, 117.	0.7	12
1191	Medication-Assisted Treatment for Substance use Disorders within a National Community Health Center Research Network. <i>Substance Abuse</i> , 2016, 37, 625-634.	1.1	22
1192	Senior Center-Based Hepatitis C Screening in Baltimore. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv217.	0.4	6
1193	Moderate Alcohol Use and Insulin Action in Chronic Hepatitis C Infection. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2417-2425.	1.1	2
1194	Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. <i>Hepatology</i> , 2016, 64, 1442-1450.	3.6	126
1195	Comparative effectiveness of ledipasvir/sofosbuvir±aribavirin vs. ombitasvir/paritaprevir/ritonavir±adasabuvir±aribavirin in 6961 genotype 1 patients treated in routine medical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 400-410.	1.9	64

#	ARTICLE	IF	CITATIONS
1196	The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. <i>Clinical Infectious Diseases</i> , 2016, 62, 298-304.	2.9	46
1197	Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 21-36.	1.4	9
1198	Infectious Diseases and the Kidney in Children. , 2016, , 1609-1654.		3
1199	Clinical Care Pathways for Patients With Hepatitis C: Reducing Critical Barriers to Effective Treatment. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv218.	0.4	26
1200	Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm ³ Is More Pronounced Among Women Than Men. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv214.	0.4	6
1201	Ganetespib radiosensitization for liver cancer therapy. <i>Cancer Biology and Therapy</i> , 2016, 17, 457-466.	1.5	12
1202	Treatment of dyslipidemia with statins by primary care providers in Veterans with and without chronic Hepatitis C. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, S30-S34.	0.5	2
1203	Safety and efficacy of ledipasvir+sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. <i>Hepatology</i> , 2016, 63, 437-444.	3.6	55
1204	Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C Virus-Infected Women. <i>Clinical Infectious Diseases</i> , 2016, 62, 980-985.	2.9	94
1205	The American College of Preventive Medicine Position Statement on Hepatitis C Virus Infection. <i>American Journal of Preventive Medicine</i> , 2016, 50, 419-426.	1.6	5
1206	An evaluation of hepatitis C knowledge and correlations with health belief model constructs among African American "baby boomers". <i>Journal of Infection and Public Health</i> , 2016, 9, 436-442.	1.9	11
1207	Simeprevir and Sofosbuvir (SMV+SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. <i>American Journal of Gastroenterology</i> , 2016, 111, 250-260.	0.2	16
1208	Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama. <i>Clinical Infectious Diseases</i> , 2016, 62, 613-616.	2.9	6
1209	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 686-692.	1.4	10
1210	An Improved and Enantioselective Preparation of the Telaprevir Bicyclic [3.3.0] Proline Intermediate and Reuse of Unwanted Enantiomer. <i>Organic Process Research and Development</i> , 2016, 20, 320-324.	1.3	14
1211	Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. <i>Clinics in Liver Disease</i> , 2016, 20, 293-312.	1.0	217
1212	Hepatitis C virus infection as a risk factor for Parkinson disease. <i>Neurology</i> , 2016, 86, 840-846.	1.5	63
1213	Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 111-116.	1.3	31

#	ARTICLE	IF	CITATIONS
1214	Shifting Away From Fee-For-Service: Alternative Approaches to Payment in Gastroenterology. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 497-506.	2.4	21
1215	Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival. <i>Journal of Hepatology</i> , 2016, 64, 326-332.	1.8	21
1216	Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index. <i>Journal of Gastroenterology</i> , 2016, 51, 380-389.	2.3	18
1217	Characterization of ADME properties of [¹⁴ C]asunaprevir (BMS-650032) in humans. <i>Xenobiotica</i> , 2016, 46, 52-64.	0.5	13
1218	HCV Prevalence in Asian Americans in California. <i>Journal of Immigrant and Minority Health</i> , 2017, 19, 91-97.	0.8	8
1219	Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. <i>Health Care Management Science</i> , 2017, 20, 16-32.	1.5	14
1220	National trends of hepatitis B and C during pregnancy across sociodemographic, behavioral, and clinical factors, United States, 1998â€“2011. <i>Journal of Medical Virology</i> , 2017, 89, 1025-1032.	2.5	20
1221	Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid. <i>Healthcare</i> , 2017, 5, 105-111.	0.6	5
1222	Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 200-210.	3.7	93
1223	A systematic model improves hepatitis C virus birth cohort screening in hospitalâ€“based primary care. <i>Journal of Viral Hepatitis</i> , 2017, 24, 477-485.	1.0	29
1224	Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. <i>Gastroenterology</i> , 2017, 152, 1090-1099.e1.	0.6	487
1225	Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant. <i>Hepatology International</i> , 2017, 11, 434-439.	1.9	6
1226	Hepatitis C virus infection and risk of thyroid cancer: A systematic review and meta-analysis. <i>Arab Journal of Gastroenterology</i> , 2017, 18, 1-5.	0.4	21
1227	Retention in buprenorphine treatment is associated with improved HCV care outcomes. <i>Journal of Substance Abuse Treatment</i> , 2017, 75, 38-42.	1.5	32
1228	Long-Term Liver Diseases after Initiation of Antiretroviral Therapy in HIV-Infected Patients with and without HBV or HCV Coinfection. <i>Journal of the International Association of Providers of AIDS Care</i> , 2017, 16, 194-200.	0.6	2
1229	Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist. <i>Infectious Agents and Cancer</i> , 2017, 12, 12.	1.2	9
1230	Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008â€“2013: A nationwide retrospective cohort study. <i>Journal of Hepatology</i> , 2017, 67, 454-461.	1.8	41
1231	Chronic hepatitis. , 2017, , 1058-1064.e2.		0

#	ARTICLE	IF	CITATIONS
1232	Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct-Acting Antiviral Era. <i>Current Epidemiology Reports</i> , 2017, 4, 174-185.	1.1	48
1233	Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III. <i>Journal of Viral Hepatitis</i> , 2017, 24, 380-388.	1.0	8
1234	Hepatitis C infection. <i>Nurse Practitioner</i> , 2017, 42, 14-23.	0.2	1
1235	Updated Review of Prevalence of Major Risk Factors and Use of Screening Tests for Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1192-1208.	1.1	64
1236	Utilization of Organs From Donors According to Hepatitis C Antibody and Nucleic Acid Testing Status: Time for Change. <i>American Journal of Transplantation</i> , 2017, 17, 2863-2868.	2.6	59
1237	Audio-computer-assisted survey interview and patient navigation to increase chronic viral hepatitis diagnosis and linkage to care in urban health clinics. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1184-1191.	1.0	4
1238	Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2017, 112, 1495-1505.	0.2	83
1239	Confluence of Epidemics of Hepatitis C, Diabetes, Obesity, and Chronic Kidney Disease in the United States Population. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1957-1964.e7.	2.4	30
1240	Hepatitis C Virus E1 protein promotes cell migration and invasion by modulating cellular metastasis suppressor Nm23-H1. <i>Virology</i> , 2017, 506, 110-120.	1.1	21
1241	Predictors of hepatitis C testing intention among African American Baby Boomers. <i>Journal of Epidemiology and Global Health</i> , 2017, 7, 119.	1.1	1
1242	Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations. <i>Value in Health</i> , 2017, 20, 736-744.	0.1	15
1243	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2017, 166, 637.	2.0	540
1244	Prevalence of Hepatitis C Screening in an HIV Primary Care Clinic. <i>Journal of the Association of Nurses in AIDS Care</i> , 2017, 28, 422-427.	0.4	1
1245	Therapeutic Considerations in HIV-Associated Neurocognitive Disorders. , 2017, , 737-751.		2
1246	Advancing the Public's Health by Scaling Innovations in Clinical Quality. <i>Public Health Reports</i> , 2017, 132, 512-517.	1.3	2
1247	Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1867-1874.	0.9	14
1248	Hepatitis C Virus Infection in the Older Patient. <i>Infectious Disease Clinics of North America</i> , 2017, 31, 827-838.	1.9	46
1249	Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3193-3199.	1.1	0

#	ARTICLE	IF	CITATIONS
1250	Short article. European Journal of Gastroenterology and Hepatology, 2017, 29, 1219-1222.	0.8	20
1251	Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?. Annals of Pharmacotherapy, 2017, 51, 961-969.	0.9	3
1252	Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy. Current Hepatology Reports, 2017, 16, 169-177.	0.4	3
1253	Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers. Hepatology, 2017, 66, 1805-1813.	3.6	92
1254	The Effect of Psychosocial Factors on Success Rates of Hepatitis C Treatment. Psychosomatics, 2017, 58, 624-632.	2.5	11
1255	Hepatitis C virus infection among patients admitted to a rheumatology ward in northern Cyprus. Egyptian Rheumatologist, 2017, 39, 245-247.	0.5	2
1256	Neighborhood Inequalities in Hepatitis C Mortality: Spatial and Temporal Patterns and Associated Factors. Journal of Urban Health, 2017, 94, 746-755.	1.8	18
1257	Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response. Alimentary Pharmacology and Therapeutics, 2017, 46, 605-616.	1.9	13
1258	Diabetes Mellitus is Associated With Higher Risk of Developing Decompensated Cirrhosis in Chronic Hepatitis C Patients. Journal of Clinical Gastroenterology, 2017, 51, 70-76.	1.1	14
1259	Diabetes Among People With Tuberculosis, HIV Infection, Viral Hepatitis B and C, and STDs in New York City, 2006-2010. Journal of Public Health Management and Practice, 2017, 23, 461-467.	0.7	2
1260	Moderate Alcohol Use Is Not Associated With Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Women: A Prospective Cohort Study. Clinical Infectious Diseases, 2017, 65, 2050-2056.	2.9	10
1261	Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD study. Cancer, 2017, 123, 5059-5078.	2.0	48
1262	Distribution of Hepatitis C Virus Genotypes and Subtypes in the Metropolitan Area of Naples, Italy, in the Era of Interferon-Free Regimens. Intervirology, 2017, 60, 82-89.	1.2	8
1263	Historical epidemiology of hepatitis C virus in select countries volume 4. Journal of Viral Hepatitis, 2017, 24, 8-24.	1.0	30
1264	Hepatitis C. Primary Care - Clinics in Office Practice, 2017, 44, 631-642.	0.7	5
1265	The impact of hepatitis C virus infection on 90-day outcomes following major orthopaedic surgery: a propensity-matched analysis. Archives of Orthopaedic and Trauma Surgery, 2017, 137, 1181-1186.	1.3	15
1266	Identifying and characterizing hepatitis C virus hotspots in Massachusetts: a spatial epidemiological approach. BMC Infectious Diseases, 2017, 17, 294.	1.3	35
1267	Burden of hepatocellular carcinoma among hispanics in South Texas: a systematic review. Biomarker Research, 2017, 5, 15.	2.8	19

#	ARTICLE	IF	CITATIONS
1268	Spending on Hepatitis C Antivirals in the United States, 2009â€“2015. <i>Pharmacotherapy</i> , 2017, 37, 65-70.	1.2	8
1269	Hepatitis Viruses. , 2017, , 1417-1425.e1.		1
1270	Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: Tail of a cohort infected in past decades. <i>Journal of Medical Virology</i> , 2017, 89, 291-297.	2.5	39
1271	Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. <i>Gastroenterology</i> , 2017, 152, 812-820.e5.	0.6	339
1272	Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2017, 52, 504-511.	2.3	16
1274	ACR Appropriateness Criteria Â® Chronic LiverÂDisease. <i>Journal of the American College of Radiology</i> , 2017, 14, S391-S405.	0.9	18
1275	Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1â€“Infected Individuals: SWIFT-C. <i>Clinical Infectious Diseases</i> , 2017, 64, 1035-1042.	2.9	42
1276	Liver Diseases in the Elderly. , 2017, , 331-339.		1
1277	Liver transplantation for chronic hepatitis C virus infection in the United States 2002â€“2014: An analysis of the UNOS/OPTN registry. <i>PLoS ONE</i> , 2017, 12, e0186898.	1.1	18
1278	Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. <i>PLoS Pathogens</i> , 2017, 13, e1006235.	2.1	47
1279	Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2017, 23, 151.	1.4	53
1280	GHOST: global hepatitis outbreak and surveillance technology. <i>BMC Genomics</i> , 2017, 18, 916.	1.2	38
1281	Racial Disparities in Hepatitis C Treatment Eligibility. <i>Annals of Hepatology</i> , 2017, 16, 530-537.	0.6	16
1282	Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection. <i>Bangladesh Journal of Pharmacology</i> , 2017, 12, 12.	0.1	5
1283	Emerging concepts in alcoholic hepatitis. <i>World Journal of Hepatology</i> , 2017, 9, 567.	0.8	32
1284	Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid Patients. <i>Health Equity</i> , 2017, 1, 156-164.	0.8	1
1285	Race affects <sc>SVR</sc> 12 in a large and ethnically diverse hepatitis Câ€“infected patient population following treatment with directâ€“acting antivirals: Analysis of a singleâ€“center Department of Veterans Affairs cohort. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00379.	1.1	19
1286	Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 546-551.	0.8	43

#	ARTICLE	IF	CITATIONS
1287	Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. Expert Opinion on Pharmacotherapy, 2018, 19, 451-456.	0.9	3
1288	Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?. Annals of Pharmacotherapy, 2018, 52, 1152-1157.	0.9	9
1289	Individual-level key associations and modes of exposure for hepatitis C virus infection in the Middle East and North Africa: a systematic synthesis. Annals of Epidemiology, 2018, 28, 452-461.	0.9	20
1290	Rural Incarcerated Women: HIV/HCV Knowledge and Correlates of Risky Behavior. Health Education and Behavior, 2018, 45, 977-986.	1.3	12
1291	Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs. Libyan Journal of Medicine, 2018, 13, 1435124.	0.8	29
1292	Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort. Digestive Diseases and Sciences, 2018, 63, 1454-1462.	1.1	5
1293	Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Alimentary Pharmacology and Therapeutics, 2018, 47, 1023-1031.	1.9	25
1295	Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy. Alimentary Pharmacology and Therapeutics, 2018, 47, 1012-1022.	1.9	50
1296	Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. Drug Metabolism and Disposition, 2018, 46, 189-196.	1.7	43
1297	Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E82-E91.	3.3	52
1298	The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Scientific Reports, 2018, 8, 150.	1.6	87
1299	Improvements in Quality of Life: A New Indication for Treating Hepatitis C Virus Infection in Persons With Substance Use Disorders. Journal of Infectious Diseases, 2018, 217, 1020-1023.	1.9	6
1300	Hepatitis C Virus Screening Among Children Exposed During Pregnancy. Pediatrics, 2018, 141, .	1.0	85
1301	Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population. Journal of Viral Hepatitis, 2018, 25, 205-208.	1.0	6
1302	Retrospective analysis on the diagnostic performances and signal-to-cut-off ratios of the Elecsys Anti-HCV II assay. Journal of Clinical Laboratory Analysis, 2018, 32, e22165.	0.9	11
1303	The Predictive Value of International Classification of Disease Codes for Chronic Hepatitis C Virus Infection Surveillance: The Utility and Limitations of Electronic Health Records. Population Health Management, 2018, 21, 110-115.	0.8	8
1304	Robust Postdonation Blood Screening Under Prevalence Rate Uncertainty. Operations Research, 2018, 66, 1-17.	1.2	20
1305	Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology, 2018, 67, 837-846.	3.6	61

#	ARTICLE	IF	CITATIONS
1306	Implementation of a multidisciplinary, team-based model to treat chronic hepatitis C in the primary care setting: Lessons learned. <i>Healthcare</i> , 2018, 6, 205-209.	0.6	8
1307	Population-level intervention and information collection in dynamic healthcare policy. <i>Health Care Management Science</i> , 2018, 21, 604-631.	1.5	6
1308	Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection. <i>International Journal of STD and AIDS</i> , 2018, 29, 334-340.	0.5	8
1309	Clinical profile of hepatitis C virus infection in a developing country: India. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 926-933.	1.4	20
1310	Hepatitis C virus testing for case identification in persons born during 1945–1965: Results from three randomized controlled trials. <i>Hepatology</i> , 2018, 67, 524-533.	3.6	18
1311	Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. <i>Journal of Viral Hepatitis</i> , 2018, 25, 354-362.	1.0	20
1312	Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy. <i>Infection</i> , 2018, 46, 93-101.	2.3	22
1313	State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015. <i>Value in Health</i> , 2018, 21, 692-697.	0.1	13
1314	Recreational Drug and Psychosocial Profile in Chronic Hepatitis C Patients Seeking Antiviral Therapy. <i>Annals of Hepatology</i> , 2018, 17, 76-84.	0.6	2
1315	Barriers in Hepatitis C Treatment in Somali Patients in the Direct Acting Antiviral Therapy Era. <i>Journal of the National Medical Association</i> , 2018, 110, 556-559.	0.6	3
1316	Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1200-1207.	0.8	15
1317	Epidemiology, Natural History, and Diagnosis of Hepatitis C. , 2018, , 428-445.e8.		1
1318	HIV and the Liver. , 2018, , 536-555.e7.		1
1319	Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. <i>PLoS ONE</i> , 2018, 13, e0209374.	1.1	12
1320	Hepatitis C virus among pregnant women and children in the USA: an emerging epidemic. <i>Future Virology</i> , 2018, 13, 855-862.	0.9	0
1321	Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 993-1002.	1.9	27
1322	Results of a Hepatitis C Virus Screening Program of the 1945–1965 Birth Cohort in a Large Emergency Department in New Jersey. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy065.	0.4	15
1323	Alcohol Use in Patients with Chronic Liver Disease. <i>New England Journal of Medicine</i> , 2018, 379, 1251-1261.	13.9	137

#	ARTICLE	IF	CITATIONS
1324	Hepatitis C infection and psychiatric burden in two imprisoned cohorts: Young offenders and opioid-maintained prisoners. <i>Health Policy</i> , 2018, 122, 1392-1402.	1.4	3
1325	Increased Risk of Hepatocellular Carcinoma Associated With Neighborhood Concentrated Disadvantage. <i>Frontiers in Oncology</i> , 2018, 8, 375.	1.3	11
1326	Impact of Cigarette Smoking Status on Pain Intensity Among Veterans With and Without Hepatitis C. <i>Pain Medicine</i> , 2018, 19, S5-S11.	0.9	2
1327	Advanced Hepatocellular Carcinoma Tumor Stage at Diagnosis in the 1945-1965 Birth Cohort Reflects Poor Use of Hepatocellular Carcinoma Screening. <i>Hepatology Communications</i> , 2018, 2, 1147-1155.	2.0	8
1328	Optimal Information Collection Policies in a Markov Decision Process Framework. <i>Medical Decision Making</i> , 2018, 38, 797-809.	1.2	3
1329	Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting. <i>International Journal of Hepatology</i> , 2018, 2018, 1-8.	0.4	7
1330	A Bayesian evidence synthesis approach to estimate disease prevalence in hard-to-reach populations: hepatitis C in New York City. <i>Epidemics</i> , 2018, 23, 96-109.	1.5	9
1331	Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 461-480.	1.9	15
1332	The Road to Hepatitis C Virus Cure. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 481-493.	1.9	3
1333	Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 347-370.	1.9	25
1334	Insulin Resistance and Metabolic Syndrome: Clinical and Laboratory Associations in African Americans Without Diabetes in the Hemochromatosis and Iron Overload Screening Study. <i>Metabolic Syndrome and Related Disorders</i> , 2018, 16, 267-273.	0.5	0
1335	A Systematic Comparison of African American and Non-African American Patients on Psychosocial Aspects of Hepatitis C Infection. <i>Journal of Religion and Health</i> , 2018, 57, 1764-1770.	0.8	2
1336	Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1339-1345.	1.3	10
1337	Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. <i>Journal of Immunology Research</i> , 2018, 2018, 1-13.	0.9	8
1338	Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013-2016. <i>Advances in Therapy</i> , 2018, 35, 1087-1102.	1.3	22
1339	Epidemiology and Modes of Transmission of HCV in Developing Countries. , 2018, , 13-22.		1
1340	Incidence and prevalence of antibody to hepatitis C virus in FDNY first responders before and after work at the World Trade Center disaster site. <i>American Journal of Industrial Medicine</i> , 2018, 61, 733-740.	1.0	1
1341	Hepatitis C and Pregnancy. , 2018, , 111-118.		0

#	ARTICLE	IF	CITATIONS
1342	The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2018, 72, 73-85.	0.8	7
1343	Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010. <i>BMC Infectious Diseases</i> , 2018, 18, 224.	1.3	31
1344	Incidence of primary liver cancer in American Indians and Alaska Natives, US, 1999â€“2009. <i>Cancer Causes and Control</i> , 2018, 29, 833-844.	0.8	23
1345	Hepatitis C Treatment in the Era of Direct-Acting Antiviral Agents. , 2018, , 209-246.		3
1346	Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers. <i>Clinical Therapeutics</i> , 2018, 40, 1234-1245.	1.1	37
1347	The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. <i>Royal Society Open Science</i> , 2018, 5, 180257.	1.1	83
1348	Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C. <i>Adolescent Health, Medicine and Therapeutics</i> , 2018, Volume 9, 103-110.	0.7	2
1349	The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey. <i>PLoS ONE</i> , 2018, 13, e0200461.	1.1	27
1350	Realâ€world effectiveness of elbasvir/grazoprevir in <sc>HCV</sc>-infected patients in the <sc>US</sc> veterans affairs healthcare system. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1270-1279.	1.0	30
1351	Provider Attitudes toward the Use of Hepatitis C Virus-Positive Organs in Kidney Transplantation. <i>American Journal of Nephrology</i> , 2019, 50, 168-176.	1.4	8
1352	Comparing drug safety of hepatitis C therapies using post-market data. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 147.	1.5	7
1353	Community screening for hepatitis C virus infection in a low-prevalence population. <i>BMC Public Health</i> , 2019, 19, 1038.	1.2	3
1354	The role of tacstd-2 level in hepatitis C patients (controlled clinical research). <i>Libyan Journal of Medicine</i> , 2019, 14, 1622363.	0.8	1
1356	Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1293-1300.	1.0	5
1357	Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis. <i>JAMA Network Open</i> , 2019, 2, e196412.	2.8	56
1358	Natural history of liverâ€related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model. <i>Journal of Medical Virology</i> , 2019, 91, 1837-1844.	2.5	12
1359	Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992â€“2016. <i>Cancer Causes and Control</i> , 2019, 30, 1377-1388.	0.8	15
1360	The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®). <i>Topics in Medicinal Chemistry</i> , 2019, , 237-280.	0.4	1

#	ARTICLE	IF	CITATIONS
1361	Charges for Alcoholic Cirrhosis Exceed All Other Etiologies of Cirrhosis Combined: A National and State Inpatient Survey Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1460-1469.	1.1	36
1362	Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 930-939.e9.	2.4	70
1363	The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 66-74.	1.9	37
1364	Preliminary Screening Results Outside the 1945-1965 Birth Cohort: A Forgotten Population for Hepatitis C?. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz178.	0.4	4
1365	An evaluation of the hepatitis C testing, care and treatment program in the country of Georgia's corrections system, December 2013 - April 2015. <i>BMC Public Health</i> , 2019, 19, 466.	1.2	8
1366	Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system. <i>PLoS ONE</i> , 2019, 14, e0216459.	1.1	20
1367	Real-world study of hepatitis C treatment with direct-acting antivirals in patients with drug abuse and opioid agonist therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 646-655.	0.6	6
1368	Community Screening, Identification, and Referral to Primary Care, for Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles. <i>Journal of Community Health</i> , 2019, 44, 1044-1054.	1.9	18
1369	Alcohol and hepatocellular carcinoma. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000260.	1.1	46
1370	Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. <i>BMJ Open</i> , 2019, 9, e026726.	0.8	34
1371	Manipulation of Type I Interferon Signaling by HIV and AIDS-Associated Viruses. <i>Journal of Immunology Research</i> , 2019, 2019, 1-10.	0.9	12
1373	Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States. <i>Annals of Hepatology</i> , 2019, 18, 360-365.	0.6	6
1374	HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era. <i>Journal of Public Health</i> , 2019, 41, e283-e289.	1.0	10
1375	The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 513-521.	1.0	2
1376	Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. <i>Epidemics</i> , 2019, 27, 86-95.	1.5	21
1377	Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. <i>Kidney International</i> , 2019, 95, 939-947.	2.6	89
1378	Hepatitis C prevalence and associated risk factors among individuals who are homeless and diagnosed with mental illness: At Home/Chez Soi Study, Vancouver, BC. <i>European Journal of Public Health</i> , 2019, 29, 242-247.	0.1	13
1379	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Gastroenterology</i> , 2019, 156, 1496-1507.e7.	0.6	32

#	ARTICLE	IF	CITATIONS
1380	Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals – a retrospective cohort study. <i>Transplant International</i> , 2019, 32, 854-864.	0.8	13
1381	Experiences with interferon-free hepatitis C therapies: addressing barriers to adherence and optimizing treatment outcomes. <i>BMC Health Services Research</i> , 2019, 19, 91.	0.9	11
1382	Temporal trends in liver cancer mortality by educational attainment in the United States, 2000-2015. <i>Cancer</i> , 2019, 125, 2089-2098.	2.0	12
1383	The Epidemiology of Hepatocellular Carcinoma in the USA. <i>Current Gastroenterology Reports</i> , 2019, 21, 17.	1.1	110
1384	The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. <i>Implementation Science</i> , 2019, 14, 26.	2.5	183
1385	Age-Related Differences in Past or Present Hepatitis C Virus Infection Among People Who Inject Drugs: National Human Immunodeficiency Virus Behavioral Surveillance, 8 US Cities, 2015. <i>Journal of Infectious Diseases</i> , 2019, 220, 377-385.	1.9	16
1386	Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago. <i>Vaccine</i> , 2019, 37, 2608-2616.	1.7	11
1388	New Face of Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1782-1788.	1.1	19
1389	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?. <i>Nutrients</i> , 2019, 11, 3048.	1.7	29
1390	Eradicating hepatitis C virus. <i>Nurse Practitioner</i> , 2019, 44, 16-27.	0.2	1
1391	Liver Disease Among Renal Transplant Recipients. , 2019, , 539-565.		0
1392	Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 385-395.	1.5	14
1393	Ethnic and Age Disparities in Outcomes Among Liver Transplant Waitlist Candidates. <i>Transplantation</i> , 2019, 103, 1425-1432.	0.5	16
1394	Prevalence and sociodemographic disparities of Hepatitis C in Baby Boomers and the US adult population. <i>Journal of Infection and Public Health</i> , 2019, 12, 32-36.	1.9	24
1395	Epidemiology and Management of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 156, 477-491.e1.	0.6	1,133
1396	Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago. <i>American Journal of Nephrology</i> , 2019, 49, 32-40.	1.4	21
1397	Efficacy and safety of alisporivir for the treatment of hepatitis C infection. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 379-384.	0.9	25
1398	Genetic and structural insights into broad neutralization of hepatitis C virus by human V _H 1-69 antibodies. <i>Science Advances</i> , 2019, 5, eaav1882.	4.7	77

#	ARTICLE	IF	CITATIONS
1399	Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV. <i>Drug and Alcohol Dependence</i> , 2019, 194, 288-295.	1.6	8
1400	Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016. <i>American Journal of Preventive Medicine</i> , 2019, 56, 8-16.	1.6	7
1401	Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. <i>JAMA Oncology</i> , 2019, 5, 497.	3.4	67
1402	Increased HCV Screening Yields Discordant Gains in Diagnoses Among Urban and Rural Veteran Populations in Texas: Results of a Statewide Quality Improvement Initiative. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2019, 45, 112-122.	0.4	2
1403	Recombinant streptavidin fusion proteins as signal reporters in rapid test of human hepatitis C virus infection. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22701.	0.9	5
1404	Clinical Epidemiology of Hepatitis C Virus. , 2019, , 149-170.		1
1405	Clinical Epidemiology of Chronic Liver Disease: Hepatocellular Carcinoma. , 2019, , 229-249.		2
1406	Identifying barriers to treatment of HCV in the primary care setting. <i>Hepatology International</i> , 2019, 13, 58-65.	1.9	15
1407	Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 75-79.	0.8	23
1408	Summary of the 2018 Kidney Disease Improving Global Outcomes (<scp>KDIGO</scp>) Guideline on hepatitis C in chronic kidney disease. <i>Seminars in Dialysis</i> , 2019, 32, 187-195.	0.7	17
1409	Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. <i>Gastroenterology</i> , 2019, 156, 254-272.e11.	0.6	1,040
1410	Sexual dimorphism in hepatitis B and C and hepatocellular carcinoma. <i>Seminars in Immunopathology</i> , 2019, 41, 203-211.	2.8	18
1411	Test4HepC: Promoting Hepatitis C Testing to Baby Boomers Using Social Media. <i>Health Promotion Practice</i> , 2020, 21, 780-790.	0.9	7
1412	Hepatitis C Virus and Hispanic Criminal Justice Clients: A Missed Opportunity. <i>Journal of Immigrant and Minority Health</i> , 2020, 22, 701-707.	0.8	4
1413	Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2020, 26, 349-358.	1.3	10
1414	Correlates of subjective hepatitis C knowledge among clinical staff in US drug treatment programs. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2020, 28, 401-409.	0.8	0
1415	Gaps in Viral Hepatitis Awareness in the United States in a Population-based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 188-195.e4.	2.4	33
1417	Hepatitis B and C virus infection and risk of haematological malignancies. <i>Journal of Viral Hepatitis</i> , 2020, 27, 4-12.	1.0	9

#	ARTICLE	IF	CITATIONS
1418	Prevalence of Hepatitis B Virus Infection Among US Adults Aged 20â€“59 Years With a History of Injection Drug Use: National Health and Nutrition Examination Survey, 2001â€“2016. <i>Clinical Infectious Diseases</i> , 2020, 70, 2619-2627.	2.9	22
1419	Candidemia in the Growing Opioid Epidemic: A Distinct and Emerging Entity. <i>Clinical Infectious Diseases</i> , 2020, 71, 1738-1740.	2.9	1
1420	Cure With Interferonâ€Free Directâ€Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virusâ€Related Hepatocellular Carcinoma From Both East and West. <i>Hepatology</i> , 2020, 71, 1910-1922.	3.6	70
1421	Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 30-36.	0.4	24
1422	Increased cancer rates in patients with chronic hepatitis C. <i>Liver International</i> , 2020, 40, 685-693.	1.9	22
1423	The Association of Abnormal Liver Tests with Hepatitis C Testing in Primary Care. <i>American Journal of Medicine</i> , 2020, 133, 214-221.e1.	0.6	4
1424	Infectious Hepatitis in Pregnancy. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 175-192.	0.6	2
1425	The ISR-1 Drug Case: A Decision-Making Exercise. <i>Journal of Management Education</i> , 2020, , 105256292095818.	0.6	0
1426	Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2956-2963.	1.1	3
1427	Budget Impact Analysis of a Computer-Delivered Brief Alcohol Intervention in Veterans Affairs (VA) Liver Clinics: A Randomized Controlled Trial. <i>Alcoholism Treatment Quarterly</i> , 2020, 38, 515-531.	0.5	1
1428	Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries. <i>JAMA Network Open</i> , 2020, 3, e208081.	2.8	6
1429	Hepatic Stellate Cells and Hepatocarcinogenesis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 709.	1.8	94
1430	Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women. <i>Obstetrics and Gynecology</i> , 2020, 135, 778-788.	1.2	16
1431	Population estimation and harm reduction among people who inject drugs in Addis Ababa, Ethiopia. <i>Harm Reduction Journal</i> , 2020, 17, 61.	1.3	1
1432	Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C. <i>JAMA Network Open</i> , 2020, 3, e2011055.	2.8	41
1433	Novel Models to Identify Census Tracts for Hepatitis C Screening Interventions. <i>Journal of the American Board of Family Medicine</i> , 2020, 33, 407-416.	0.8	3
1434	A Big Step Forward in Hepatitis C Screening. <i>Clinical Liver Disease</i> , 2020, 15, 149-152.	1.0	3
1435	ACR Appropriateness Criteriaâ® Chronic Liver Disease. <i>Journal of the American College of Radiology</i> , 2020, 17, S70-S80.	0.9	12

#	ARTICLE	IF	CITATIONS
1436	Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system. <i>Preventive Medicine Reports</i> , 2020, 17, 101036.	0.8	12
1437	Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 24.	1.0	10
1438	Aldehyde Dehydrogenase, Liver Disease and Cancer. <i>International Journal of Biological Sciences</i> , 2020, 16, 921-934.	2.6	63
1439	Rare Causes of Isolated and Progressive Splenic Lesions: Challenges in Differential Diagnosis, Evaluation, and Treatment of Primary Splenic Lymphomas. <i>Clinical Medicine Insights Blood Disorders</i> , 2020, 13, 1179545X2092618.	0.3	3
1440	Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013-2016. <i>Hepatology Communications</i> , 2020, 4, 355-370.	2.0	58
1441	The role of syringe exchange programs and sexual identity in awareness of pre-exposure prophylaxis (PrEP) for male persons who inject drugs. <i>International Journal of Drug Policy</i> , 2020, 77, 102671.	1.6	27
1442	Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study. <i>Cancer Causes and Control</i> , 2020, 31, 321-332.	0.8	20
1443	Factors influencing treatment outcome in hepatitis C virus minority patients at an inner-city hospital. <i>Medicine (United States)</i> , 2020, 99, e19505.	0.4	2
1444	Non-invasive Assessment of Liver Fibrosis. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 255-269.	0.3	3
1445	The Urgent Need for Hepatitis C Screening in Pregnant Women. <i>Obstetrics and Gynecology</i> , 2020, 135, 773-777.	1.2	7
1446	The association between metabolic syndrome and Hepatitis C virus infection in the United States. <i>Cancer Causes and Control</i> , 2020, 31, 569-581.	0.8	7
1447	Hepatitis C Testing Among Perinatally Exposed Infants. <i>Pediatrics</i> , 2020, 145, .	1.0	35
1448	Disparities in Hepatocellular Carcinoma Incidence in California: An Update. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 79-87.	1.1	9
1449	Carcinoma hepatocelular en hAgado no cirr3tico: caracterAsticas clAnicas y resultados en Veracruz, MÃ©xico. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 2021, 86, 4-12.	0.4	2
1450	Excellent Safety and Sustained Virologic Response to Direct-Acting Antivirals Treatment in HCV-Infected Geriatric Patients: A Real-World Data. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1327-1334.	1.1	3
1451	A Randomized Trial Comparing Brief Advice and Motivational Interviewing for Persons with HIV-HCV Co-infection Who Drink Alcohol. <i>AIDS and Behavior</i> , 2021, 25, 1013-1025.	1.4	9
1452	Hepatitis C virus infection mortality trends according to three definitions with special concern for the baby boomer birth cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 317-325.	1.0	4
1453	Sociodemographic features associated with Hepatitis C Virus (HCV) in pregnant females: A tertiary care centre study from Malwa region of Punjab (North India). <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 2679.	0.3	1

#	ARTICLE	IF	CITATIONS
1454	Hepatocellular carcinoma in the noncirrhotic liver: Clinical features and outcomes in Veracruz, Mexico. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2021, 86, 4-12.	0.1	1
1455	Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression and drinking motives. <i>Journal of Viral Hepatitis</i> , 2021, 28, 699-709.	1.0	2
1456	Declining US Hepatocellular Carcinoma Rates, 2014â€“2017. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e330-e334.	2.4	9
1457	Willingness to participate in research among black patients with liver disease: A national cross-sectional study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 982-993.	1.0	2
1458	The association between hepatitis C virus infection and renal cell cancer, prostate cancer, and bladder cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2021, 11, 10833.	1.6	9
1459	Association of hepatitis C infection and acute coronary syndrome. <i>Medicine (United States)</i> , 2021, 100, e26033.	0.4	2
1461	Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18â€“70 years from three countries. <i>PLoS ONE</i> , 2021, 16, e0253005.	1.1	5
1462	Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use. <i>World Journal of Gastroenterology</i> , 2021, 27, 3223-3237.	1.4	2
1463	Diagnostic Accuracy of Serum Hyaluronan for Detecting HCV Infection and Liver Fibrosis in Asymptomatic Blood Donors. <i>Molecules</i> , 2021, 26, 3892.	1.7	5
1464	Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination. <i>Journal of Preventive Medicine and Public Health</i> , 2021, 54, 251-258.	0.7	23
1465	Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. <i>Kidney International Reports</i> , 2021, 6, 1788-1798.	0.4	2
1466	TLR3TLR7 as Differentially Expressed Markers Among Viral, Nonviral, and Autoimmune Diseases in Egyptian Patients. <i>Viral Immunology</i> , 2021, 34, 607-621.	0.6	0
1467	â€œSobriety equals getting rid of hepatitis Câ€: A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults. <i>Journal of Substance Abuse Treatment</i> , 2021, 127, 108337.	1.5	6
1468	Analysis of genetic and clinical factors associated with buprenorphine response. <i>Drug and Alcohol Dependence</i> , 2021, 227, 109013.	1.6	2
1469	Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus. <i>Clinics in Liver Disease</i> , 2021, 25, 817-829.	1.0	3
1470	Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108438.	1.5	7
1473	Surveillance for Hepatitis C. , 2015, , 93-124.		2
1474	Epidemiology, Risk Factors, and Natural History of Chronic Hepatitis C. , 2009, , 33-70.		5

#	ARTICLE	IF	CITATIONS
1475	Infectious Diseases and the Kidney. , 2009, , 1235-1273.		5
1476	Sex Differences in Immunity and Inflammation: Implications for Brain and Behavior. , 2016, , 1-26.		1
1477	Disorders of the Liver and Biliary Tract. , 2010, , 1153-1171.		4
1478	Chronic Viral Hepatitis. , 2010, , 1593-1617.		9
1481	HIV Co-Infection Drug Toxicity. , 2012, , 683-699.		1
1482	ACR Appropriateness Criteria Â® Chronic LiverÂDisease. Journal of the American College of Radiology, 2017, 14, S103-S117.	0.9	20
1483	Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health, The, 2019, 4, e137-e147.	4.7	352
1484	Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	0.8	4
1485	Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles. Journal of General Virology, 2016, 97, 2883-2893.	1.3	27
1486	Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection. Journal of General Virology, 2012, 93, 1673-1679.	1.3	8
1487	Hepatitis C Virus. , 0, , 1599-1616.		2
1488	The swinging thyroid in hepatitis C infection and interferon therapy. BMJ Case Reports, 2009, 2009, bcr0720080464-bcr0720080464.	0.2	1
1489	NF. Evaluating Anti Î²-2 Glycoprotein as Rapid Thromboembolic Marker Among HCV Patients in Egypt. American Journal of Life Sciences, 2013, 1, 1.	0.3	1
1490	Predicting response to hepatitis C therapy. Journal of Clinical Investigation, 2009, 119, 5-7.	3.9	6
1491	Prophylactic Antidepressant Treatment in Patients With Hepatitis C on Antiviral Therapy: A Double-Blind, Placebo-Controlled Trial. Psychosomatics, 2010, 51, 401-408.	2.5	35
1492	The Costs and Impacts of Testing for Hepatitis C Virus Antibody in Public STD Clinics. Public Health Reports, 2007, 122, 55-62.	1.3	27
1493	Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritransplant Setting: A Case Report. American Journal of Case Reports, 2016, 17, 605-610.	0.3	1
1494	Hepatitis C Virus Infection in Guinea-Bissau: A Sexually Transmitted Genotype 2 with Parenteral Amplification?. PLoS ONE, 2007, 2, e372.	1.1	27

#	ARTICLE	IF	CITATIONS
1495	Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy. PLoS ONE, 2008, 3, e2123.	1.1	45
1496	Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients. PLoS ONE, 2011, 6, e26783.	1.1	41
1497	A Novel Multiplex Real-Time PCR Assay for the Concurrent Detection of Hepatitis A, B and C Viruses in Patients with Acute Hepatitis. PLoS ONE, 2012, 7, e49106.	1.1	12
1498	Correlation of Viral Loads with HCV Genotypes: Higher Levels of Virus Were Revealed among Blood Donors Infected with 6a Strains. PLoS ONE, 2012, 7, e52467.	1.1	20
1499	WNT Signaling Pathway Gene Polymorphisms and Risk of Hepatic Fibrosis and Inflammation in HCV-Infected Patients. PLoS ONE, 2013, 8, e84407.	1.1	16
1500	The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0141715.	1.1	74
1501	Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient. PLoS ONE, 2015, 10, e0144638.	1.1	3
1502	Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0149966.	1.1	46
1503	Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175. PLoS ONE, 2016, 11, e0152036.	1.1	11
1504	Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS ONE, 2016, 11, e0163644.	1.1	79
1505	Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence. PLoS ONE, 2017, 12, e0177022.	1.1	15
1506	Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients. Journal of Clinical and Translational Hepatology, 2018, 6, 1-5.	0.7	2
1507	Assessment of Knowledge, Attitudes, and Practices Regarding Chronic Hepatitis C Treatment and Its Challenges: A Survey of Internal Medicine Residents in a Community Hospital. Gastroenterology Research, 2018, 11, 31-35.	0.4	2
1508	Seroprevalencia de la hepatitis C en adultos de MÃ©xico: ¿un problema de salud pÃºblica emergente?. Salud Publica De Mexico, 0, 49, s395-s403.	0.1	40
1510	The correlation between RT-PCR and ELISA assay on hepatitis C positive serum samples. Pure and Applied Biology, 2016, 5, .	0.1	2
1511	Racial and Ethnic Disparities in Knowledge About Hepatitis C. The Open General & Internal Medicine Journal, 2007, 1, 1-5.	0.3	3
1512	A Primary Care-based Collaborative Hepatitis C Clinic: Clinical Structure and Virologic Outcomes with Direct Acting Antiviral Therapy. Open Medicine Journal, 2016, 3, 70-78.	0.5	1
1513	Development of a Flow Cytometry Live Cell Assay for the Screening of Inhibitors of Hepatitis C Virus (HCV) Replication. The Open Virology Journal, 2012, 6, 97-102.	1.8	7

#	ARTICLE	IF	CITATIONS
1514	Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells. The Open Virology Journal, 2014, 8, 1-8.	1.8	6
1515	Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment: Observational Pilot Study. Journal of Medical Internet Research, 2020, 22, e15532.	2.1	12
1516	"Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign. JMIR Research Protocols, 2015, 4, e13.	0.5	6
1517	Hepatitis C crÃ³nica: aspectos clÃ³nicos, serolÃ³gicos y de tratamiento en dos centros de atenciÃ³n en BogotÃ¡, Colombia. Revista Colombiana De Gastroenterologia, 2014, 29, 424-432.	0.1	2
1518	Hepatitis C screening in commercially insured U.S. birth-cohort patients: Factors associated with testing and effect of an EMR-based screening alert. Journal of Translational Internal Medicine, 2018, 6, 82-89.	1.0	27
1519	Chronic hepatitis C in Austria, 1992â€“2006: genotype distribution and demographic factors. Eurosurveillance, 2010, 15, 19492.	3.9	15
1520	Legionella, springtime and potting soils. Eurosurveillance, 2010, 15, 19497.	3.9	5
1521	HBsAg, anti-HCV and anti-HIV seroprevalance among drug users : A retrospective assessment. Noropsikiyatri Arsivi, 2019, 56, 186-190.	0.2	4
1522	Prevention of Hepatocellular Carcinoma. , 2009, , 36-61.		2
1523	Survival rates of early-stage HCV-related liver cirrhosis patients without hepatocellular carcinoma are decreased by alcohol. Journal of Clinical Biochemistry and Nutrition, 2010, 48, 167-169.	0.6	4
1524	KASL clinical practice guidelines: Management of Hepatitis C. Clinical and Molecular Hepatology, 2014, 20, 89.	4.5	35
1525	Geographic differences in the epidemiological features of HCV infection in Korea. Clinical and Molecular Hepatology, 2014, 20, 361.	4.5	11
1526	Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. Clinical and Molecular Hepatology, 2014, 20, 368.	4.5	13
1527	KASL clinical practice guidelines: management of hepatitis C. Clinical and Molecular Hepatology, 2016, 22, 76-139.	4.5	68
1528	The effect of moderate alcohol drinking in nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 2020, 26, 662-669.	4.5	34
1529	The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection. The Korean Journal of Hepatology, 2012, 18, 29.	1.5	4
1530	Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen. Journal of Health Economics and Outcomes Research, 2019, 6, 1-19.	0.6	2
1531	Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World Journal of Gastroenterology, 2008, 14, 3416.	1.4	42

#	ARTICLE	IF	CITATIONS
1532	Chronic hepatitis C is a common associated with hepatic granulomas. World Journal of Gastroenterology, 2008, 14, 6366.	1.4	15
1533	Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World Journal of Gastroenterology, 2006, 12, 7239.	1.4	74
1534	Acute hepatitis C: Prospects and challenges. World Journal of Gastroenterology, 2007, 13, 6455.	1.4	5
1535	Is chronic hepatitis C virus infection a risk factor for breast cancer?. World Journal of Gastroenterology, 2010, 16, 3687.	1.4	12
1536	Hepatitis C virus infection and health-related quality of life. World Journal of Gastroenterology, 2012, 18, 2295.	1.4	25
1537	Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World Journal of Gastroenterology, 2013, 19, 3207.	1.4	16
1538	Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World Journal of Gastroenterology, 2013, 19, 7846.	1.4	74
1539	Epidemiology and natural history of hepatitis C virus infection. World Journal of Gastroenterology, 2014, 20, 9270-80.	1.4	131
1540	Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World Journal of Gastroenterology, 2015, 21, 7412.	1.4	42
1541	Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World Journal of Gastroenterology, 2015, 21, 8293.	1.4	24
1542	Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World Journal of Gastroenterology, 2015, 21, 10749.	1.4	23
1543	Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World Journal of Gastroenterology, 2015, 21, 10811.	1.4	41
1544	Alcoholic liver disease and hepatitis C virus infection. World Journal of Gastroenterology, 2016, 22, 1411.	1.4	41
1545	Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World Journal of Gastroenterology, 2019, 25, 2229-2239.	1.4	8
1546	Viral infections and the kidney: HIV, hepatitis B, and hepatitis C.. Cleveland Clinic Journal of Medicine, 2007, 74, 353-360.	0.6	24
1547	Hepatitis C virus: Prevention, screening, and interpretation of assays. Cleveland Clinic Journal of Medicine, 2010, 77, 616-626.	0.6	23
1548	Protease inhibitors: Silver bullets for chronic hepatitis C infection?. Cleveland Clinic Journal of Medicine, 2012, 79, 213-222.	0.6	22
1549	Current status of hepatocellular carcinoma in the United States. Chinese Clinical Oncology, 2013, 2, 45.	0.4	5

#	ARTICLE	IF	CITATIONS
1550	Pathobiology and Treatment of Hepatitis Virus-Related Thrombocytopenia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009023.	0.5	16
1551	Psychiatric Care of the Patient With Hepatitis C. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010, 12, .	0.6	22
1552	Telaprevir. <i>Journal of Postgraduate Medicine</i> , 2013, 59, 42-47.	0.2	10
1553	Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C. <i>Journal of Addiction Research & Therapy</i> , 2011, 02, 2-10.	0.2	17
1554	Demographic characteristics and intravenous drug use among hepatitis C patients in the Kota Setar district, Kedah, Malaysia. <i>Epidemiology and Health</i> , 2015, 37, e2015032.	0.8	6
1555	HIV Prevalence among HCV Egyptian Infected Patients and Its Impact on the Result of HCV Treatment. <i>Advances in Infectious Diseases</i> , 2013, 03, 71-77.	0.0	4
1556	Hepatitis C genotype 6: A concise review and response-guided therapy proposal. <i>World Journal of Hepatology</i> , 2013, 5, 496.	0.8	26
1557	Vertical hepatitis C virus transmission: Main questions and answers. <i>World Journal of Hepatology</i> , 2014, 6, 538.	0.8	40
1558	Vertical transmission of hepatitis C virus: Current knowledge and perspectives. <i>World Journal of Hepatology</i> , 2014, 6, 643.	0.8	73
1559	Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment. <i>World Journal of Hepatology</i> , 2016, 8, 1318.	0.8	19
1560	Is the 25-year hepatitis C marathon coming to an end to declare victory?. <i>World Journal of Hepatology</i> , 2017, 9, 921.	0.8	6
1561	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. <i>World Journal of Hepatology</i> , 2017, 9, 352.	0.8	50
1562	Seroprevalence of Hepatitis B and C Infections among Healthy Volunteer Blood Donors in the Central California Valley. <i>Gut and Liver</i> , 2013, 7, 66-73.	1.4	8
1563	Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea. <i>Gut and Liver</i> , 2017, 11, 426-433.	1.4	5
1564	AVALIAÇÃO DO NÍVEL DE CONHECIMENTO DE ADOLESCENTES A RESPEITO DA TRANSMISSÃO E PREVENÇÃO DAS HEPATITES B E C. <i>Journal of Tropical Pathology</i> , 2009, 38, .	0.1	2
1565	The Use of Telemedicine for the Management of Hepatitis C & the California Telehealth Network. , 0, , .		1
1566	Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon- α 2b Plus Ribavirin: Effect on Work Performance. A Randomized Clinical Trial. <i>Hepatitis Monthly</i> , 2014, 14, e11608.	0.1	22
1567	Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. <i>Hepatitis Monthly</i> , 2016, 16, e37089.	0.1	66

#	ARTICLE	IF	CITATIONS
1568	The Long-Term Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus: A Modeling Study. Iranian Red Crescent Medical Journal, 2014, 16, e13484.	0.5	7
1569	A Review of the Natural History of Chronic Hepatitis C Infection. North American Journal of Medicine & Science, 2014, 07, 001.	3.8	7
1570	Prevention of Viral Hepatitis. , 2007, , 127-155.		1
1571	Hepatitis C Virus. , 2008, , 1089-1096.		0
1572	Hepatitis C in Special Populations. , 2009, , 97-134.		0
1573	Viral Hepatitis, A Through E, In Pregnancy. , 2009, , 353-373.		0
1574	HEPATITIS C VIRUS. , 2009, , 2380-2394.		0
1575	Anti-HCV Agents in Development. , 2009, , 159-183.		0
1576	Current and Future Therapy of Chronic Hepatitis C. , 2009, , 71-96.		0
1580	Epidemiology and Natural History of Hepatitis C in Children. , 2010, , 55-66.		0
1584	Viral Hepatitis C. , 2011, , 427-432.		2
1586	Hepatitis Virus Infections. , 2011, , 469-477.e3.		0
1587	Racial Disparities in HIV and Liver Disease. , 2012, , 189-194.		0
1588	Epidemiology of Liver Disease in Human Immunodeficiency Virus-Infected Persons. , 2012, , 9-13.		1
1589	Does Treatment Alter the Natural History of Chronic HCV?. , 2012, , 103-112.		0
1590	Treating Chronic HCV Without Interferon and/or Ribavirin. , 2012, , 261-269.		0
1595	Hepatitis C Virus (HCV) Genotype Assay (LiPA). , 2012, , 141-151.		0
1597	Viral Liver Diseases. , 2012, , 383-390.		0

#	ARTICLE	IF	CITATIONS
1598	Hepatitis C Virus. , 2012, , 1105-1112.e4.		1
1599	COBASÂ® AmpliPrep/COBASÂ® TaqManÂ® HCV Test. , 2012, , 153-170.		0
1600	Acute viral hepatitis. , 2012, , 34-52.		1
1601	Human Immunodeficiency Virus, Hepatitis B and Hepatitis C Virus Infections Among Injecting and Non-Injecting Drug Users in Inner City Neighborhoods. , 0, , .		0
1603	Serological prevalence of hepatitis B virus and hepatitis C virus infection in the elderly population. European Journal of Gastroenterology and Hepatology, 2012, 24, 1.	0.8	14
1605	Other Drug Use. , 2013, , 129-145.		0
1607	Management algorithm for genotype 1 hepatitis C virus. F1000prime Reports, 2013, 5, 24.	5.9	1
1608	Effect of Differentially Expressed MicroRNAs 602 and 323-5p on Hepatitis C Virus Genotype 1b Viral Load in Infected Liver Cells. Journal of Infectious Disease and Therapy, 2014, 02, .	0.1	1
1609	Safety and Efficacy of Pegylated Interferon alpha-2a and Ribavirin Combination in Treatment of Egyptian Patients with Chronic Hepatitis C Genotype-4. IOSR Journal of Pharmacy, 2014, 04, 07-13.	0.1	0
1611	Liver Disease in Renal Transplant Recipients. , 2014, , 247-255.		1
1612	Hepatitis Viruses: Hepatitis C. , 2014, , 765-783.		0
1613	Clinical Evaluation of Chronic Hepatitis C and Indications for HCV Treatment. North American Journal of Medicine & Science, 2014, 07, 017.	3.8	0
1615	Liver Disease among Renal Transplant Recipients. , 2014, , 511-536.		0
1616	Changing Epidemiology of Chronic Hepatitis C in Adana. Viral Hepatitis Journal, 2014, 20, 15-18.	0.1	2
1617	Iron Load and Serum Hecidin in Hepatitis C Virus-Related Hepatocellular Carcinoma. Euroasian Journal of Hepato-gastroenterology, 2012, 2, 24-27.	0.1	1
1618	Prevalence of Hepatitis C Virus in the Population of Albania for the Period 2007-2010. Open Access Macedonian Journal of Medical Sciences, 2014, 2, 525-528.	0.1	1
1619	A psychiatric pharmacist in a liver clinic managing treated patients with chronic hepatitis C viral infection. Mental Health Clinician, 2014, 4, 266-270.	0.5	0
1620	Oxidative Stress in Chronic Viral Hepatitis. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 241-277.	0.4	0

#	ARTICLE	IF	CITATIONS
1621	Understanding and Reducing Risks via Infection in LBT Women. , 2015, , 23-35.		1
1622	Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia. Srpski Arhiv Za Celokupno Lekarstvo, 2015, 143, 35-41.	0.1	0
1623	Hypothesis Testing and Interval Estimation. , 2015, , 206-257.		0
1624	Hepatitis C as an epidemiological problem in the polish population. Medical and Biological Sciences, 2015, 29, 41.	0.2	3
1626	Management of Hepatitis C Virus Infection - New Era Has Been Started. Faridpur Medical College Journal, 2015, 9, 92-97.	0.0	0
1628	Epidemiology of hepatitis C in the Moscow Region: data from the Moscow Regional Registry and screening for HCV antibodies. Al'manah Klinicheskoy Meditsiny, 2016, 44, 689-696.	0.2	1
1629	Update on Hepatitis C Virus and HIV Coinfection. Journal of Clinical and Translational Hepatology, 2016, 1, 109-15.	0.7	1
1630	Hepatitis C and HIV Neurological Implications. , 2017, , 625-643.		0
1631	Resistance to Cyclophilin Inhibitors. , 2017, , 59-85.		0
1632	The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. Journal of Clinical and Translational Hepatology, 2017, 5, 59-66.	0.7	14
1634	FEATURES OF CIRCULATION OF HEPATITIS C VIRUS IN KHABAROVSK REGION. Zhurnal Mikrobiologii i Immunologii, 2017, , 43-51.	0.3	2
1635	School adolescents' knowledge concerning hepatitis C virus (HCV). Pedagogy and Psychology of Sport, 2017, 3, 33.	0.2	0
1636	FREQUENCY OF DETECTION OF ANTIBODIES TO HEPATITIS C VIRUS AMONG CONVENTIONALLY HEALTHY POPULATION OF RUSSIAN FEDERATION. Zhurnal Mikrobiologii i Immunologii, 2017, , 99-106.	0.3	1
1639	Pretransplant Evaluation and Care. , 2018, , 737-752.e5.		0
1640	Treatment of Hepatitis C. , 2018, , 446-463.e3.		0
1641	Frequency of Various Risk Factors in HCV Positive Patients in Initial Diagnostic Phase. Occupational Diseases and Environmental Medicine, 2018, 06, 23-36.	0.9	0
1642	Hepatitis C Infection Patterns at a Tertiary Care Center in New York: A Cross-Sectional Study. Cureus, 2018, 10, e2225.	0.2	0
1643	Scientific and Ethical Considerations for Increasing Minority Participation in Clinical Trials. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1644	Hepatitis C testing among adults born between 1945 and 1965 in Turkey: a multicentre study. Central European Journal of Public Health, 2018, 26, 83-86.	0.4	0
1645	Epidemiology of Chronic Liver Disease in the United States. , 2019, , 57-74.		1
1647	Frequency of Hypothyroidism in Chronic Hepatitis C patients treated with Standard Interferon Therapy. Pakistan Biomedical Journal, 2021, 1, .	0.0	0
1648	Å¼nc¼ basamak bir hastaneye baÅvuran hastalarda HBsAg ve anti-HCV seroprevalans±: Alt± yÄll±k retrospektif veriler. Ege Tıp Dergisi, 0, , 149-153.	0.1	0
1649	Emergency department targeted screening for hepatitis C does not improve linkage to care. World Journal of Gastroenterology, 2020, 26, 4878-4888.	1.4	5
1651	Mathematical Modeling of Chronic Hepatitis C Treatment's Effect on the Evolution of its Complications. , 2021, , .		0
1652	National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. Preventing Chronic Disease, 2008, 5, A74.	1.7	63
1653	Hepatitis-C prevalence in an urban native-American clinic: a prospective screening study. Journal of the National Medical Association, 2007, 99, 389-92.	0.6	18
1655	Treatment options for HCV nonresponders and relapse patients. Gastroenterology and Hepatology, 2010, 6, 1-12.	0.2	1
1656	Skin rash during chronic hepatitis C therapy. Gastroenterology and Hepatology, 2010, 6, 323-5.	0.2	4
1657	Review. Gastroenterology and Hepatology, 2010, 6, 387-8.	0.2	0
1658	Management of recurrent hepatitis C following liver transplantation. Gastroenterology and Hepatology, 2010, 6, 637-45.	0.2	8
1659	IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterology and Hepatology, 2011, 7, 366-73.	0.2	5
1660	The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C. Hepatitis Monthly, 2011, 11, 240-6.	0.1	10
1661	Hepatitis C virus treatment complicated by rheumatoid arthritis. Gastroenterology and Hepatology, 2011, 7, 774-6.	0.2	0
1663	Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterology and Hepatology, 2012, 8, 305-12.	0.2	23
1664	The feasibility and acceptability of a multimedia hepatitis C prevention program for Hispanic HIV-infected persons. Ethnicity and Disease, 2008, 18, S2-195-9.	1.0	3
1666	Management of hepatitis C virus infection: the basics. Topics in Antiviral Medicine, 2012, 20, 154-61.	0.1	15

#	ARTICLE	IF	CITATIONS
1667	Experiences of Oxford House Residents Living with the Hepatitis C Virus. , 2013, 2, 57-63.		2
1668	Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Topics in Antiviral Medicine, 2013, 21, 27-35.	0.1	24
1669	New markers for diagnosis and management of chronic hepatitis C virus infection. Annals of Gastroenterology, 2013, 26, 98-99.	0.4	1
1670	Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. P and T, 2014, 39, 345-52.	1.0	12
1671	Factors contributing to health disparities in liver transplantation in a Hispanic population. Puerto Rico Health Sciences Journal, 2012, 31, 199-204.	0.2	4
1672	Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males. International Journal of Molecular Epidemiology and Genetics, 2014, 5, 164-76.	0.4	10
1674	Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. North American Journal of Medicine & Science, 2014, 7, 21-27.	3.8	5
1675	Hepatitis C screening. Ochsner Journal, 2014, 14, 664-8.	0.5	13
1676	Hepatitis C virus antibody prevalence, demographics and associated factors among persons screened at Hawai'i community-based health settings, 2010-2013. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2015, 74, 9-15.	0.4	3
1677	Estimating the true prevalence of hepatitis C in rhode island. Rhode Island Medical Journal (2013), 2014, 97, 19-24.	0.2	4
1678	Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics. Annals of Hepatology, 2015, 14, 234-42.	0.6	11
1679	Molecular and contextual markers of hepatitis C virus and drug abuse. Molecular Diagnosis and Therapy, 2009, 13, 153-79.	1.6	3
1680	Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease. Journal of Family Practice, 2010, 59, S37-42.	0.2	11
1681	Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight U.S. sites, 2005-2011. Morbidity and Mortality Weekly Report, 2013, 62, 357-61.	9.0	21
1682	Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection. International Journal of Preventive Medicine, 2014, 5, S179-92.	0.2	5
1683	Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. American Journal of Translational Research (discontinued), 2015, 7, 2510-8.	0.0	13
1684	Anti-roads and rings autoantibodies can occur in the hepatitis c-na \tilde{v} e population. Journal of Preventive Medicine and Hygiene, 2013, 54, 175-80.	0.9	10
1685	Development of a Measure of Hepatitis C-alcohol Knowledge. Journal of Alcohol and Drug Education, 2014, 58, 7-18.	2.0	8

#	ARTICLE	IF	CITATIONS
1686	Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2016, 12, 293-9.	0.2	13
1688	Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Mono-infection Treatment. <i>Gastroenterology and Hepatology</i> , 2014, 10, 706-715.	0.2	0
1689	Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United States. <i>Gastroenterology and Hepatology</i> , 2017, 13, 98-104.	0.2	6
1691	Rapid hepatitis C testing among persons at increased risk for infection—Wisconsin, 2012-2013. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 309-11.	9.0	14
1692	Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines. <i>American Health and Drug Benefits</i> , 2018, 11, 30-37.	0.5	2
1693	Increasing hepatitis C screening in a large integrated health system: science and policy in concert. <i>American Journal of Managed Care</i> , 2018, 24, e134-e140.	0.8	4
1694	Integrating Care for Patients With Chronic Liver Disease and Mental Health and Substance Use Disorders. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2018, 35, S14-S23.	0.6	10
1695	Patterns of Hepatitis C-Related Inpatient Mortality in the United States in the Era of Direct-Acting Antivirals. <i>Journal of Gastroenterology and Hepatology Research</i> , 2020, 9, 3169-3175.	0.2	0
1696	HCV disease burden and population segments in Switzerland. <i>Liver International</i> , 2022, 42, 330-339.	1.9	14
1697	The Impact of Patient Characteristics on Diagnostic Test Performance. <i>Small Methods</i> , 2022, , 2101233.	4.6	0
1698	Level of knowledge of prevention of hepatitis C virus infection among nursing students. <i>Journal of Education, Health and Sport</i> , 2020, 10, 126-136.	0.0	0
1699	The Relationship Between Anti-HCV Screening and Clinical Features of Inpatients in Addiction Center. <i>Noropsikiyatri Arsivi</i> , 2022, , .	0.2	0
1700	Secular trends in cryoglobulinemia mortality in the USA in the era of direct-acting antivirals. <i>Arthritis Research and Therapy</i> , 2022, 24, 41.	1.6	1
1701	Global prevalence of hepatitis C in prisoners: a comprehensive systematic review and meta-analysis. <i>Archives of Virology</i> , 2022, 167, 1025-1039.	0.9	7
1702	Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?. <i>Seminars in Cancer Biology</i> , 2022, 86, 1175-1185.	4.3	2
1704	Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years) Tj ETQ _{0,1} 1 0.784314 rgBT	1.0	1
1705	Viral hepatitis: Past, present, and future. <i>World Journal of Gastroenterology</i> , 2022, 28, 1405-1429.	1.4	29
1709	Acute Hepatitis: Treat Immediately or Give a Chance to Spontaneously Clear?. , 0, , 25-33.		0

#	ARTICLE	IF	CITATIONS
1711	Association of antigenic properties to structure of the hepatitis C virus NS3 protein. <i>In Silico Biology</i> , 2011, 11, 203-12.	0.4	0
1712	PEG-Interferon- α ± ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study. <i>Farmacia Hospitalaria</i> , 2015, 39, 29-43.	0.6	1
1713	Future Treatment of Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2007, 12, 1015-1026.	0.6	13
1715	Assessment of Alcohol and Other Substance Use in Patients With Chronic Liver Disease. <i>Clinical Liver Disease</i> , 2022, 20, 61-65.	1.0	1
1716	Progress in Reducing Disparities in Premature Mortality in the USA: a Descriptive Study. <i>Journal of General Internal Medicine</i> , 2022, 37, 2923-2930.	1.3	3
1717	Inferior Survival Is Associated With Socioeconomic Deprivation in Hepatocellular Carcinoma. <i>Journal of Surgical Research</i> , 2022, 279, 228-239.	0.8	6
1718	Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8083.	1.8	13
1719	Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China. <i>BioMed Research International</i> , 2022, 2022, 1-8.	0.9	1
1720	Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic. <i>PLoS ONE</i> , 2022, 17, e0272518.	1.1	0
1721	Attitudes and perceptions of mothers towards childhood vaccination in Greece: lessons to improve the childhood COVID-19 vaccination acceptance. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	5
1722	Patient characteristics and neighborhood attributes associated with hepatitis C screening and positivity in Philadelphia. <i>Preventive Medicine Reports</i> , 2022, 30, 102011.	0.8	0
1723	Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
1724	Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress. <i>Journal of Infection and Public Health</i> , 2023, 16, 64-70.	1.9	0
1725	Factors impacting medication adherence in a birth cohort at higher risk for Hepatitis C infection. <i>Medicine (United States)</i> , 2022, 101, e32354.	0.4	1
1726	A Novel Information-Theory-Based Genetic Distance That Approximates Phenotypic Differences. <i>Journal of Computational Biology</i> , 2023, 30, 420-431.	0.8	2
1727	Viral Markers and Their Relevance in Liver Disease and Transplantation. , 2023, , 75-92.		0
1728	Global treatment rate and barriers to direct-acting antiviral therapy: A systematic review and meta-analysis of 146 studies and 1â€‰%760â€‰%352 hepatitis C virus patients. <i>Liver International</i> , 2023, 43, 1195-1203.	1.9	4
1729	Delays in fibrosis staging reduce the likelihood of achieving hepatitis C treatment and cure. <i>Infectious Diseases</i> , 2023, 55, 309-315.	1.4	0

#	ARTICLE	IF	CITATIONS
1730	Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen. <i>Journal of Health Economics and Outcomes Research</i> , 0, , 1-19.	0.6	0
1731	Evaluation of Structured, Semi-Structured, and Free-Text Electronic Health Record Data to Classify Hepatitis C Virus (HCV) Infection. <i>Gastrointestinal Disorders</i> , 2023, 5, 115-126.	0.4	0
1742	Therapeutic potential of oleanolic acid in liver diseases. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	1.4	0